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Abstract Keratan sulfate (KS) is a storage material in
mucopolysaccharidosis IV (MPS IV). However, no detailed
analysis has been reported on subclasses of KS: mono-
sulfated KS and di-sulfated KS. We established a novel
method to distinguish and quantify mono- and di-sulfated
KS using liquid chromatography–tandem mass spectrometry
and measured both KS levels in various specimens.
Di-sulfated KS was dominant in shark cartilage and rat
serum, while mono-sulfated KS was dominant in bovine
cornea and human serum. Levels of both mono- and
di-sulfated KS varied with age in the blood and urine from
control subjects and patients with MPS II and IVA.
The mean levels of both forms of KS in the plasma/serum
from patients with MPS II, IVA, and IVB were
elevated compared with that in age-matched controls.
Di-sulfated KS provided more significant difference
between MPS IVA and the age-matched controls than
mono-sulfated KS. The ratio of di-sulfated KS to total
KS in plasma/serum increased with age in control subjects
and patients with MPS II but was age independent in
MPS IVA patients. Consequently, this ratio can discriminate
younger MPS IVA patients from controls. Levels of mono-
and di-sulfated KS in urine of MPS IVA and IVB
patients were all higher than age-matched controls for all
ages studied.
In conclusion, the level of di-sulfated KS and its ratio to
total KS can distinguish control subjects from patients with
MPS II, IVA, and IVB, indicating that di-sulfated KS may
be a novel biomarker for these disorders.
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Introduction
Keratan sulfate (KS), a linear polymer glycosaminoglycan
(GAG), is composed of alternating D-galactose (Gal) and
N-acetyl-D-glucosamine (GlcNAc) residues linked to
b1 ! 4 and b1 ! 3, respectively. KS attaches to core
proteins including aggrecan, luminican, keratocan,
mimecan, and fibromodulin with fucose and sialic acid
and is distributed in the articular cartilage, cornea, brain,
and various endothelial cells (Funderburgh 2000). KS is
almost always sulfated on C (6) of GlcNAc, while C (6) of
Gal is sulfated to a variable extent, depending on the tissue
and age (Bhavanandan and Meyer 1968). KS chains of
fibromodulin in articular cartilage are highly sulfated
compared to that in the cornea (Lauder et al. 1997;
Nieduszynski et al. 1990), and the levels of sulfation in
cornea and cartilage increase during normal aging (Liles
et al. 2010; Brown et al. 1998).
Mucopolysaccharidosis IV includes two subtypes,
mucopolysaccharidosis IVA and IVB (MPS IVA, Morquio
A syndrome; MPS IVB, Morquio B syndrome), caused by
the deficiency of N-acetylgalactosamine-6-sulfate sulfatase
(GALNS) and b-galactosidase (b-gal), respectively. Either
enzyme deficiency results in accumulation of undegraded KS
especially in cells and extracellular matrix (ECM) of
cartilage and cornea. Patients with a classic (severe) form
of MPS IVA have a unique systemic skeletal dysplasia
including short-trunk dwarfism, kyphoscoliosis, coxa valga,
odontoid hypoplasia, abnormal gait, joint mobility problems,
restriction of chest wall movement, and a life span of 20–30
years if an appropriate orthopedic intervention is unavailable.
Patients with an attenuated form have a milder skeletal
involvement, and most have normal life span (Dũng et al.
2013; Yasuda et al. 2013; Tomatsu et al. 2011, 2012a, 2013a,
b; Northover et al. 1996; Montaño et al. 2007, 2008; Suzuki
et al. 2001; Hendriksz et al. 2013; M€ollmann et al. 2013;
Harmatz et al. 2013). Patients with MPS IVB show a milder
phenotype of skeletal dysplasia than patients with the severe
form of MPS IVA. Consequently, clinical features of MPS
IVB are similar to those in patients with an attenuated form
of MPS IVA.
We have established a reproducible, sensitive, and
specific assay technique to measure KS in blood, urine,
and dried blood spot (DBS) specimens using liquid
chromatography–tandem mass spectrometry (LC-MS/MS)
(Tomatsu et al. 2010a, b, 2013a; Oguma et al. 2007a, b;
Hintze et al. 2011). Similar methods have been validated in
another laboratory (Martell et al. 2011). KS levels in blood
and urine in patients with MPS IVA are associated with age
and clinical severity (Tomatsu et al. 2010c) and are
decreased with enzyme replacement therapy (ERT) on
mouse model and bone marrow transplantation (BMT) in
a patient with MPS IVA (Tomatsu et al. 2008; Chinen et al.
2014). Thus, KS levels in the blood and/or urine should be
a suitable biomarker for early diagnosis, screening, clinical
severity, and therapeutic efficacy in MPS IVA (Tomatsu
et al. 2008, 2010c, 2013a). However, there is significant
overlap of KS levels between age-matched controls and
patients with MPS IVA, especially in patients older than
10 years of age, suggesting that better biomarkers or
methodology for MPS IVA are needed (Tomatsu et al.
2010c). Blood KS level was also elevated in patients with
MPS II and MPS IVB, resulting in difficulty to separate
MPS IVA from MPS II and MPS IVB or other types
of MPS by total KS (Tomatsu et al. 2005, 2010c).
Patients with MPS IVA and IVB have a deficiency
of the enzyme that directly involves KS metabolism,
N-acetylgalactosamine-6-sulfate sulfatase (GALNS) and
b-galactosidase, respectively. Therefore, elevation of KS
in the blood and urine of these types of MPS is natural;
however, it is unexpected that patients with other types of
MPS, in which responsible enzymes do not directly involve
the catabolic pathway of KS, have the elevation of KS in
the blood and urine as well.
GALNS removes the sulfate at C(6) in Gal of the
di-sulfated KS, Gal(6S)b1 ! 4GlcNAc(6S), producing
mono-sulfated KS, Galb1 ! 4GlcNAc(6S). Our previous
results showed that the proportion of di-sulfated KS in total
KS in the patients with MPS IVA is higher than that in the
control subjects (Tomatsu et al. 2010c); but the low
sensitivity and specificity of the assay to detect di-sulfated
KS limited further studies. Improvement of the assay
method to separate di-sulfated KS and mono-sulfated KS
was needed to distinguish MPS IVA, control subjects, and
other types of MPS precisely.
In this study, we have determined di-sulfated KS levels
and the proportion of di-sulfated KS in total KS in the
blood and urine of control subjects and patients with MPS
II, IVA, and IVB by using a novel LC-MS/MS method.
We have compared its feasibility of di-sulfated KS with
mono-sulfated KS as a biomarker for MPS.
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Materials and Methods
Materials
Polymer KS
Two purified polymer KS samples were supplied by
Seikagaku Co. (Tokyo, Japan). One originated from bovine
cornea (KS-I), and the other, from shark cartilage (KSP).
The ratio of sulfation in these two polymer KS samples was
investigated in comparison with human dried blood spot
(DBS), serum and urine, and rat serum.
Subjects
Blood specimens (plasma/serum) were collected from 58
patients with MPS II (phenotype: severe, 47; attenuated,
11), 35 patients with MPS IVA (phenotype: severe, 32;
undefined, 3), and five patients with MPS IVB (all
attenuated) with informed consent. Urine specimens were
collected from 14 patients with MPS IVA (all severe) and
five patients with MPS IVB (all attenuated) with informed
consent. Information of age and clinical phenotype of each
patient was obtained. Plasma/serum and urine samples were
similarly obtained from 144 and 44 healthy controls,
respectively. The diagnosis of MPS II, MPS IVA, and
MPS IVB was made on the basis of enzyme activity
(iduronate-2-sulfatase, GALNS, and b-gal, respectively)
being less than 5% of levels found in normal plasma,
leukocytes, or fibroblasts. Clinical severity for patients with
MPS IVAwas classified based on patient age and height, as
described previously (Montaño et al. 2008; Tomatsu et al.
2012b). The phenotype of patients with MPS IVB was
determined using the same classification. Clinical severity
for patients with MPS II was classified based according to
CNS involvement (Rozdzynska et al. 2011). In previous
experiments by LC-MS/MS, we confirmed that there is no
difference of GAG value in specificity and sensitivity
between plasma and serum (Oguma et al. 2007a, b;
Tomatsu et al. 2010b, c).
Enzymes and Standard
Keratanase II from Seikagaku Co. was used to digest
“polymer” KS to disaccharides. Keratanase II can digest
polymers that contain either mono-sulfated KS, Galb1 ! 4
GlcNAc(6S), or di-sulfated KS, Gal(6S)b1 ! 4GlcNAc
(6S). Gel permeation chromatography (GPC)-HPLC study
showed that 60 % of KS-I was digested with keratanase II
(Tomatsu et al. 2013a, 2014). Di-sulfated KS (L4;
20 mg/ml), polymer KS (20 mg/ml), and chondrosine for
internal standard (IS) (1 mg/ml) supplied by Seikagaku Co.
were prepared separately in ddH2O. Standard working
solutions of KS-I (0.1, 0.2, 1.0, 2.0, and 10.0 mg/ml) and
IS solution (5 mg/ml) were prepared.
Keratanase II produced in Seikagaku Co. will be
available upon request.
Methods
Sample Preparation
Plasma/serum, urine specimens, and standards were
prepared as follows: Ten micro liter of each plasma/serum
and urine sample and 90 ml of 50 mM Tris–hydrochloric
acid buffer (pH 7.0) were placed in wells of AcroPrep™
Advance 96-Well Filter Plates that have Ultrafiltration
Omega 10 K membrane filters (PALL Corporation, NY,
USA). The filter plates were placed on the receiver and
centrifuged at 2,000 g for 15 min to remove free
disaccharides. The membrane plates were transferred to a
fresh receiver plate. Standards were added to unused wells
of the filter plate. Ten micro liter of IS solution (5 mg/ml),
80 ml of 50 mM Tris–hydrochloric acid buffer (pH 7.0), and
10 ml of keratanase II (2 mU per sample) were added to
each filter well. The plate was incubated in a water bath at
37C for 15 h and centrifuged at 2,000 g for 15 min. The
receiver plate containing disaccharides was stored at 20C
until injection to LC-MS/MS.
Apparatus
The chromatographic system consisted of 1260 Infinity
Degasser, binary pump, auto-injector, thermostatted column
compartment, and 1290 Infinity Thermostat (Agilent
Technologies, Palo Alto, CA, USA) and a Hypercarb
column (2.0 mm i.d. 50 mm, 5 mm, Thermo Electron,
USA). The column temperature was kept at 60C. The
mobile phase was a gradient elution from 0.025%
ammonia to 90% acetonitrile in 0.025% ammonia. The
gradient condition was programmed as follows: The initial
composition of 0% acetonitrile was kept for 0.1 min,
linearly modified to 30% over 1.8 min, maintained at 30%
for 0.3 min, returned to 0% over 0.01 min, and finally
maintained at 0% for 2.5 min. The flow rate was 0.6 ml/min.
The 6460 Triple Quad mass spectrometer (Agilent
Technologies) was operated in the negative ion detection
mode with thermal gradient focusing electrospray
ionization (Agilent Jet Stream technology, AJS). The
parameters of Jet Stream technology were as follows:
drying gas temperature, 350C; drying gas flow, 11 l/min;
nebulizer pressure, 35 psi; sheath gas temperature, 400C;
sheath gas flow, 11 l/min; capillary voltage, 4,000 V; and
nozzle voltage, 2,000 V. A m/z 462 precursor ion and m/z
97 product ion were used to detect and quantify the mono-
sulfated KS, and a m/z 542 precursor ion and m/z 462
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product ion were used to detect and quantify the di-sulfated
KS (Zhang et al. 2005). A m/z 354.29 precursor ion and m/z
193.1 product ion were used to detect the IS. Peak areas for
all components were integrated automatically using QQQ
Quantitative Analysis software (Agilent Technologies), and
peak area ratios (area of analytes/area of IS) were plotted
against concentration by weighted linear regression. Raw
data of LC-MS/MS were automatically preserved. The
concentration of each disaccharide was calculated using
QQQ Quantitative Analysis software. The data of urine
samples were corrected by creatinine (Cre) levels with
Creatinine (urinary) Colorimetric Assay Kit (Cayman
Chem. MI, USA).
Method Validation
The recoveries of analytes were determined by adding
di-sulfated KS to control serum, comparing the control
serum without standard di-sulfated KS. Intraday precision
evaluated as coefficient of variation (CV) was determined
by replicate analyses (n ¼ 5) of three different control
specimens (serum, plasma, and urine). Interday precision
was determined by replicate analyses (n ¼ 5) of three
different serum specimens (serum, plasma, and urine) on
three separate days.
The selectivity of the assay was investigated by
processing and analyzing five independent samples by the
procedure described above without enzymatic digestion.
Calibration curves were constructed by plotting the peak
area ratio of the analytes to IS against the concentration of
the analytes. Each calibration curve consisted of seven
calibration points.
Statistical Analysis
Patients were grouped by age as follows: 0 to <3years
(years), 3 to <5 years, 5 to <10 years, 10 to <15 years, 15
to <20 years, and 20 years and above. Mono-sulfated and
di-sulfated KS value (mg/ml) as well as proportion of
di-sulfated KS in serum/plasma and urine was summarized
by age groups and patient groups (control, MPS II, MPS
IVA, and MPS IVB). Data were summarized using mean
and standard deviation (SD). Age-adjusted standardized
values of mono-sulfated and di-sulfated KS were calculated
for MPS IVA patients. Corresponding concentration of
control subjects was used as a reference for standardization.
Specifically, for the age-matched group, standardized
mono-sulfated KS of MPS IVA patients ¼ (mono-sulfated
KS for patients in the age-matched group of MPS IVA –
mean mono-sulfated KS for control subjects in the age-
matched group)/(SD of mono-sulfated KS for control
subjects in the age-matched group). The mean age-adjusted
standardized mono- and di-sulfated KS of MPS IVA
patients was compared using t-test. In addition, numbers
and percentages of MPS IVA patients with mono- and
di-sulfated KS levels in serum/plasma and urine more than
2 and 3 SD above the mean of age-matched controls were
estimated. Chi-square test and logistic regression analysis
were performed to compare the proportion of MPS IVA
patients with mono- and di-sulfated KS more than 2 and 3
SD above the mean of age-matched controls. The odds ratio
(OR) and p value are presented. Test and model
assumptions were checked before statistical analyses. All
tests were two-tailed at the level of significance of 0.05.
Analysis was performed using SPSS for Windows (version
22.0, IBM, Chicago, IL, USA).
Results
Sulfation Pattern of KS
The peak of di-sulfated KS eluted at 3.22 min and was
clearly detected by MRM conditions of m/z 542 of the
precursor ion and m/z 462 of product ion (Fig. 1a). It was
also detected by multiple reaction monitoring (MRM)
conditions of m/z 462 of the precursor ion and m/z 97 of
product ion, presumably due to loss of sulfate in the
fragmentor. After digestion of KS-I (bovine cornea) by
keratanase II, a major peak of mono-sulfated KS (m/z 462
precursor, m/z 97 product) eluted at 3.06 min, and a minor
peak of di-sulfated KS eluted at 3.22 min (Fig. 1b). After
digestion of KPS (shark cartilage), only the di-sulfated KS
peak was observed (Fig. 1c). These sulfation patterns of
KS-I and KSP were confirmed by using GPC-HPLC. GPC
analysis also showed that the proportion of di-sulfated KS
vs. mono-sulfated KS in KS-I was 42% vs. 58 , while KPS
contained nearly 100% of di-sulfated KS (data not shown).
Thus, the results by LC-MS/MS were consistent with those
by GPC-HPLC.
In human serum specimens from normal control subjects
digested by keratanase II, two peaks corresponding to
mono- and di-sulfated KS were observed (Fig. 1d). The
ratio of forms of sulfated KS was similar to that in bovine
cornea. Serum sample from control rat showed a different
pattern compared to human serum sample. Total level of
KS in rat serum was much lower than that in human serum
and the major form was di-sulfated KS (Fig. 1e). A human
urine sample also showed the presence of mono- and
di-sulfated KS with a higher proportion of di-sulfated KS
than seen in human serum (Fig. 1f). In human DBS, two
peaks corresponding to mono- and di-sulfated KS were
detected, and the ratio of forms of sulfated KS was similar
to that in human serum (Fig. 1g). These findings suggest
that the sulfation pattern of KS depends on the tissue,
species, and specimen analyzed.
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Calibration Curves
Calibration curves for both of mono- and di-sulfated KS
obtained on five separate days were linear over the
concentration ranges of 0.1–10 mg/ml. The correlation
coefficients (r) were not less than 0.99.
Precision and Accuracy
The mean recoveries of di-sulfated KS in control serum
were 91.2% and 101.5% at concentration of 5.0 and
2.5 mg/ml, respectively. Mean recoveries of mono-sulfated
KS in control serum are more than 87% at concentrations
of 5.0 and 2.5 mg/ml (Oguma et al. 2007a, b). Results of
intra- and inter-assay precision for mono- and di-sulfated
KS in control serum are as follows: The intra-assay
precision values/coefficient of variation (CV) determined
from the analysis of mono- and di-sulfated KS are less than
6.8 and 14.6% in serum, 5.1 and 9.4% in plasma, and 14.1
and 12.9% in urine, respectively. The inter-assay precision
values/CVs for these disaccharides are less than 6.5 and
14.3% in serum, 6.7 and 8.2% in plasma, and 12.3 and
15.8% in urine, respectively. These results demonstrate the
reproducibility and accuracy of the method.
Analysis of Mono- and Di-sulfated KS
Blood Mono-sulfated KS: Galb1 ! 4GlcNAc(6S)
The mono-sulfated KS values for the plasma/serum samples
from 58 MPS II patients (average age 11.5, range 2–35
years), 35 MPS IVA patients (average age 15.9 years, range
3.4–56 years), 5 MPS IVB patients (average age 15.8 years,
range 12.7–18.3 years), and 144 control subjects (average
age 5.1 years, range 0–80 years) are described in Table 1
and Fig. 2a. In the control subjects, levels of mono-sulfated
KS were relatively constant (approx. 3.0 mg/ml) up to the
age of 10 years, after which they steadily declined before
a
b
c
d
e
f
Di-sulfated KS
Mono-sulfated KS
Di-sulfated KS
Di-sulfated KS
Mono-sulfated KS
Di-sulfated KS
Mono-sulfated KS Di-sulfated KS
Mono-sulfated KS
Di-sulfated KS
Mono-sulfated KS
Di-sulfated KS
g
Fig. 1 Chromatogram for KS after digestion of keratanase II. (a) Di-
sulfated KS standard. (b) KS-I: bovine cornea. (c) KSP: shark
cartilage. (d) Human serum. (e) Rat serum. (f) Human urine. (g)
Human dried blood spot (DBS). Blue line showed the MRM condition
as m/z 462 precursor ion and m/z 97 product ion, which detected both
mono- and di-sulfated KS. Red line showed the MRM condition as m/
z 542 precursor ion and m/z 462 product ion, which detected di-
sulfated KS only
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stabilizing in late teenage years to less than 1.5 mg/ml
(Table 1). By contrast, levels of mono-sulfated KS in the
blood of patients with MPS IVA were higher than those in
age-matched control subjects (Table 1, Fig. 2a). There was
not a clear separation of mono-sulfated KS levels between
control subjects and patients with MPS IVA (Fig. 2a).
The levels of mono-sulfated KS were also compared
between patients with MPS II and IVB and age-matched
controls (Table 1, Fig. 2a). In the patients with MPS II, no
differences were seen between attenuated and severe
phenotypes in mono-sulfated KS. Fifty-four out of 58
(93%) and 43 out of 58 (74%) patients with MPS II had
plasma/serum mono-sulfated KS levels more than 2 SD and
3 SD above the mean of age-matched controls, respectively
(Table 1). Three out of five (60%) patients with MPS IVB
had plasma/serum mono-sulfated KS levels more than 2 SD
above the mean of age-matched controls (Table 1).
Blood Di-sulfated KS: Galb1(6S) ! 4GlcNAc(6S)
Plasma/serum di-sulfated KS values in patients with MPS
II, IVA, and IVB and the control subjects are shown in
Table 1 and Fig. 2b. Levels of di-sulfated KS in the blood
from control subjects were also age dependent, similar to
that seen for mono-sulfated KS. Di-sulfated KS concentra-
tion stayed relatively constant until 15 years of age (approx.
1.5 mg/ml) and then gradually decreased to 0.9 mg/ml in
adults (Table 1). The levels of di-sulfated KS in the blood
of patients with MPS IVA were significantly higher than
those in age-matched control subjects (Table 1, Fig. 2b).
Twenty-four out of 35 (69%) and 31 out of 35 (89%)
patients with MPS IVA had mono- and di-sulfated KS
levels in the blood more than 2 SD above the mean of age-
matched controls, respectively. The proportion for di-
sulfated KS is significantly higher than for mono-sulfated
KS (p ¼ 0.041). The likelihood of having di-sulfated KS
levels more than 2SD above the mean of age-matched
controls is significantly higher than that of having mono-
sulfated KS levels in MPS IVA patients, OR ¼ 3.63,
p ¼ 0.048. Eighteen out of 35 (51%) and 28 out of 35
(80%) patients had mono- and di-sulfated KS levels in the
blood more than 3 SD above the mean of age-matched
controls. Similarly, the proportion of MPS IVA patients
with di-sulfated KS levels more than 3 SD above the mean
age-matched control was significantly higher than that with
mono-sulfated KS levels, OR ¼ 3.78, p ¼ 0.01. These
Table 1 Levels of blood mono- and di-sulfated KS, and proportion of blood di-sulfated KS in total KS of patients with MPS and control subjects
Age Control MPS II MPS IV A MPS IVB
Mano-sulfated KS (mg/ml)
0–2.9 3.80  0.82 (n ¼ 83) 5.5 (n ¼ 1)
3–4.9 3.91  0.92 (n ¼ 19) 6.34  1.42 (n ¼ 6)*** 4.17  1.39 (n ¼ 2)
5–9.9 3.55  0.59 (n ¼ 22) 7.11  2.38 (n ¼ 23)*** 4.93  0.83 (n ¼ 10)***
10–14.9 2.22  0.53 (n ¼ 12) 5.79  2.1 (n ¼ 13)*** 4.16  1.22 (n ¼ 9)*** 3.82  0.20 (n ¼ 2)
15–19.9 1.80  0.64 (n ¼ 4) 4.32  1.46 (n ¼ 7)* 3.93  1.07 (n ¼ 8)** 2.98  1.67 (n ¼ 3)
20- 1.26  0.23 (n ¼ 4) 3.47  1.69 (n ¼ 8)* 2.04  0.63 (n ¼ 3)*
Di-sulfated (mg/ml)
0–2.9 1.33  0.34 (n ¼ 83) 2.69 (n ¼ 1)
3–4.9 1.56  (– ¼ 19) 2.85  1.08 (n ¼ 6)*** 2.46  1.30 (n ¼ 2)
5–9.9 1.57  0.29 (n ¼ 22) 4.05  1.66 (n ¼ 23)*** 3.08  0.70 (n ¼ 10)***
10–14.9 1.20  0.32 (n ¼ 12) 3.47  1.19 (n ¼ 13)*** 2.99  0.90 (n ¼ 9)*** 2.32  0.48 (n ¼ 2)
15–19.9 1.01  0.31 (n ¼ 4) 2.71  0.81 (n ¼ 7)** 2.30  0.50 (n ¼ 8)*** 1.66  1.22 (n ¼ 3)
Proportion of blood di-sulfated KS in total KS (%)
0–2.9 25.9  2.7 (n ¼ 83) 32.8 (n ¼ 1)
3–4.9 28.6  3.3 (n ¼ 19) 30.4  4.1 (n ¼ 6) 36.2  5.0 (n ¼ 2)
5–9.9 30.6  2.3 (n ¼ 22) 35.8  3.0 (n ¼ 23)*** 38.3  4.2 (n ¼ 10)*** 37.6  3.7 (n ¼ 2)
10–14.9 35.2  4.5 (n ¼ 12) 37.6  3.6 (n ¼ 13) 39.1  2.8 (n ¼ 9)* 37.6  3.7 (n ¼ 2)
15–19.9 36.1  2.6 (n ¼ 4) 39.0  2.5 (n ¼ 7) 37.1  4.1 (n ¼ 8) 34.4  5.3 (n ¼ 3)
20– 42.0  1.1 (n ¼ 4) 41.0  3.6 (n ¼ 8) 41.6  8.1 (n ¼ 3)
Proportion is calculated as di-sulfated KS/total KS  100 (%)
Data represent the mean  SD values
*, ** and ***; significantly different from the control at p < 0.05, 0.01, and 0.001, respectively
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findings indicate that di-sulfated KS is a better indicator
than mono-sulfated KS to distinguish between MPS IVA
patients and age-matched controls (cutoff 2 SD,
p ¼ 0.0002; 3 SD, p ¼ 0.0003 by chi-square test).
Nevertheless, two MPS IVA patients who had not received
any therapy had blood levels of di-sulfated KS that were
indistinguishable from controls (Fig. 2b).
Patients with MPS IVB had higher levels of plasma/
serum di-sulfated KS than age-matched controls, but
differences were not significant for this small set of patients
(Table 1, Fig 2b). Fifty-four out of 58 MPS II patients
(93%) had di-sulfated KS levels that were more than 2SD
above the mean of age-matched controls (Table 1). The
enzyme defect in MPS II causes accumulation of heparin
sulfate and dermatan sulfate, and consequently elevation of
di-sulfated KS must be an indirect effect.
Correlation Between Mono-sulfated KS and Di-sulfated KS
Levels in the Blood
A strong correlation between levels of mono- and di-
sulfated KS was observed (r2 ¼ 0.7733) for both patients
and controls. We found that the contribution of di-sulfated
KS to total KS increased with age in the controls but was
age independent in MPS IVA patients (Table 1, Fig. 2c).
Thus, the proportion of di-sulfated KS in total KS was more
discriminating in patients up to 15 years of age. The two
patients aged 3.6 and 13.4 who had low levels of di-
sulfated KS also had low levels of mono-sulfated KS, so
they could be distinguished from controls by the ratio of
di-sulfated KS to total KS (Fig. 2c). The fraction of di-
sulfated KS in total KS in the patients with MPS II aged
5–10 years significantly increased compared to age-
matched controls, but there was considerable overlap in
individual values (Table 1, Fig. 2c). Ratio differences
between patients with MPS IVB and controls were not
significant.
Urine Mono-sulfated KS
The mono-sulfated KS values for the urine samples from 14
MPS IVA patients (average age 16.6 years, range 3.6–56
years), 5 MPS IVB patients (average age 15.8 years, range
12.7–18.3 years), and 44 control subjects (average age 5.1
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Fig. 2 Levels of blood mono- and di-sulfated KS and proportion of
blood di-sulfated KS in total KS of patients with MPS and control
subjects. (a) Mono-sulfated KS, (b) Di-sulfated KS, and (c) Proportion
of blood di-sulfated KS in total KS. Results of all specimens from
patients and control subjects were plotted on a semilogarithmic scale
(a, b) and regular scale (c) with respect to age
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years, range 0–54 years) are shown in Table 2 and Fig. 3a.
Levels of mono-sulfated KS in the urine were also age
dependent (Fig. 3a). The level was highest in newborns
(40 mg/mg Cre) and decreased until 15 years of age and
reached a plateau in twenties and older (1.0 mg/mg Cre,
Table 2). The levels of mono-sulfated KS in the urine of
patients with MPS IVAwere significantly higher than those
in age-matched control subjects (Table 2, Fig. 3a). All
patients with MPS IVA had levels of mono-sulfated KS that
were higher than 3 SD above the mean of the age-matched
controls. In contrast to blood samples, levels of urine
mono-sulfated KS in patients with MPS IVB significantly
increased as well, and all of them were more than 3 SD
above the mean of age-matched controls (Table 1, Fig. 3a).
Urine Di-sulfated KS
In the control subjects, levels of urine di-sulfated KS were
relatively constant (approx. 30 mg/mg Cre) up to 10 years
of age and, thereafter, steadily declined to less than
5.0 mg/mg Cre in late teenage years (Table 2). The levels
of urine di-sulfated KS in patients with MPS IVA were
significantly higher than those in age-matched control
subjects (Table 2, Fig. 3b). All patients with MPS IVA
had urine levels of di-sulfated KS that were more than 3 SD
above the mean of the age-matched controls. Levels of
urine di-sulfated KS in patients with MPS IVB significantly
increased, and two out of five patients with MPS IVB were
more than 3 SD above the mean of age-matched controls
(Table 2, Fig. 3b).
Correlation Between Mono-sulfated KS and Di-sulfated KS
Levels in the Urine
There was a strong correlation between mono- and di-
sulfated KS for both patients and controls (r2 ¼ 0.7556).
We found that the contribution of di-sulfated KS to total KS
in the urine was higher than that in the blood and also
increased with age in the controls and was age independent
in MPS IVA patients (Fig. 3c, Table 2). The proportion of
di-sulfated KS in total KS in the patients with MPS IVB
was significantly lower than that in patients with MPS IVA
( p < 0.001) and age-matched control subjects (p < 0.001)
(Fig. 3C, Table 2).
Discussion
In this study, we have demonstrated (1) that the peak of di-
sulfated KS is separated from the mono-sulfated KS as a
pure single peak by the LC column using the m/z 542 di-
sulfated precursor ion and m/z 462 product ion, (2) that the
levels of blood and urine mono-sulfated and di-sulfated KS
in control subjects are age dependent and decline with age,
(3) that blood and urine mono- and di-sulfated KS levels in
patients with MPS IVA are significantly higher than those
Table 2 Levels of urine mono- and di-sulfated KS, and proportion of urine di-sulfated KS in total KS of patients with MPS and control subjects
Age Control MPS IVA MPS IVB
Mono-sulfated KS (mg/mg Cre)
0–29.9 40.36  27.29 (n ¼ 20)
3–9.9 21.56  8.81 (n ¼ 8) 97.24  59.45 (n ¼ 7)**
10–19.9 5.71  1.68 (n ¼ 13) 45.18  26.80 (n ¼ 5)*** 25.41  16.33 (n ¼ 5)**
20– 1.07  0.33 (n ¼ 6) 14.74  2.84 (n ¼ 2)
Di-sulfated KS (mg/mg Cre)
0–2.9 31.35  14.66 (n ¼ 20)
3–9.9 31.01  18.89 (n ¼ 8) 253.06  147.91 (n ¼ 7)**
10–19.9 10.45  2.32 (n ¼ 13) 102.18  58.81 (n ¼ 5)*** 21.02  11.76 (n ¼ 5)*
20– 3.59  1.21 (n ¼ 6) 27.93  8.45 (n ¼ 2)
Proportion of urine di-sulfated KS in total KS %
0–2.9 45.38  8.52 (n ¼ 20)
3–9.9 57.20  11.07 (n ¼ 8) 71.99  3.45 (n ¼ 7)**
10–19.9 64.92  4.74 (n ¼ 13) 69-48  6.16 (n ¼ 5) 46.31  2.86 (n ¼ 5)***
20– 76.77  1.88 (n ¼ 6) 65.12  2.58 (n ¼ 2)
Proportion is calculated as di-sulfated KS/total KS  100 (%)
Data represent the mean  SD values
*, ** and ***; significantly different from the control at p < 0.05, 0.01, and 0.001, respectively
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in age-matched control subjects, (4) that the level of blood
and urine di-sulfated KS distinguishes control subjects and
patients with MPS IVA more clearly than that of mono-
sulfated KS, (5) that the ratio of blood di-sulfated KS to
total KS increases with age and was significantly elevated
in patients with MPS IVA under 15 years of age compared
to control subjects, (6) that levels of mono- and di-sulfated
KS in the urine provide a clear difference between patients
with MPS IVA and MPS IVB and age-matched controls,
and (7) that blood mono- and di-sulfated KS levels are
significantly higher in patients with MPS II than those in
age-matched control subjects. In addition, total KS and
levels of sulfation depend on species and tissues examined.
KS is comprised of repeating sulfated disaccharide units
of Gal and GlcNAc (Galb1-4GlcNAcb1-3). The process of
KS biosynthesis consists of (1) N-acetylglucosaminylation,
(2) 6-sulfation of a GlcNAc residue, and (3) galactosylation.
KS polymers are extended by the action of glycosyltrans-
ferases that alternately attach Gal and GlcNAc residues. KS
is generally sulfated on C (6) of GlcNAc, while the C (6) of
Gal is sulfated to a variable extent, depending on the tissue
and age (Bhavanandan and Meyer 1968).
In previous studies, we identified mono- and di-sulfated
KS using the same MRM condition of m/z 462 precursor
ion and m/z 97 product ion using LC-MS/MS, but the two
forms were not separately quantified completely (Oguma
et al. 2007a, b; Hintze et al. 2011), resulting in an overlap
of the values between mono- and di-sulfated KS. In this
study we detected and quantified the di-sulfated KS using
the m/z 542 precursor ion and m/z 462 product ion which is
specific to di-sulfated KS and confirmed that the peak of di-
sulfated KS is separated from the mono-sulfated KS as a
pure single peak by the LC column. Thus, we have
established more appropriate conditions for detecting
mono- and di-sulfated KS separately compared to the
previous method (Oguma et al. 2007a). We clearly show
that KS in shark cartilage is mostly di-sulfated, while in
bovine cornea mono-sulfated KS is dominant. This finding
is consistent with the fact that KS chains of fibromodulin in
cartilage are highly sulfated compared to that in the cornea
(Lauder et al. 1997; Nieduszynski et al. 1990). Our data
also show that the level of both mono- and di-sulfated KS
in the blood of control subjects decline with age, while the
degree of sulfation (i.e., proportion of di-sulfated KS in
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Fig. 3 Levels of urine mono- and di-sulfated KS and proportion of
blood di-sulfated KS in total KS of patients with MPS and control
subjects. (a) Mono-sulfated KS, (b) Di-sulfated KS, and (c) Proportion
of urine di-sulfated KS in total KS. Results of all specimens from
patients and control subjects were plotted on a semilogarithmic scale
(a, b) and regular scale (c) with respect to age
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total KS) increases with age. Both mono- and di-sulfated
forms of KS are found in the growth plates, articular
cartilage, ECM, cornea, and brain. This age-dependent
alteration of KS level in the plasma/serum can be explained
by decreased KS synthesis after the growth plate is closed.
An increase of sulfation in blood and urine KS is
compatible with that observed in the cartilage and cornea
during normal aging (Liles et al. 2010; Brown et al. 1998).
Gal sulfation levels increase during adolescence and early
adulthood and then remain fairly constant in human
articular cartilage (Brown et al. 1998).
KS is involved in specific biological functions including
tissue hydration, cellular recognition of protein ligands,
axonal guidance, cell motility, and embryo implantation
(Chakravarti et al. 1998; Weyers et al. 2013; Imagama et al.
2011; Funderburgh et al. 1997; Graham et al. 1994). KS has
been implicated in physiological and pathological status:
(1) cushion in joints, (2) glial scar formation in spinal cord
injury, (3) transparency in the cornea, and (4) skeletal
dysplasia in patients with MPS IV. However, the physio-
logical roles and distributions of the individual sulfated KS
and its increased sulfation with age are not fully understood
due to lack of accurate quantitative method to measure
mono- and di-sulfated KS. The current method will
shed light on the implication of physiological roles and
distributions of the individual sulfated KS.
Total KS level in the plasma/serum can be used as a
biomarker for MPS IVA (Tomatsu et al. 2008, 2010c,
2012b, 2013a; Hintze et al. 2011; Martell et al. 2011);
however, there are substantial overlaps of KS values
between control subjects and MPS IVA patients, especially
for patients older than 15 years of age, and consequently
total KS alone is not a good biomarker for MPS IVA
patients of all ages. GALNS, an enzyme involved in the
first step of degradation of polymer KS, hydrolyzes the C
(6) sulfate of Gal from di-sulfated KS, Gal(6S)b1
! 4GlcNAc(6S), to produce mono-sulfated KS, Galb1
! 4GlcNAc(6S). Therefore, as GALNS is deficient in
patients with MPS IVA, di-sulfated KS would be expected
to increase in the plasma/serum more clearly than mono-
sulfated KS, as confirmed in this study. In this study, di-
sulfated KS was found to improve discrimination between
MPS IVA patients and controls compared to total KS and
mono-sulfated KS and consequently may be a better
biomarker for early diagnosis, screening, assessment of
disease severity, and monitoring therapeutic efficacy for
MPS IVA.
Levels of di-sulfated KS do not distinguish all MPS IVA
patients from controls and may be affected by disease
status. Most KS is synthesized in cartilage, and conse-
quently blood KS reflects the amount of KS derived from
cartilage. If cartilage turnover is reduced by prior loss,
reduced activity, or other means, total blood KS could be
lower in MPS IVA patients than in controls. Reduced total
turnover of KS can be controlled in part by measuring the
ratio of di-sulfated KS in total KS. This ratio allowed us to
distinguish the two MPS IVA patients under 20 years of age
who had low levels of di-sulfated KS from controls.
Overall, this study has shown that the level of di-sulfated
KS distinguishes patients with MPS IVA and control
subjects better than that of mono-sulfated KS alone.
It is noteworthy that levels of KS are elevated in the
blood from not only MPS IVA patients but around 90% of
MPS II and other types of MPS patients (Tomatsu et al.
2005; Rowan et al. 2013; current study). The level of KS in
the blood from MPS II patients was as high as that seen in
MPS IVA patients. MPS II is caused by deficiency of
iduronate-2-sulfatase, an enzyme that is not directly
involved in the degradation of polymer KS, and conse-
quently the mechanism of elevation of KS in these patients
must differ from that seen in MPS IVA patients. In contrast
to results from the blood, only 35% of levels of KS in the
urine from MPS II patients were more than 2SD above the
mean of age-matched controls. Several mechanisms have
been proposed to account for a secondary elevation of
blood KS in patients with MPS II and other types of MPS
(Tomatsu et al. 2005): (1) Synthesis of KS could be induced
by inflammation caused by storage of other GAGs. (2)
GALNS activity could be inhibited by the increased
concentrations of heparan sulfate in patients with MPS II
(and some other MPS types) (Rowan et al. 2013). (3) KS
secretion into the circulation could be due to damage of
cartilage and its ECM caused by accumulation of other
GAGs and its subsequent inflammation. It is well known
that the degradation of proteoglycans occurs early in joint
damage and that fragments are released into the synovial
fluid and subsequently the serum (Dingle et al. 1975;
Ratcliffe et al. 1988). Blood KS levels have been associated
with severity of skeletal dysplasia in mouse models of MPS
I, III, IVA, and VII (Rowan et al. 2013). (4) Polymer KS
could be co-deposited with the other accumulated GAGs,
hindering the interaction between KS and its catabolizing
enzymes. (5) Alterations in the extent and distribution of
fucosylation, sialylation, and sulfation on KS could make
KS resistant to degradation (Tai et al. 1994). One or a
combination of these mechanisms could contribute to a
secondary elevation of KS. Regardless of the mechanism,
our data show that KS levels in the blood is a good
biomarker for MPS II and is better at distinguishing MPS II
patients from controls than KS levels in the urine. A larger
study including more patients with MPS II and other types
of MPS will be required to establish age-dependent changes
of KS in these disorders.
We did not see a significant elevation of either sulfated
form of KS in the plasma/serum of patients with MPS IVB.
Patients with MPS IVB have a milder phenotype compared
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with those in MPS IVA, so lower levels of secretion of KS
would be expected. The proportion of di-sulfated KS in
patients with MPS IVB is not as high as that seen in MPS
IVA. There were only 5 MPS IVB patients in this study,
and none have severe disease and none were younger than
12 years of age. Further studies including younger and
severe-type patients with MPS IVB are required to
determine the significance of sulfation levels of KS for this
disorder.
Urine mono- and di-sulfated KS showed an age-
dependent decline, similar to that seen for sulfated KS in
the plasma/serum. Elevation of total urine KS in patients
with MPS IVA has been reported (Tomatsu et al. 2010c;
Martell et al. 2011). KS in the urine more clearly
distinguishes patients with MPS IVA and MPS IVB from
age-matched controls than levels in the plasma/serum, even
for older patients. All urine samples from the five MPS IVB
patients had a ratio of di-sulfated KS to total KS that is
lower than that in age-matched controls. While deficiency
of GALNS in MPS IVA would be expected to increase the
proportion of di-sulfated KS, deficiency of b-gal in MPS
IVB would not be expected to have any direct effect on
sulfation levels. A larger study with more control subjects
and patients is required to establish di-sulfated KS in the
urine as a biomarker for MPS IVA and MPS IVB and to
determine the mechanism by which sulfation levels are
affected differentially in the plasma/serum and urine of
MPS IVA and IVB patients.
Nevertheless, the proportion of di-sulfated KS in total
KS in urine appears to be a useful biomarker to distinguish
patients with MPS IVA and MPS IVB. Although not tested
in this study, the measurement of mono- and di-sulfated KS
could be potentially useful for monitoring the outcome of
ERT and other therapies for MPS IVA.
Conclusions
In conclusion, we have developed a method to evaluate
mono- and di-sulfated KS levels in a variety of specimens
by LC-MS/MS systems, leading to understanding of
species-specific and/or tissue-specific KS level and its
sulfation level, and the age-dependent alteration of KS
and its sulfation level. Significant difference in sulfation
levels of KS between control subjects and patients with
MPS IVA demonstrates that the di-sulfated KS is a potential
biomarker for this disease.
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Highlights
• Sulfation level of KS varies with age and species.
• Importance of level of di-sulfated KS and ratio of KS
sulfation.
• Di-sulfated KS can be used as a biomarker for several
types of MPS.
• Level of blood KS is age dependent and species
dependent.
• The reader will understand the importance of a new
biomarker for MPS II, IVA, and IVB.
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Abstract Introduction: Nearly all children in Canada with
an inherited metabolic disease (IMD) are treated at one of
the country’s Hereditary Metabolic Disease Treatment
Centres. We sought to understand the system of care for
paediatric IMD patients in Canada in order to identify
sources of variation and inform future research priorities.
Methods: Treatment centres were contacted by email and
invited to complete a web-based survey. The questionnaire
addressed, for each centre, the population size served and
scope of practice, available human resources and clinic
services and research capacity. Survey responses were
analyzed descriptively.
Results: We received responses from 13 of the 14
treatment centres invited to participate. These centres
represent at least 85% of the Canadian population, with
over half of the centres located in southern Ontario and
Quebec. All centres reported paediatric patients with IMDs
as their main patient population. A variety of dedicated staff
was identified; every centre reported having at least one
physician and one dietician. The most common ancillary
services available included telehealth (11/12 respondents)
and biochemical genetic laboratory testing (10/12), with a
high variability of access to on-site laboratory tests. A
majority of centres indicated access to additional off-site
services, but barriers to these were reported. All but one
centre indicated previous experience with research.
Conclusions: The variation we identified in the organi-
zation of care highlights the need to investigate the
association between practice differences and health out-
comes for paediatric IMD patients to inform policies that
establish equitable access to services that are beneficial.
Introduction
Although individually rare, collectively, inherited metabolic
diseases (IMDs) represent a substantial population health
burden in Canada and internationally. Studies have estimated
the Canadian birth prevalence for diagnosed IMDs to be from
1 in 2,500 to 1 in 1,900 (Applegarth et al. 2000; Auray-Blais
et al. 2007). The currently observed Canada-wide preva-
lence of all IMDs is likely somewhat higher than both these
estimates, due to a number of factors including improved
identification strategies such as expanded newborn screen-
ing (Schulze et al. 2003; Wilcken et al. 2003), improved
diagnostic services and awareness of less recognized
conditions, longer survival for IMD patients due to newly
developed therapies and immigration of populations at
higher risk of particular IMDs.
The majority of health care in Canada is publically
funded to provide care to all based on need rather than
ability to pay (Health Canada 2011). Public health
insurance programmes in all provinces and territories cover
both primary and secondary physician and hospital care,
with limited coverage for allied health services outside of
hospitals (Health Canada 2011). Coverage for pharmaceut-
icals and other products relevant to IMD, such as medical
foods or supplements, varies amongst provinces and
territories (Health Canada 2011). Nearly all children in
Canada diagnosed with an IMD receive specialized care at
one of 16 Hereditary Metabolic Disease Treatment Centres.
At these centres, paediatric IMD patients have access to
specialist physicians and services to manage diagnosis,
treatment and follow-up care.
The goal of this study was to provide a broad overview
of the organization of specialized care for IMD children in
Canada, in order to identify areas of practice variation and
inform priorities for future research examining how service
provision affects outcomes. We invited Canadian Heredi-
tary Metabolic Disease Treatment Centres to complete a
survey to:
1. Describe their centre’s scope of practice, in terms of the
population and types of patients served
2. Identify the human resources available and the specific
clinical services offered or to which they have access
3. Describe their research capacity
Methods
Sample Selection and Survey Implementation
The recently established Canadian Inherited Metabolic
Diseases Research Network (CIMDRN) is a practice-based
research network that aims to inform care and ultimately to
improve outcomes for children with IMD in Canada and
beyond (Potter et al. 2013). Fourteen of the 16 Canadian
Hereditary Metabolic Treatment Centres form the practices
in this research network. By email, we invited one
metabolic physician at each of these 14 centres to
participate in the survey. Physicians were asked to seek
assistance from other knowledgeable staff at the centre as
needed. The survey was administered online, between
January and March 2013 using FluidSurveys (www.fluid-
surveys.com), a secure online questionnaire tool. Ethics
approval was obtained from The Children’s Hospital of
Eastern Ontario Research Ethics Board.
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Questionnaire Content and Data Analysis
Survey questions were divided into three categories:
1. Scope of practice (patient populations)
2. Human resources and clinic services
3. Research capacity
The questionnaire required approximately 30 minutes to
complete. We used Microsoft Excel (2011) to conduct
descriptive analysis, reporting relevant means and propor-
tions.
Results
Scope of Practice
Of the 14 centres invited to participate in the survey, we
received completed surveys from 13 (response rate of
93%). These 13 centres care for the majority of IMD
children in all ten provinces and three territories in Canada,
serving geographic catchments with populations of 500,000
to over six million and representing at least 85% of the
Canadian population (Fig. 1). Over half of the participating
centres are located in southern Ontario and Quebec (Fig. 1).
Five centres were classified as large clinics serving
populations of over two million, four centres were
considered mid-sized serving >1–2 million people and
the remaining four were classified as small serving one
million or fewer people.
All centres reported their main patient population as
IMD patients; phenylketonuria (PKU) was the most
common diagnosis. Some clinics also reported providing
services to patients with non-IMD conditions (e.g. neuro-
logic disorders, autism, other genetic diseases). All centres
reported at least 20 paediatric IMD patients currently in
their care; six centres (46%) reported having over 100
paediatric IMD patients. Eight respondents indicated a
second clinic in their catchment area providing some
diagnostic or treatment services to IMD patients; these
were mainly neurology clinics or adult care facilities and a
specific clinic in New Brunswick for PKU patients. Four
(31%) centres reported a separate adult clinic in the same
catchment area to help manage the transition from
paediatric to adult care; 12/13 centres reported having adult
(>18 years old) IMD patients under their care, including
pregnant women.
Human Resources and Clinic Services
All participating centres reported at least one physician and
one registered dietician on staff. Other staff identified
included nurses, genetic counsellors, pharmacists, psychol-
ogists, social workers, administrative assistants and
research coordinators (Fig. 2a). Number of staff varied
across centres (Fig. 2b), and as expected, larger centres
reported more staffing resources. Roles for staff members
included clinical, administrative, teaching and research
responsibilities. Physicians, nurses, dieticians and genetic
counsellors are most heavily involved in primary patient
contact, initial consultations and case coordination, with
some contributions from social workers and psychologists.
77% (10/13) of centres reported that they use an inter-
professional model of care for their patients. We defined
‘inter-professional care’ in the questionnaire as an
integrated approach to health-care delivery in which the
collaboration amongst practitioners of different disciplines
or with different skills and knowledge allows for the
delivery of patient health care by the most appropriate
health-care practitioner.
The most common ancillary services provided by the
centres (i.e. in addition to direct patient care) were
telehealth (11/12 centres who responded to these ques-
tions), biochemical genetic laboratory testing (10/12), a
specialized pharmacy (8/12) and a dispensary for medical
foods/supplements (8/12). Patient/family workshops (7/12)
and patient/family support groups (6/12) were also
provided by some centres. Over 80% of the centres reported
access to other services for patients and families, either
within or outside the clinic. These services included
additional prenatal genetic diagnostic care (11/13 centres),
genetic counselling (10/12) and social work (11/13). When
asked about barriers to patients’ access to services, several
centres reported challenges associated with access to nutri-
tional services (e.g. feeding devices, parenteral nutrition)
and psychological services, mainly due to long wait lists
and/or being located off-site. There was high variability
amongst the 12 centres that reported on the availability of
specific on-site laboratory tests (Table 1). The tests most
commonly available were urinalyses for organic acids and
plasma/urine amino acid analyses (92% of centres).
Research Capacity
Twelve of the 13 responding centres (92%) indicated
previous involvement with research including industry-
funded trials (11/12 centres), survey or interview-based
studies (9/12), diagnostic studies (8/12), retrospective
studies using chart abstraction (7/12) and nonindustry-
funded trials (5/12). Staff responsibilities specific to
research were highly variable, but involvement
included physicians, nurses, dieticians, genetic counsellors,
administrative assistants and research coordinators. Impor-
tant reasons for participating in research included: contri-
buting to the improvement of care for IMD patients
(100%), contributing to the scientific understanding of
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IMDs (100%) and building professional and inter-centre
relationships (92%). Centres expressed barriers to involve-
ment in research related to workload (100%) and concerns
about research sustainability due to limited funds (85%).
Discussion
Summary and Interpretation
We found important variation in the organization of care in
Canada for paediatric IMD patients. Variation in IMD
management has been noted in other jurisdictions (Leonard
2006), and although the results of our survey are from
Canadian clinics, there is much that could be pertinent to
health care for IMDs internationally. Specifically, the
variation we identified highlights the need for evaluative
evidence to better understand whether these differences in
care are associated with differences in patient outcomes and
provides an opportunity to generate that evidence using
observational study designs that capitalize on practice varia-
tion as ‘natural experiments’ (Horn and Gassaway 2007).
Our survey results demonstrate variation in human
resources and services available at Canadian IMD treatment
centres. This variation in clinical infrastructure may reflect
clinical heterogeneity in the complex needs of patients with
different types of IMDs, including the needs of specific
high-risk populations at some of the centres (e.g. First
Nations or founder populations, immigrant communities).
Further research is needed to determine a more specific
Fig. 1 Population density map of Canada using the most recent
census data (Statistics Canada 2011) indicating the location of all 16
Hereditary Metabolic Disease Treatment Centres. Centres participating
in CIMDRN are indicated in yellow. Centres highlighted in green
were not part of CIMDRN at the time of data collection. Survey data
was collected from January–March 2013
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profile of IMD patients across centres; precise patient
numbers for these rare diagnoses are challenging to
estimate accurately, as is the distribution of patients by
age, ethnic background, disease severity and presence of
co-morbidities. Alternatively, differences may reflect differ-
ences in provincial/territorial health service organization
and prioritization.
Similar to trends in both the United States and the
United Kingdom, we also found that many adult IMD
patients in Canada are being treated in paediatric centres
(Burton et al. 2006; Berry et al. 2013). Consideration of the
transition from paediatric to adult health care is a current
priority as new therapies make it possible for greater
numbers of IMD patients to survive into adulthood
(Dionisi-Vici et al. 2002; Lee 2002; M€utze et al. 2011).
There is growing evidence that suggests it is beneficial for
centres to establish transition protocols and, depending on
the volume of patients in a centre, separate clinics for adult
patients (Lee 2002; M€utze et al. 2011; Sirrs et al. 2014).
Not surprisingly, centres that serve a larger population
have more resources. However, what is not known is the
ratio of resources to patients at the centres, whether the
organization of resources at the centres is effective or not
and how these factors are linked to clinical and patient-
centred outcomes. There is also limited evidence regarding
the value of allied health services for particular IMD
populations, such as psychology and occupational therapy.
Similar to our study findings, barriers to these services have
been reported elsewhere (Camfield et al. 2004; Berry et al.
2013). Research to answer these questions is necessary to
determine what resources and services should be offered at
each centre to optimize health outcomes.
Staff Position Full-time Equivalent (FTE) Staff
Median Minimum Maximum
Physician 1 0.3 4.5
Nurse 0.5 0 3
Dietician 1 0.2 2.8
Genetic Counsellor 0.1 0 2
Psychologist 0 0 0.5
Social Worker 0.1 0 1
Pharmacist 0 0 0.2
Administrative Assistant 0.6 0 3
Research Coordinator 0 0 3
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Fig. 2 (a) Proportion of IMD centres (n ¼ 13) reporting staff position at their centre and (b) median number of full-time equivalent staff for
participating IMD centres (n ¼ 13), indicating minimum and maximum values
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In addition to availability, access is another concern.
Although the location of the treatment centres is propor-
tionate to the geographic distribution of the Canadian
population, as well as the birth prevalence of IMDs,
patients living in more northern or remote areas have to
travel a considerable distance for specialized metabolic
care. Further research is needed to determine ascertainment
of IMD patients in remote areas and how clinical and
patient-centred outcomes are affected by having limited
geographic access to services. There were several centres
with only one dedicated IMD physician. This may pose
problems with access to care for IMD patients outside
regular hours. Although our survey was not able to delve
into this issue in detail, it is an important consideration for
further study. Services such as laboratory testing can be
accessed elsewhere; however, turnaround time, costs and
quality assurance are important to consider. All centres
must send out samples for some metabolic and/or genetic
testing as not even the largest centres are able to perform all
relevant testing, thus adding another source of variation
amongst centres which could potentially impact on care
delivery. This issue also raises the question of whether
some services can be effectively delivered in patients’ home
communities rather than at a distant metabolic clinic.
Although Canada has established centres to provide care
for IMD patients, the variation in clinical infrastructures we
identified reflects the lack of a central mechanism to guide
minimum care standards. This is further exemplified with
the lack of a national strategy for newborn screening. In
Canada, newborn screening programmes are unique to each
province and territory, differing in the panel of disorders
screened, technologies used, follow-up processes, legal
structures and governance (Therrel and Adams 2007;
Wilson et al. 2010; Morrison and Dowler 2011). Canada
also lacks a national metabolic laboratory network that
could set standards and provide coordination for
biochemical genetic laboratory tests, on which IMD
patients rely for diagnosis, monitoring and informing
treatment (Burton et al. 2006; Leonard 2006; Leonard and
Morris 2006). Reimbursement decisions for drug funding
also differ across the provinces and territories. Health
Canada recently announced the development of a Canadian
orphan drug framework intended to provide Canadians with
better, timelier access to orphan drugs and to encourage and
facilitate clinical research in the area of rare diseases
(Lee and Wong 2014). Once practice-based research studies
have determined what aspects of the system of care have
the greatest impact on health outcomes for IMD patients, a
mechanism to implement research findings nationally will
be critical.
In conclusion, although the majority of Canadian
paediatric IMD patients are receiving care from one of the
Hereditary Metabolic Disease Treatment Centres, the
specific resources and services available vary greatly across
the country. This variation in the organization of care for
IMDs across Canada presents a unique opportunity for
observational practice-based research to determine whether
patterns of care are associated with clinically significant
differences in patient outcomes.
Limitations
Despite a high response rate (93%), our study was limited
by the small number of responding centres (n ¼ 13),
because of the small number of IMD treatment centres in
Canada. Nevertheless, the geographic catchments served by
the responding centres support the representativeness of our
sample. The three ‘missing’ centres would likely add
further variation to that found amongst the surveyed
centres. Survey questions were broad to account for
variability amongst clinics; however, some important
details may have been missed that could help explain some
of the observed variation in services.
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Abstract Maternal phenylketonuria (MPKU) is a well-
recognized complication of PKU and one of the most
potent teratogenic syndromes of pregnancy. Virtually all
offspring from untreated pregnancies in women with classic
PKU have intellectual disabilities and microcephaly. Con-
genital heart disease and intrauterine growth retardation
occur many times more often than expected in the general
population. Control of maternal blood phenylalanine during
pregnancy prevents most if not all of these complications.
Previous studies demonstrated the benefits of treatment in
terms of birth parameters and early development. In this
study, physical examinations, a medical history, and
neuropsychological evaluation were obtained in 47 children
from 24 mothers with PKU who received treatment during
pregnancy. Mothers were interviewed and administered an
abbreviated IQ test. Associations between maternal factors
and offspring outcomes were also analyzed.
The 21 male and 26 female offspring ranged in age from
1 month to 26 years with 21 (62%) over 6 years. Results
indicated mean intercanthal distances above the 70th
percentile. Microcephaly was present in 19% of offspring,
with head circumference below the third percentile. None of
the offspring had cardiac anomalies. Mean offspring IQ was
94  19, with 12% performing in the range of intellectual
disability (IQ < 70). Among children >5 years of age, 25%
had learning disabilities, 31% had attention deficit hyperac-
tivity disorder (ADHD), 22% were on ADHD medication,
and 34% had a diagnosis of anxiety and/or depression.
Among the 24 mothers, 12 reported following the diet for
PKU. Only one woman on diet had a blood phenylalanine
concentration <360 mmol/L (recommended range) and the
majority had indications of poor nutritional status. Mean
maternal Full Scale IQ was 94  16 (range ¼ 61–117),
with 25% performing in the borderline intellectual range
(IQ < 85). Verbal IQ was significantly lower than Perfor-
mance IQ (p ¼ 0.01, CI 2.7, 16.1). On the self-report Beck
Depression Inventory, Second Edition, 25% received scores
indicating mild to moderate depression, and on the Beck
Anxiety Inventory, 46% reported mild to moderate anxiety.
Offspring IQ correlated with maternal metabolic control
during pregnancy (r ¼ 0.51), maternal IQ (r ¼ 0.62), and
socioeconomic position (r ¼ 0.48). Offspring with
ADHD, learning disabilities, or emotional disturbances
were more likely to have mothers with anxiety and/or
depression. To ensure optimal offspring outcomes, health-
care providers need to assess maternal nutrition, blood
phenylalanine concentrations, cognitive abilities, and socio-
economic position. Interventions can then be initiated that
reduce psychosocial stressors and enhance adherence to diet
and positive parenting, which in turn can lead to better
cognitive functioning, behavior, and emotional well-being
in their children.
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Introduction
Maternal phenylketonuria (MPKU) is a well-recognized
complication of PKU and one of the most potent terato-
genic syndromes of pregnancy. Virtually all offspring from
untreated pregnancies in women with severe PKU have
intellectual disabilities and microcephaly. Congenital heart
disease and intrauterine growth retardation occur many
times more often than expected in the general population
(Lenke and Levy 1980). The frequencies of these abnor-
malities in offspring are lower when the woman has a
milder form of PKU but are still much greater than
normally expected (Lenke and Levy 1980; Levy et al.
2003; G€uttler et al. 2003).
Control of the maternal blood phenylalanine during
pregnancy prevents most if not all of these complications
(Lenke and Levy 1980; Rohr et al. 1987; Koch et al. 2003).
The International Maternal PKU Collaborative Study
(MPKUCS), a prospective, longitudinal study, showed that
this was especially true if dietary therapy with control of
maternal phenylalanine began before pregnancy or within
the first 6 weeks of gestation (Koch et al. 2003.) In the
MPKUCS, 228 children who were born to mothers with
treated PKU or untreated mild hyperphenylalaninemia were
compared to 70 control subjects at 7 years of age. Offspring
cognitive outcome negatively correlated with the number of
gestational weeks that elapsed until maternal metabolic
control was achieved (r ¼ 0.61). Behavioral outcome
was similarly affected. Postnatal measurement of stimula-
tion in the home was also related to offspring IQ (Waisbren
and Azen 2003). However, the MPKUCS followed off-
spring only to age 7 years, thus was not able to evaluate
cognitive performance into the more challenging school
years.
The ability of the mother with PKU to provide a secure
and intellectually stimulating environment for her offspring
needs further examination. Poor metabolic control in adults
with PKU is associated with deficits in executive function-
ing, including planning, organization, and behavioral
inhibition as well as fatigue, health problems, depression,
and anxiety (Koch et al. 2010; Brumm et al. 2010), all of
which may limit parenting ability and result in a suboptimal
environment for the offspring.
In this study, we examined offspring, ages 1 month to 26
years, from treated maternal PKU pregnancies and analyzed
associations between maternal factors, including current
adherence to recommendations for treatment, and offspring
outcomes, such as cognitive abilities and emotional/behav-
ioral characteristics.
Methods
Participants
Families with children in which the mother has PKU
requiring dietary treatment (excluding non-PKU mild
hyperphenylalaninemia) were invited to participate in this
study. Classification of degree of PKU in the mothers was
established as set forth by the European multicenter study
(Guldberg et al. 1998) and was based on at least two of the
following indictors: confirmatory or untreated blood phe-
nylalanine level; dietary tolerance for phenylalanine; and
phenylalanine hydroxylase (PAH) genotype. The study was
approved by the institutional review board (IRB) of Boston
Children’s Hospital. The parents and children in each
family were seen in the Clinical and Translational Study
Unit (CTSU) of Boston Children’s Hospital. The mother in
each family as well as all offspring above the age of 6 years
gave informed consent/assent. Nine fathers consented
to having a photo taken for comparison of offspring
physiognomy.
Evaluations
Clinical
A detailed health history was obtained from the mothers
and a health and developmental history was obtained on the
offspring. The mothers and offspring received a general
physical examination as well as a neurologic assessment.
Dysmorphology in offspring was evaluated through meas-
urements of inner and outer canthal distances, interpupillary
distance, lengths of the palpebral fissures, and the lengths
of both ears (Hall et al. 2007). Frontal and side photographs
of the face were obtained on the offspring and, for
comparison, on the mothers and fathers. Parental photo-
graphs allowed for identification of dysmorphic features
associated with maternal PKU and not simply reflective of
familial characteristics.
Nutrition
Mothers were interviewed about their current diets (includ-
ing a questionnaire about the use of medical foods,
avoidance of protein, and other nutrition therapies) and
asked to provide a 24 h diet recall. Laboratory studies
included plasma amino acids, hemoglobin and hematocrit,
prealbumin, 25-hydroxy vitamin D, red blood cell folate,
iron, ferritin, zinc, and vitamin B12. The mother’s
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adherence to diet during pregnancy was assessed by the
review of pregnancy blood phenylalanine results, and
assignment was made into one of three categories: (1)
Excellent: on diet prior to conception, blood phenylalanine
<360 mmol/L throughout pregnancy; (2) Good: on diet
prior to conception, blood phenylalanine <360 mmol/L by
10 weeks gestation; (3) Fair: blood phenylalanine
<600 mmol/L by second trimester; and (4) Poor: on diet
after conception and blood phenylalanine not in control
until the second trimester or after.
Neuropsychological
Mothers were administered the Wechsler Abbreviated Scale
of Intelligence (WASI) (Wechsler 1999). They also com-
pleted self-report measures of adaptive behavior (Adaptive
Behavior Assessment System—Second Edition (ABAS-II))
(Harrison and Oakland 2003), executive functioning
(Behavior Rating Inventory of Executive Functioning
(BRIEF)) (Gioia et al. 2000), anxiety (Beck Anxiety Index
(BAI)) (Beck and Steer 1993), and depression (Beck
Depression Index—Second Edition (BDI-II)) (Beck et al.
1996).
The offspring were administered age-appropriate meas-
ures of intellectual development: Bayley Scales of Infant
and Toddler Development, Third Edition (Bayley 2003), for
children less than 36 months of age; Wechsler Preschool
and Primary Scales of Intelligence, Third Edition (WPPSI-
III) (Wechsler 2002), for ages 4–6 years; and the WASI for
offspring ages 7 years and older. In addition, the offspring
completed the Beery-Buktenica Developmental Test of
Visual Motor Integration, Sixth Edition (VMI) (Beery
et al. 2010), which measures visual-spatial abilities and
fine motor coordination. The mothers rated their children
using age-appropriate forms of the ABAS-II, BRIEF, and a
measure of emotional well-being, Behavior Assessment
System for Children, Second Edition (BASC-II) (Reynolds
and Kamphaus 2003).
Statistical Analyses
We report descriptive statistics for the offspring and mother
characteristics and outcomes, including mean and standard
deviation or median and range as appropriate. Two-group
comparisons of continuous variables use the Wilcoxon
rank-sum test of median values, and comparisons of
categorical variables use Fisher’s exact test. For distribu-
tional reasons, we report Spearman’s correlation coeffi-
cients for rank associations of continuous variables.
Because of multiple child observations per mother, we use
a Monte Carlo bootstrap approach with 10,000 iterations to
calculate 95% confidence intervals (CIs) and p-values for
correlations of child and maternal outcomes. Similarly we
used linear models fit with generalized estimating equations
(GEE) to compare mean values of child outcomes between
groups.
Results
Sample Demographics
The 24 mothers were well into their childbearing years
(Table 1) and 10/24 (42%) completed a bachelor’s degree in
college. The majority were married and had middle-class
socioeconomic status. The Hollingshead Index of Social
Position (Hollingshead 1957) ranged from 15 to 73, where
low scores indicate higher levels of education and employ-
ment. In our sample, 9/23 (39%) families were in the lowest
two Hollingshead social positions (scores >43).
There were 77 pregnancies among the mothers with 56/
77 (73%) of pregnancies resulting in live births (including
2 sets of twins), 16/77 (21%) spontaneous abortions, and
5/77 (6%) terminations. Of the 58 live births, one offspring
suffered asphyxia at birth, with associated cerebral palsy,
and was excluded from the study since her condition was
judged by her physicians as not related to her mother’s
PKU. One offspring with PKU was included since he had
been in excellent metabolic control since birth. An
additional 10/58 (17%) were unavailable due to living in
another state, working or no longer in contact with the
mother. A total of 47 offspring (81%) were available for
study. The majority were of school age or older, with 29/47
(62%) ages 6–18 years. Also included in the sample were
Table 1 Sample demographics
Mean  SD, range or n (%)
Mothers (n ¼ 24)
Age (years) 39  7, 24–49
Education (years) 14  3, 9–18
Hollingshead–Redlich social position 39  19, 15–73
Marital status
Married 19 (79)
Single 3 (13)
Divorced 2 (8)
Offspring (n ¼ 48)
Mean  SD age (years) 8.5  6.2, 0–26
Ages 0–3 years (infancy) 12 (26)
Ages 4–5 years (preschool) 6 (13)
Ages 6–18 years (school age) 26 (55)
Ages 19+ years (adult) 3 (6)
Sex 21 males (44)
27 females (56)
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12 infants (<3 years), 6 preschool-aged children (ages 4–5
years), and 3 young adults (ages 19–26 years). Among the
47 offspring, 18 (38%) were from pregnancies in which
adherence to medical recommendations was rated as
excellent, 15 (32%) in which adherence was good, 10
(21%) in which adherence was fair, and 4 (9%) in which
adherence was poor.
Offspring Outcomes
Dysmorphology
The only facial dysmorphology noted in the offspring was
hypertelorism; the mean percentile distances were
73  25% for the inner canthal distance, 89  12% for
outer canthal distance, and 83  22% for the interpupillary
distance. Other features of facial dysmorphology that have
been reported in treated MPKU such as epicanthal folds,
elongated and smooth philtrum, and high-arched palate
were not observed. Comparisons between facial photo-
graphs of maternal PKU offspring and their parents
revealed no other dysmorphic findings. None of the
offspring had congenital heart disease. The mean head
circumference of the offspring was in the 48th percentile
but with the wide range of <3–99%. Nine (19%) of the 47
offspring had head circumference <3 percentile, indicating
microcephaly.
Cognitive Functioning and Emotional Well-Being
Child cognitive and emotional outcomes are presented in
Table 2. The mean Cognitive, Language, and Motor
Composite scores on the Bayley Scales of Infant and
Toddler Development, Third Edition, were well within the
average range (85–115). Infants received a mean DQ of
113  12, while preschool children attained a mean IQ of
96  19 and older children attained the same mean Full
Scale IQ of 96  19. The mean IQ for the three adults in
the study was 81  15, considerably lower than the IQ of
the school-aged children. The correlation between age and
Table 2 Offspring cognitive and emotional outcomes
Outcome Mean  SD Range n (%) outside normative rangea
Bayley scales of infant and Toddler development, third edition (ages < 3 years)
Bayley cognitive 113  12 95–130 0/9 (0)
Bayley language composite 112  12 94–132 0/9 (0)
Bayley motor composite 101  11 82–124 1/9 (11)
Intelligence test (WPPSI-III or WASI) (ages > 3 years)b
Full Scale IQ 94  19 53–138 9/36 (25)
Verbal IQ 94  20 55–150 12/36 (33)
Performance IQ 97  17 56–127 7/36 (19)
Vocabulary subtest (WASI) 45  13 20–69 8/24 (33)
Block design subtest (WASI) 48  11 23–65 4/24 (17)
Similarities subtest (WASI) 44  12 20–66 8/24 (33)
Matrix reasoning subtest (WASI) 48  14 20–65 5/24 (21)
Visual-spatial skills
Visual motor integration test (VMI) 89  16 45–118 10/33 (30)
Adaptive behavior assessment system, second edition (ABAS-II)
General adaptive composite (GAC) 97  19 43–130 9/45 (20)
Conceptual 99  20 49–133 11/46 (24)
Social 102  17 61–133 8/46 (17)
Practical 92  18 42–120 11/46 (24)
Behavior assessment system for children, second edition (BASC-2)
BASC somatization 46  11 33–69 6/38 (16)
BASC attention problems 50  10 33–76 6/38 (16)
a Thresholds indicating performance within normative range on neuropsychological measures:
– >85 for BSID, IQ, VMI, and ABAS-II scales
– >40 for WASI subtest scores
– <60 for BASC-2
b 24 offspring received a WASI and 12 preschool children received the WPPSI-III
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Full Scale IQ in offspring over age 3 years was -0.32
(p ¼ 0.06). Overall, 6/26 (23%) offspring attained a Full
Scale IQ in the borderline range (IQ 70–85) and 3/26
(12%) performed in the range of intellectual disabilities
(IQ < 70). Difficulties in fine motor coordination and
visual-spatial skills were noted on the VMI, for which the
child is asked to copy a series of increasingly complex
geometric figures. The mean score on the VMI was
89  16, with 10/33 children (30%) at least one standard
deviation below the normal mean of 100.
The mean score on the ABAS-II General Adaptive
Composite (GAC) was comparable to Full Scale IQ. The
mother’s responses indicated that children had relative
weaknesses in the practical domain and strengths in the
social realm.
Scores on the Behavior Assessment System for Children,
Second Edition, were generally within the average range.
These mothers perceived their children as well adjusted and
well behaved. The only two scales with moderately
elevated scores were Somatization (physical complaints)
and Attention Problems, both with 6/38 (16%) in the at-risk
range.
However, the mother’s answers to direct questions
related to school functioning and medical intervention
suggest that maternal PKU offspring experience trouble-
some symptoms not readily detected by intelligence testing
or the parent questionnaires we administered. Among the
children at least 5 years of age, 8/32 (25%) had learning
disabilities, 10 had attention deficit hyperactivity disorder
(ADHD) (31%) with 7 on ADHD medication (22%), and
11 had been diagnosed with anxiety and/or depression
(34%). These percentages are above rates reported for the
general population in which 1.9% of children are known to
have learning disabilities (Brault 2012), 5.1% are labeled as
having ADHD (2014a), 6.5% are on medication for ADHD
in Massachusetts (ADHD 2014b), and 15–20% of children
suffer from anxiety or depression (Beesdo et al. 2009). In
addition, two children in our sample had been diagnosed
with bipolar disorder, and one teenaged boy suffered from
substance abuse.
Maternal Outcomes
Maternal Health and Nutrition
Among the 24 mothers, 16 (67%) had severe PKU, 6 (25%)
had moderate PKU, and 2 (8%) had mild PKU. History and
physical examination of the mothers did not reveal any
major abnormalities. One mother had a papular erythema-
tous rash on both arms, another mother had recurrent basal
cell carcinomas, and a third mother had mild eczema.
Among 22 mothers whose height and weight were
measured, 5 (23%) had body mass index (BMI) in the
normal range, 10 (45%) were overweight, 6 (27%) were
obese, and 1 (5%) was underweight. All 24 women
answered the questionnaire about diet practices, and 12
(50%) reported following a diet for PKU although 14
(58%) reported taking a PKU formula/medical food.
Among 12 women responding to a question about formula
consumption, 9 (75%) reported taking at least 75% of the
amount of prescribed medical food. Overall, 16/23 mothers
(70%) reported restricting protein intake.
Of the 10 women who reported being off-diet, 3 (30%)
stated that they restricted protein, and one of them also
reported taking medical food. Among the entire sample,
3/24 women (13%) were treated with tetrahydrobiopterin
(sapropterin dihydrochloride or Kuvan®), a cofactor for
phenylalanine hydroxylase. No women were treated with
large neutral amino acid (LNAA) therapy.
Laboratory indices of maternal nutritional intake are
presented in Table 3. Results are stratified by self-report of
phenylalanine-restricted diet. Laboratory values for phenyl-
alanine, tyrosine, vitamin B12, and RBC folate differed
significantly between the on- and off-diet groups. While the
on-diet group had significantly lower blood phenylalanine
compared to the off-diet group, overall only 3/23 mothers
(15%) had blood phenylalanine levels less than 600 mmol/L
at time of the study and none had blood phenylalanine
<360 mmol/L.
Vitamin D was abnormally low in 1/3 (33%) of on-diet
mothers and 5/7 (71%) of those off-diet. Prealbumin values
were predominantly in the normal range, suggesting
adequate protein intake. Hemoglobin and hematocrit values
were normal and did not differ significantly between the
groups. Vitamin B12 and RBC folate were significantly
higher in the on-diet group.
Maternal Cognitive and Emotional Outcomes
As noted in Table 4, mean scores were within the average
range (85–115) on the Wechsler Abbreviated Scale of
Intelligence (WASI). The mean maternal Full Scale IQ was
94  16, with 6/24 mothers (25%) having a Full Scale
IQ < 85 (one standard deviation below the population
normal mean.) Maternal Performance IQ was on average
9.4 points higher than Verbal IQ, reflecting reduced
vocabulary and verbal reasoning abilities (p ¼ 0.01, 95%
CI 2.7–16.1 points higher).
The ABAS-II measures self-reported functioning in a
variety of domains, including cognitive, social and practi-
cal. The mothers rated themselves slightly above the
population norm of 100 on all dimensions, with a mean
overall score of 110  10. Among the 23 mothers
completing this questionnaire, only 1 (4%) received a score
<85, which on this test similarly represents more than one
standard deviation below the population mean.
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Table 3 Median and range of dietary intake and laboratory findings in mothers with PKU on and off a phenylalanine-restricted diet (figure in
parenthesis indicates number of women with values out of recommended range)
On-diet (n ¼ 12) Off-diet (n ¼ 10) Reference values p-valuea
Phenylalanine (mmol/L) 816; 389–1,610 (10/12) 1,319; 395–1,934 (9/10) 120–600b 0.04
Tyrosine (mmol/L) 47; 30–112 (1/12) 32; 25–36 (5/9) 32–122 0.03
Prealbumin (g/dL) 27; 23–43 (1/12) 25; 20–35 (0/10) 20–40 0.64
Vitamin D (ng/mL) 40.2; 25.3–43.4 (1/3) 28.7; 21.2–39.2 (5/7) 30–80 0.34
Vitamin B12 (pg/mL) 844.5; 197–1,336 (6/12) 328; 223–859 (0/9) 211–946 0.02
Ferritin (mg/dL) 53.5; 18–108 (0/12) 67; 15–198 (2/9) 13–150 0.11
Hemoglobin (g/dL) 13.5; 12.4–14.3 (0/12) 13.2; 12.3–14.7 (0/9) 11.5–16 0.52
Hematocrit (%) 39.5; 35.8–43.1 (0/12) 38.5; 35.6–41.4 (0/9) 34–44 0.27
Plasma Zinc (ng/mL) 119; 58–193 (4/12) 128.5; 94–158 (1/8) 70–150 0.42
RBC folate (ng/mL) 922; 579–1,468 (3/12) 828; 417–862 (1/9) 468–1,258 0.03
a p-values from the Wilcoxon rank-sum test
b Recommended blood phenylalanine range for adults with PKU
Table 4 Maternal neuropsychological outcomes
Mean  SD Range Outside normal boundsa (%)
All mothers
Full Scale IQb 94  16 61–117 6/24 (25)
Verbal IQ 90  16 59–113 7/18 (39)
Performance IQ 100  16 69–126 3/18 (17)
ABAS GAC 110  11 83–128 1/23 (4)
ABAS Conceptual 106  18 39–120 2/23 (9)
ABAS Social 104  21 26–120 4/23 (17)
ABAS Practical 108  14 63–120 1/23 (4)
BRIEF GEC 46  10 35–76 1/23 (4)
Beck depression inventory 8.3  9.8 0–39 6/24 (25)
Beck anxiety inventory 6.7  7.0 0–30 11/24 (46)
Mothers on formula
Full Scale IQ 100  11 79–117 1/14 (7)
Verbal IQ 96  13 80–109 3/9 (33)
Performance IQ 105  14 83–126 1/9 (11)
Beck depression inventory 5.8  7.2 0–26 2/14 (14)
Beck anxiety inventory 3.9  4.3 0–12 5/14 (36)
Mothers not on formula
Full Scale IQ 86  19 61–115 5/10 (50)
Verbal IQ 85  18 59–113 4/9 (44)
Performance IQ 95  18 69–123 2/9 (22)
Beck depression inventory 11.7  12.1 0–39 4/10 (40)
Beck anxiety inventory 10.6  8.3 0–30 6/10 (60)
ABAS GAC Adaptive Behavior Assessment System, General Adaptive Composite; BRIEF GEC Behavior Rating Inventory of Executive Function,
Global Executive Composite
Thresholds for normal neuropsychological test measures used:
– >¼85 for IQ measures
– <¼64 for BRIEF GEC
– <¼13 for Beck Depression Inventory
– <¼7 for Beck Anxiety Inventory
a Six mothers received the 2-subtest form of the WASI, which yields only a Full Scale IQ
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The mothers did not report themselves as having
difficulties in executive functioning, as measured by the
BRIEF. Of the 23 mothers completing this self-report
questionnaire, 1 (4%) received a score >65 on the Global
Executive Composite (GEC).
Emotionally, a different picture emerged, with 6/24
mothers (25%) receiving scores on the self-report Beck
Depression Inventory, Second Edition (BDI-II) > 13, indi-
cating mild to moderate depression, and 11/24 mothers
(46%) reporting mild to moderate anxiety on the Beck
Anxiety Inventory (BAI) with scores >7. These percen-
tages are higher than reported in the general population,
where annual rates are 9.5% for depression and 18.1% for
anxiety (Kessler et al. 2005).
Mean scores on all measures of cognitive functioning
were directionally higher for mothers on-diet (defined as
taking formula). Moreover, 2/14 on-diet mothers (14%)
self-reported depression on the BDI-II compared to 4/10
off-diet mothers (40%) (Fisher p ¼ 0.19), and 5/14 on-diet
mothers (27%) self-reported anxiety on the BAI compared
to 6/10 off-diet mothers (60%) (Fisher p ¼ 0.41).
Correlations Between Offspring Outcome and Maternal
Characteristics
As expected, offspring IQ correlated highly with maternal
metabolic control during pregnancy (r ¼ 0.51, p ¼ 0.002,
95% CI (0.19, 0.74)), maternal IQ (r ¼ 0.62, p ¼ 0.0001,
95% CI (0.33, 0.81)), and the Hollingshead Index of Social
Position (Hollingshead 1957) (r ¼ 0.48, p ¼ 0.005, 95%
CI (0.68, 0.12)). Offspring IQ was not associated with
current maternal blood phenylalanine level (r ¼ 0.10,
p ¼ 0.55, 95% CI (0.44, 0.25)), diet status (on- or off-
diet) (mean difference 0.6, p ¼ 0.96), or maternal marital
status (mean difference 4.6, p ¼ 0.38).
Children whose mothers had depression or anxiety were
at risk for behavioral difficulties, psychiatric problems, and
learning disabilities: 7/11 (64%) of children with anxiety or
depression, 6/10 (60%) of children with ADHD, and 6/8
(75%) children with learning disabilities had mothers with
anxiety or depression.
Discussion
The purpose of this study was to obtain a longer-term
assessment of offspring from treated MPKU pregnancies
and to identify maternal and environmental characteristics
associated with offspring outcome. Published results of
offspring outcome from treated maternal PKU have been
limited to developmental studies of the neonatal and early
infancy periods or to cognitive assessments in the first few
years of childhood. The oldest offspring from treated
maternal PKU pregnancies in our previous New England
study was 4 years old (Rohr et al. 1987), and the
evaluations of offspring in the MPKUCS ended at age 7
years (Koch et al. 2003; Waisbren and Azen 2003). In this
study, 62% of the offspring were older than age 5 years
with the oldest age 26 years. This study extended the length
of follow-up into adolescence and early adulthood and also
examined emotional and behavioral characteristics of these
offspring. Particular attention was given to those factors of
PKU in the mothers that might affect their ability to provide
a secure and stimulating environment for their offspring.
None of the maternal PKU offspring in our study had
evidence of heart disease or a history of having had
congenital heart disease. The mean head circumference of
the 48th percentile was within the expected range for the
general population although in several instances, MPKU
might have had a lingering adverse effect on head growth
since 19% had a head circumference below the 3rd
percentile, lower than the 31% for microcephaly among
offspring in the MPKUCS. Facial dysmorphology included
evidence of hypertelorism, as previously reported (Rouse
et al. 1997, 2000), but other facial features reported as due
to MPKU were absent. In summary, we found growth and
somatic development in the offspring similar to the general
population.
Despite the variability in current adherence to the diet for
PKU, the majority of women who participated in this study
perceived themselves as functioning well in their daily
lives. Nonetheless, 25% performed in the borderline
intellectual range, much higher than the 12.3% reported in
epidemiological studies (e.g., Hassiotis et al. 2008) and
higher than the 15.9% expected based on the normal
population curve for IQ. Their mean IQ was 94, lower
than that of adults with PKU recently studied in Europe
(Weglage et al. 2013). In the study of 57 adults with PKU,
the mean IQ was 100.6 compared to an IQ of 110.4 in a
matched control group. However, the group of mothers in
our study taking their medical food (formula) was 100, the
same as that in the European study. Nearly 40% of mothers
in our study were in the two lowest categories of
socioeconomic position. Closer examination of their scores
on tests of verbal expression, verbal reasoning, depression,
and anxiety revealed vulnerabilities that may have an
important impact on their parenting skills and hence on
their children’s development and well-being.
Within the general population, individuals with IQ in the
borderline range are significantly more likely to be at social
disadvantage, experience neurotic disorders (such as anxiety
and depression), and suffer from substance misuse. They
take psychotropic medications and seek emergency services
at a higher rate but are not more likely to seek psychotherapy
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(Hassiotis et al. 2008). Other studies report that adults with
borderline IQ are at risk for poor occupational attainment and
depression (Seltzer et al. 2009).
Children of parents with borderline IQ, anxiety, or
depression also seem to be negatively affected, not so
much during the preschool period but after age 7 years,
with increased rates of conduct disorders and emotional and
attention problems (Whitely et al. 2011). Likewise in our
study of maternal PKU offspring, children under age 3
years exhibited fewer cognitive or behavioral deficits than
children older than 3 years. By school age, the children
were much more likely to have ADHD, learning disabil-
ities, and anxiety or depression than children in the general
population. This suggests that the deficits noted later in
childhood may be related not only to prenatal effects but
also to environmental circumstances, including the home
environment, maternal depression, anxiety, and educational
opportunities. We found that the majority of school-aged
maternal PKU offspring with behavioral disturbances,
emotional difficulties, or low IQ had mothers who were
depressed or anxious. The percentage of children with
psychiatric symptoms or low IQ may be even higher than
we reported, given that one mother appeared to be an
“outlier.” Her 5 offspring had a range of problems including
anxiety and depression, ADHD, low IQ, and learning
disabilities, but she rated herself as having no anxiety or
depression. Based on clinical observation and prior medical
reports, however, she experiences both anxiety and depres-
sion. If she had rated herself as such, all offspring with
ADHD, all with low IQ, all with learning disabilities, and
82% of those with anxiety and depression would have
mothers who were experiencing anxiety or depression.
While there was overlap between current maternal blood
phenylalanine results for the on- and off-diet groups,
median blood phenylalanine concentrations were lower in
the on-diet group. Notably, only one woman on diet had
blood phenylalanine concentration <360 mmol/L, which is
considered to be safe for an MPKU pregnancy (Vockley
et al. 2014). The typical “on-diet” approach for this
population consisted of taking about 75% of the prescribed
phenylalanine-free or low-phenylalanine medical food
(formula) for PKU and avoiding high-protein foods such
as meat, eggs, nuts, and dairy products. Few women strictly
reduced their phenylalanine intake, as evidenced by
elevated plasma phenylalanine concentrations.
The women off-diet were at significantly higher risk of
having low blood tyrosine, which may be counterintuitive
since the off-diet group consumes more natural protein.
However, medical food is a source of tyrosine and may
account for the significantly higher blood tyrosine in the
on-diet group. Other discrepancies between amino acid
values in the two groups are notable, especially higher
blood concentrations of the large neutral amino acids—
valine, leucine, and tryptophan—in the on-diet group.
Valine and leucine are large neutral amino acids (LNAAs)
which compete for transport of phenylalanine into the brain.
High amounts of LNAAs in the blood block phenylalanine
uptake as well as promote neurotransmitter synthesis (Pietz
et al. 1999).
Half of the women had 25-OH vitamin D results below
the lower limit of 30 ng/mL, but only one had severe
vitamin D deficiency (<20 ng/mL) (Christesen et al. 2012).
A recent Cochrane review indicates that vitamin D
supplementation and higher levels of 25-OH vitamin D in
pregnant women have been associated with increased birth
weight. Moreover, observational studies show a positive
effect of vitamin D status on other health outcomes in
children. Indices of iron nurtiture (hemoglobin, hematocrit,
ferritin) were normal in both groups, as were zinc and
folate. Plasma vitamin B12 was significantly lower in the
off-diet group compared to the on-diet group, again
indicating that the medical food is a significant source of
vitamin B12 in the diets of mothers with PKU. Vitamin
B12 deficiency in adults with PKU is a well-established
phenomenon arising from diets that do not contain either
medical food or animal products (Hvas et al. 2006).
The prevalence of overweight women with PKU (45%)
and obesity (27%) was somewhat above national norms that
indicate 64% of the population is either overweight or
obese Fryar and Ogden 2014; Fryar et al. 2014. Female
children with PKU have been reported to have a higher
incidence of being overweight or obese in a single study
(Burrage et al. 2012). In a previous study of pregnant
women, a bimodal distribution of prepregnancy weight was
observed with nearly equal numbers of overweight and
underweight women (Rohr et al. 2004).
The suboptimal nutritional status of these women with
PKU may have implications for their emotional well-being.
For example, recent studies demonstrate associations
between low vitamin D or low vitamin B12 and depression
(Anglin et al. 2013; Kalita et al. 2013), and low tyrosine has
been implicated in depressive symptoms in PKU (Sharman
et al. 2012). Moreover, anxiety and agoraphobia have long
been recognized as symptoms of poor metabolic control in
PKU patients (Waisbren and Levy 1991; Brumm et al.
2004).
Very few women were being treated with tetrahydro-
biopterin supplementation and none with large neutral
amino acids. The women who were enrolled in the study
were older, and many were off-diet and not seen frequently
in clinic. Thus, they may be part of the “lost generation” of
adults with PKU who do not have the opportunity to learn
about updated therapies for PKU (Burton and Leviton
2010). However, this MPKU follow-up study offered an
opportunity to update women about treatment options, and
yet none chose to change their current treatment. Responses
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to the nutrition questionnaire may provide insight into this
behavior. About half of the women who were off-diet
reported that they had tried to return to diet at some point in
the postpartum period. When asked about obstacles to
returning to diet, the most common responses were not the
expected ones (difficulty with formula, protein restriction,
or insurance) but rather that they did not perceive a need for
any treatment. Only one mother reported lack of access to
treatment as an obstacle.
One limitation of this study was the use of self-report
and parental report instruments. Rates of offspring difficul-
ties may be underestimated in our study, since the mothers
tended not to report themselves or their children as
functioning below the average range while cognitive test
scores tended to suggest otherwise. Subgroup comparisons
of on-diet versus off-diet women or children with versus
without cognitive deficits or mood disorders involved small
sample sizes.
Conclusion
The primary conclusion of this study is that maternal diet
influences offspring outcome—before, during, and after
pregnancy. Mothers who are well treated from the very
beginning of their lives have a higher IQ and therefore
often a higher SES, both of which were found to correlate
with offspring outcome. They are also less likely to be
anxious or depressed which was a determining factor in
offspring with ADHD, anxiety, depression, and low IQ.
While maternal metabolic control during pregnancy
explains much about offspring outcomes, other parental
characteristics may also contribute to the increased rates of
low IQ and attention problems in these children, and these
appear to be directly related to diet and medical food intake.
Moreover, it takes time for the maternal PKU offspring’s
problems to emerge. Most social-emotional problems were
not evident until the children were school-aged. For this
reason, it is important that MPKU offspring have psycho-
logical evaluations throughout childhood and adolescence
and that mothers continue to receive therapy for PKU
throughout the lifespan. Evidence for positive maternal
PKU pregnancy outcomes is now well established. This
study illustrates that risks associated with maternal PKU do
not end with the birth of the infant, but continue throughout
the child’s life. To ensure optimal offspring outcomes,
healthcare providers need to assess maternal nutrition,
blood phenylalanine concentrations, cognitive abilities,
mood, and socioeconomic position. Interventions can then
be initiated that reduce psychosocial stressors and enhance
adherence to medical recommendations and positive par-
enting, which in turn can lead to better cognitive function-
ing, behavior, and emotional well-being in the children.
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Abstract Long-term follow-up of neuropsychological
functioning in metabolic disorders remains difficult due to
limited opportunities for comprehensive neuropsychologi-
cal evaluations. This study examined the validity of using
the Adaptive Behavior Assessment System, Second Edition
(ABAS-II), and the Behavior Rating Inventory of Executive
Function (BRIEF) for assessing developmental status in
metabolic disorders and for identifying individuals at risk
for cognitive deficits. Results from individuals with urea
cycle disorders, phenylketonuria, galactosemia, and fatty
acid oxidation disorders were obtained on the ABAS-II and
BRIEF and were compared to results obtained from
neuropsychological testing performed on the same day.
Correlations between scores on the ABAS-II and develop-
mental or IQ tests for individuals with urea cycle disorders
ranged from 0.48 to 0.72 and concordance rates for scores
greater than a standard deviation below the normative mean
ranged from 69 to 89%. Correlations ranged from 0.20 to
0.68 with concordance ranging from 73 to 90% in the other
metabolic disorders. For the BRIEF, correlations with other
tests of executive functioning were significant for urea
cycle disorders, with concordance ranging from 52 to 80%.
For the other metabolic disorders, correlations ranged from
0.09 to 0.55. Concordance rates for at-risk status on the
BRIEF and executive functioning tests ranged from 55% in
adults to 80% in children with other metabolic disorders.
These results indicate that the ABAS-II and BRIEF
together can confidently be used as an adjunct or
supplementary method for clinical follow-up and for
research on functional status involving infants, children,
and adults with metabolic disorders.
Introduction
In spite of the risks to development, children and adults
with metabolic disorders may not receive neuropsychologi-
cal evaluations as part of routine care in the metabolic
clinic. This situation occurs because of limited access to a
psychologist who specializes in metabolic disorders and
because of challenges to obtaining insurance approval for
assessments. Consequently, individuals with these disorders
often go years without a neurodevelopmental or neuropsy-
chological evaluation and thus receive needed interventions
only after symptoms become severe and are far more
difficult to treat. Moreover, research into the neuropsycho-
logical effects of metabolic disorders is hindered by the
lack of uniform follow-up assessments.
Recognition of the need for a method for assessing
psychological functioning and for gathering a standard data
set in metabolic disorders led a team of 10 psychologists
and a psychiatrist to select instruments to serve as a
Uniform Assessment Method. The goal was to develop
validated, short, and inexpensive standardized protocols
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that would be relevant throughout the life span, could be
completed by parents or the affected adults, could be
available in Spanish as well as English, and could be
administered, scored, and interpreted by non-psychologists.
In addition, instruments were chosen for their power to
identify children or adults in need of further evaluation,
treatment modifications, or closer monitoring (Waisbren
and White 2010). Among the instruments selected were the
Adaptive Behavior Assessment System, Second Edition
(ABAS-II) (Harrison and Oakland 2003), and the Behavior
Rating Inventory of Executive Function (BRIEF) (Gioia
et al. 2000). Other instruments included were the Behavior
Assessment System for Children – Second Edition (BASC-
2) (Reynolds and Kamphaus 2004) and, for adults, the Beck
Depression Inventory, Second Edition (Beck et al. 1996), and
the Beck Anxiety Inventory (Beck and Steer 1993). While
the questionnaires selected were already well validated in the
general population, their psychometric properties had not
been described for individuals with metabolic disorders. The
purpose of this Uniform Assessment Method is not to find a
substitute for intelligence testing or comprehensive neuro-
psychological evaluations but rather to establish a quick,
valid, and feasible means to assess functioning for routine
clinical follow-up, registries, and research studies.
In this report, results from the ABAS-II and BRIEF
obtained on individuals with urea cycle disorders (UCDs),
phenylketonuria (PKU), galactosemia, and fatty acid oxida-
tion disorders (FAODs) were compared to results obtained
from neuropsychological testing performed on the same day.
PKU, galactosemia, and FAODs were selected for compari-
son to UCDs because they represent metabolic disorders with
neuropsychological impact for which comparable test results
were available from other research studies or medical records.
We did not include the BASC-2 or the Beck Depression or
Anxiety Inventories because they were not routinely available
in the research databases or medical records.
Metabolic Disorders
Urea Cycle Disorders
UCDs interfere with the hepatic ammonia detoxification
pathway, leading to hyperammonemia and other biochemi-
cal abnormalities. Absence or deficiency of the first four
enzymes in the urea cycle (carbamoyl phosphate synthetase
I (CPSI), ornithine transcarbamylase (OTC), argininosucci-
nate synthetase (ASS), argininosuccinate lyase (ASL))
leads to hyperammonemia within the first few days of life.
Deficiency or absence of arginase 1 (ARG1) leads to other
neurological and developmental problems, although hyper-
ammonemia is not as common (Summar et al. 2008).
Ornithine transcarbamylase (OTC) deficiency, the most
common of the urea cycle disorders (OMIM 311250), is an
X-linked inherited disorder, in which males are more
severely affected. Many females remain asymptomatic
throughout their lives, although subtle neuropsychological
deficits arise that can interfere with functioning in day-to-
day life (Gyato et al. 2004; Gropman et al. 2010). The
clinical symptoms related to these disorders are variable,
ranging from neonatal death due to complications of
hyperammonemia to normal cognitive and developmental
outcomes throughout life (Krivitzky et al. 2009). Newborn
screening has recently become available for several of the
urea cycle disorders (Beck et al. 2011), and while early
diagnosis and treatment may reduce the frequency and
severity of hyperammonemic episodes (Summar 2001),
they do not eliminate risks of reduced cognitive abilities,
maladaptive behaviors, and poor executive functioning
(Krivitzky et al. 2009; Ah Mew et al. 2013).
Phenylketonuria (PKU)
PKU (OMIM 261600) is an autosomal recessive disorder
that affects the body’s ability to metabolize phenylalanine
into tyrosine, the precursor of the neurotransmitter, dopa-
mine. Untreated PKU is associated with severe intellectual
disabilities, seizures, eczema, motor difficulties, and signif-
icant behavioral problems. Fortunately, universal, manda-
tory newborn screening in the United States and in most
developed countries around the world permits the identifi-
cation and early treatment of this inborn error of metabo-
lism. Treatment consists of a low-protein diet and a
supplemental formula that provides all the necessary parts
of protein without the “offending” amino acid (Scriver and
Kaufman 2001). With early treatment, most children with
PKU develop well, with intellectual abilities within the
average range (Waisbren et al. 2007). However, many
individuals experience executive functioning deficits
(Christ et al. 2010), attention deficit disorder (Antshel and
Waisbren 2003), and psychiatric problems, including
anxiety and depression (Brumm et al. 2010).
Galactosemia
Galactosemia (OMIM 230400) is a rare, inherited metabolic
disorder in which the metabolism of galactose is impaired,
due to insufficiency or absence of the enzyme, galactose-1-
phosphate (Fridovich-Keil and Walter 2008). If left
untreated, classic galactosemia can cause severe neonatal
sepsis, cataracts, and death. Those who survive the
newborn period often experience intellectual disability,
speech and language delay, and motor deficits. With early
identification through newborn screening and treatment
with a galactose-restricted diet, the more severe consequen-
ces of this disorder are prevented. However, almost every
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child with galactosemia has speech/language delay, and
many have minor to moderate motor deficits (Bosch 2006).
Adults also exhibit motor deficits, depression, and anxiety
(Waisbren et al. 2012).
Fatty Acid Oxidation Disorders
Mitochondrial fatty acid oxidation is a complex process
involving transport of activated acyl-coenzyme A (CoA)
moieties into the mitochondria and sequential removal of
two carbon acetyl-CoA units. This process in the mitochon-
dria provides energy for many tissues including heart and
skeletal muscle and is critically important during times of
fasting or physiologic stress (Vockley and Whiteman 2002).
Disorders of fatty acid oxidation, the most common of
which is medium-chain acyl-CoA dehydrogenase defi-
ciency (OMIM 607008), interrupt this cycle and lead to a
deficit in the conversion of fat into energy. Most patients
with fatty acid oxidation defects are now identified through
newborn screening, and as a result, mortality and morbidity
rates have vastly improved (Wilcken 2010). However, devel-
opmental delays are not uncommon, particularly in the area of
speech and language (Iafolla et al. 1994; Waisbren et al. 2013).
This summary of metabolic disorders exposes the
continued neuropsychological and behavioral risks con-
fronting patients with these conditions. Without adequate
developmental and neuropsychological screening and
follow-up, their needs often remain unrecognized.
Instruments
The Adaptive Behavior Assessment System, Second Edi-
tion (ABAS-II) (Harrison and Oakland 2003), spans the
entire life span, from early infancy to adulthood. The
ABAS-II is a checklist of a broad range of skill areas
related to development, behavior, and cognitive abilities.
Parents or other informants can complete the age-appropri-
ate form (0–5 years, 6–21 years). For capable adults there
is a self-report form, as well as a parent/informant version.
The ABAS-II includes subscales for communication,
community use, functional academics, home living, health
and safety, leisure, self-care, self-direction, social, and
work. A scaled score of 10  3 represents the mean. Four
composite scores are derived from the sum of the scaled
scores: general adaptive composite (GAC), conceptual,
social, and practical. These composite scores have a mean
of 100 and a standard deviation of 15. The ABAS-II
standardization sample included 1,670 respondents. The
ABAS-II GAC has a correlation of 0.54 with the Wechsler
Preschool and Primary Scale of Intelligence (WPPSI-III)
and 0.41 with the Wechsler Intelligence Scale for Children,
Fourth Edition (WISC-IV). Computerized scoring and
interpretation programs are now available. This question-
naire takes 10–15 min to complete.
The Behavior Rating Inventory of Executive Function
(BRIEF) (Gioia et al. 2000) provides theoretically and
empirically derived clinical scales that measure aspects of
executive function. Executive functioning can be thought of
as the ability to keep information in mind for problem
solving. It involves such cognitive processes as memory,
attention, planning, organization, and the ability to shift
attention from one thought to another. The clinical scales
form broad indices of behavior and cognition and an overall
score, the global executive composite (GEC). For this
study, parent response forms for school-aged children were
analyzed, although there is also a preschool version. A self-
report form and an informant response form are available
for adults, permitting a uniform measure across all ages. All
forms were standardized on normative samples representing
a broad variety of race/ethnicity, age, and geographical
population density. A T score of 50  10 represents the
mean of the T-score distribution, and a score of 65
represents 1.5 standard deviations above the mean, which
is the recommended cut point for an “abnormally elevated”
score and is considered “clinically significant.” The
questionnaire is completed within 10–15 min.
Methods
This study incorporated information from research data sets
and medical records. Parents of children with urea cycle
disorders or adults with urea cycle disorders participating in
a longitudinal study completed the ABAS-II and BRIEF as
part of comprehensive neuropsychological evaluations
(Seminara et al. 2010; Krivitzky et al. 2009; Ah Mew
et al. 2013). Additional reports on results from this study
are forthcoming. Data on children with PKU, galactosemia,
and fatty acid oxidation disorders were obtained from a
review of medical records from Boston Children’s Hospital,
where the questionnaires from the Uniform Assessment
Method have been used for the past 5 years at the time of
routine psychological evaluation. (See Waisbren et al. 2013,
for a review of results on children with FAODs.) Data on
adult women with PKU were obtained from a study of
maternal PKU (Waisbren et al. in press) that included
administration of the ABAS-II, BRIEF, and intelligence
testing. Data on adults with galactosemia were obtained
from a study that also included the ABAS-II, BRIEF, and
neuropsychological assessment (Waisbren et al. 2012).
Approval for these various studies was obtained by
the Boston Children’s Hospital Committee on Clinical
Investigations (IRB) or other metabolic centers where the
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research was being conducted. Approval was also received
to conduct a medical record review of Boston Children’s
Hospital patients.
Mean and standard deviations were calculated to
describe the scores on the ABAS-II, BRIEF, developmental
tests, intelligence tests, and scales that measured aspects of
executive functioning. T tests and analysis of variance were
used to evaluate differences in scores between males and
females and across the different disease groups. We
categorized results according to the following age groups:
infants (<3 years), preschool children (3–5 years), school-
aged children (6–17 years), and adults (18+ years).
Results from subjects with PKU, galactosemia, and fatty
acid oxidation disorders were combined into an “other
metabolic disorders” group, due to relatively few cases with
these disorders. This “other metabolic disorders” group was
compared to results from subjects with UCDs. For 41 cases
in the urea cycle group, a parent or informant completed the
ABAS-II for adult subjects. Analyses were performed with
and without these cases, and occasionally a difference in
results was noted. Occasionally, subjects were rated more
than once on the ABAS-II or BRIEF at the time of a
neuropsychological evaluation, and their data were
included in the analyses. Results from the BRIEF were
derived only from school-aged children and adults.
Pearson correlation coefficients were computed to assess
strength of relationships between the ABAS-II and meas-
ures of cognitive functioning. For infants, the GAC from
the ABAS-II was compared to the cognitive composite
score from the Bayley Scales of Infant and Toddler
Development, Third Edition (Bayley 2005). For older
children and adults, the ABAS-II GAC was compared to
the full-scale IQ obtained from the Wechsler Preschool and
Primary Scales of Intelligence, Third Edition (WPPSI-III)
(Wechsler 2002), the Wechsler Intelligence Scale for
Children, Fourth Edition (WISC-IV) (Wechsler 2003), the
Wechsler Adult Intelligence Scale, Fourth Edition (WAIS-
IV) (Wechsler 2008), or the Wechsler Abbreviated Scale of
Intelligence (WASI) (Wechsler 1999), depending on the age
of the subject and instrument used for clinical or research
purposes. Pearson correlations were also calculated to
assess the strength of associations between the BRIEF
Global Executive Composite (GEC) and two scales from
instruments that measure aspects of executive functioning,
specifically working memory as measured by the California
Verbal Learning Test (CVLT), Trial 5 (Delis et al. 2000;
Tremont et al. 2000), and planning as measured by the
block design subtest from the Wechsler intelligence tests
(Weiss et al. 2006).
Concordance (agreement) between the ABAS-II and
developmental or intelligence tests provided a measure of
validity of the ABAS-II to identify children at risk and in
need of further evaluation. A score of 85 (1 standard
deviation below the published mean) represented the cut
point for determining a risk for problems in adaptive
functioning on the ABAS-II General Adaptive Composite
(GAC) and for risk of developmental delay or intellectual
deficits on the Bayley Cognitive Composite and full-scale
IQ on the WPPSI-III, WISC-IV, WAIS-IV, or WASI.
Concordance between the BRIEF GEC and the two
scales measuring aspects of executive functioning was also
determined. For the BRIEF GEC, the cut point for
executive functioning deficits is 65, as specified by the
BRIEF manual. On the CVLT trial 5, a score one standard
deviation below the mean ( 1.0) represented risk for
executive functioning deficits. For the block design subtest
from the Wechsler scales of intelligence, the cut point for
risk of deficits was set at 7 or below (or 40 on the WASI).
In addition to measuring agreement, percents for receiver
operating characteristic (ROC) area under the curve (AUC)
were calculated.
Results
As noted in Table 1, 516 individuals were rated on the
ABAS-II and 265 individuals were rated on the BRIEF.
More females than males were included in the study. The
mean age of the sample was 13.8 years but ranged from
infancy to middle age. Differences in scores on the ABAS-
II or BRIEF between males and females were noted only
when parent ratings of adults with UCDs on the ABAS-II
were included with the self-ratings of adults with UCDs
(p < 0.04).
The mean score on the ABAS-II GAC was lower for the
combined UCD cases (86  23) than for the combined
other metabolic disorders (mean ¼ 99  16, p < 0.0001).
Similarly, scores on the BRIEF were higher (indicating
greater difficulties in executive functioning) for the UCD
cases (mean ¼ 57  12) compared to the cases with other
metabolic disorders (mean ¼ 53  13, p < 0.01). Signifi-
cant differences were not noted on the ABAS-II or BRIEF
among individuals with PKU, galactosemia, or FAODs.
As noted in Table 2, mean scores on the ABAS-II GAC
were within the low-average to high-average range for all
study groups as were mean scores for the Bayley Cognitive
Composite and full-scale IQ. The correlations between the
ABAS-II GAC and the Bayley Cognitive Composite in
infants or full-scale IQ in children and adults ranged from
0.20 to 0.70, with the correlations consistently high among
school-aged children 6–17 years of age. For children and
adults with urea cycle disorders, mean scores on the two
measures were within 1–4 points. For children with other
metabolic disorders, mean scores derived from parent
ratings were 9 to 18 points lower than scores on tests
administered directly (Bayley Scales or Wechsler intelli-
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gence tests), despite generally high correlations. For adults
with the other metabolic disorders, the opposite was true,
with mean self-rated ABAS-II GAC 10 points higher than
full-scale IQ.
For the UCD cases, the communication subscale from the
ABAS-II correlated with the Bayley Language Composite
score (r ¼ 0.60, p < 0.000001). The motor subscale from
the ABAS-II correlated with the Bayley Motor Composite
score (r ¼ 0.57, p < 0.00001). These data were not avail-
able for subjects with the other metabolic disorders.
Table 3 presents comparisons between the BRIEF global
executive composite (GEC) and scores on two tests that
measure aspects of executive functioning (working memory
and planning). Among adults with UCDs, confidence
intervals for the correlations indicate that the GEC was
associated with working memory as measured by the
CVLT. For children and adults with UCDs, the BRIEF
GEC also correlated with scores on block design, measur-
ing planning and organization. Although correlations were
high between the GEC and aspects of executive functioning
for subjects with other metabolic disorders, these associa-
tions did not reach significance. In general, individuals with
UCDs exhibited deficits on both the CVLT and block
design. For individuals with the other metabolic disorders,
scores on block design remained relatively intact, while
particular vulnerabilities were noted in working memory, as
measured by the CVLT.
For the ABAS-II GAC, concordance refers to agreement
with the Bayley Cognitive Composite or full-scale IQ in
terms of a score above or below the cut point indicative of
risk for developmental delay or cognitive deficit. As noted
in Table 2, overall concordance ranged from 69 to 90%.
Table 1 Total number and mean age of individuals with each disorder rated on the ABAS-II and BRIEF and number of males and females
Disorder
ABAS-IIa ABAS-IIb BRIEF Mean age  standard
deviation
Female Male
N N (% of total) N (% of total)
Urea cycle disorders 282 323 174 11.2  11.0 208 (67%) 115 (56%)
Phenylketonuria 94 94 56 19.8  17.6 66 (21%) 28 (14%)
Galactosemia 68 68 24 18.6  15.4 30 (9%) 38 (19%)
Fatty acid oxidation disorders 31 31 11 5.2  3.7 8 (3%) 23 (11%)
Totals 475 516 265 13.8  13.9 312 (100%) 204 (100%)
a ABAS-II using only self-report for adults
b ABAS-II using self-report for adults when available, supplemented by parent reports in the absence of a self-report
Table 2 Mean (standard deviation) scores on the ABAS-II general adaptive composite (GAC), Bayley cognitive composite, correlations with IQ
tests, and concordance with scores below the cut point for the ABAS-II GAC
Neurocognitive
instrument N
ABAS-II
GAC
Bayley cognitive
composite IQ
Pearson
correlation (r)
Confidence
interval for r Concordancea
UCD
Children <3 years 105 87  19 89  19 0.48 (0.32,0.62) 73/105 (69%)
Children 3–5 years 50 86  20 91  20 0.67 (0.48,0.80) 37/50 (74%)
Children 6–17 years 132 83  22 89  21 0.64 (0.53,0.73) 93/13 (70%)
Adults 18+b 47 105  13 103  15 0.54 (0.30,0.72) 42/47 (89%)
Adults 18+c 86 98  18 95  21 0.72 (0.59,0.80) 74/86 (86%)
Other metabolic disorders
Children <3 years. 34 100  12 118  17 0.21 (0.16, 0.53) 27/30 (90%)
Children 3–5 40 97  16 108  12 0.20 (0.12, 0.48) 34/40 (85%)
Children 6–17 44 90  19 101  17 0.68 (0.47, 0.81) 37/44 (84%)
Adults 18+ 75 103  15 93  18 0.42 (0.22, 0.59) 55/75 (73%)
a Concordance includes all test results from each participant. Cut points for ABAS-II, Bayley cognitive composite, and full-scale IQ  85
b UCD using only self-report for adults
c UCD using self-report for adults when available, supplemented by parent reports in the absence of a self-report
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As noted in Table 3, concordance rates between the BRIEF
GEC and either the CVLT or block design ranged from 52
to 80%, with agreement generally higher for the CVLT,
measuring working memory, than for block design, mea-
suring planning as well as visual spatial abilities.
For the ABAS-II GAC, ROC AUC summarizing overall
sensitivity and specificity is 69% for infants with UCDs and
24% for infants with other metabolic disorders. The ROC
AUC is 80% or higher for school-aged children and above
70% for adults with UCDs and other metabolic disorders.
For the BRIEF GEC, the ROC AUC is 60% for school-
aged children with UCDs and 84% for school-aged children
with other metabolic disorders. For adults, it is above 60%
for both individuals with UCDs and individuals with other
metabolic disorders.
Discussion
In this study, 515 individuals with metabolic disorders
contributed data from the ABAS-II and 265 contributed
data from the BRIEF. Data from these questionnaires were
compared to scores obtained through neurodevelopmental
or neuropsychological testing. This study focused on
UCDs, galactosemia, PKU, and FAODs because data on
these populations were available. The assessment method
proposed here could easily be applied to the many other
metabolic disorders that also present at various ages and are
associated with a broad range of psychological outcomes.
Mean scores on the ABAS-II GAC and the Bayley
Cognitive Composite or IQ tests from individuals with
urea cycle disorders were within 4 points. For the other
metabolic disorders, the ABAS-II GAC mean scores tended
to be lower than the Bayley Cognitive Composite or full-
scale IQ for children, but higher than full-scale IQ for
adults.
The correlations between the ABAS-II GAC and full-
scale IQ ranged from 0.62 to 0.68 in school-aged children,
considerably higher than the correlation between the GAC
and the WISC-IV full-scale IQ (r ¼ 0.41) reported in the
ABAS-II manual. When discrepancies occurred in this
study, parent ratings usually indicated problems, whereas
the cognitive composite or full-scale IQ was within the
average range. A review of medical records and scores on
other neuropsychological tests suggested that nearly all
these children had attention deficits, hyperactivity, or other
behavioral problems. These children received higher scores
on an IQ test than on the ABAS-II, which identifies
potential behavioral as well as cognitive risk factors.
Strong correlations were noted among scores from UCD
individuals between the BRIEF GEC and block design for
school-aged children and adults. The GEC was also highly
Table 3 Pearson correlations between BRIEF questionnaires global executive composite (GEC) and tests of executive functioning by study group
and age and concordance with scores above the cut point for the BRIEF and below the cut point on the block design or CVLT
Study/age group N
BRIEF GEC
mean (SD)
Test Pearson
correlation
Confidence
interval for r ConcordanceaN, mean (SD)
UCD
6–17 years 112 58  12 CVLT 0.16 (0.34, 0.025) 74/112 (66%)
0.37  1.39 75/143 (52%)
143 60  12 Block Design* 0.35 (0.49, 0.20)
7.2  3.9
18+ years 43 53  10 CVLT 0.42 (0.64, 0.14) 30/43 (70%)
0.48  1.28 38/60 (63%)
60 54  11 Block Design 0.38 (0.58, 0.14)
6.7  4.3
Other metabolic
disorders
6–17 years 10 61  14 CVLT 0.55 (0.88, 0.12) 8/10 (80%)
0.35  1.1 23/35 (64%)
35 58  13 Block design 0.09 (0.41, 0.25)
10  3
18+ years 9 54  9 CVLT 0.55 (0.89, 0.18) 5/9 (55%)
1.67  1.62
29 49  10 Block design 0.26 (0.58, 0.11) 19/29 (66%)
9  4
a Cut points: BRIEF  65; CVLT  1.0; block design 7 (scores on block design from the WASI were converted to scaled scores)
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correlated with the CVLT for adults with UCDs. Scores on
the BRIEF from individuals with the other metabolic
disorders were not significantly correlated with scores on
the CVLT or block design. With test scores from only 9 to
35 individuals, this aspect of the study may have been
underpowered.
The analyses for this study were limited to the summary
scores on the ABAS-II and BRIEF. The subscales for both
these instruments may prove to be valid as additional
outcome measures. However, assessment of these subscales
was beyond the scope of this study, which relied on existing
data sets.
It is important to remember that adaptive functioning, as
assessed by the ABAS-II, is not equivalent to intellectual
functioning, since it describes a much broader range of
behaviors, including social relationships, self-help skills, and
ability to get along in the community. Similarly, executive
functioning as measured by the BRIEF is not equivalent to
isolated skills of memory and planning but includes
attention, inhibition, organization, and other abilities. Given
that the potential bias is in the direction of overidentification
of at-risk children, assessments based on the ABAS-II and
BRIEF will be unlikely to miss a child who has a
developmental delay or deficit in executive functioning.
Ideally, the ABAS-II and BRIEF will be incorporated in
every metabolic disorder study that includes measures of
functioning so that results can be compared across studies
and meta-analyses can be easily conducted. Uniform
assessments with the ABAS-II and BRIEF can overcome
the problems of small sample sizes and insufficient
resources when examining functioning in newborn screen-
ing or when conducting long-term follow-up studies.
Use of the ABAS-II and BRIEF for assessing every child
identified with a metabolic disorder will increase the
likelihood of insurance coverage for further evaluations
when needed and permit early identification of those
requiring early interventions or treatment modifications.
Moreover, inclusion of anonymous results from these
measures in longitudinal registries will provide critical data
for evaluating the efficacy of newborn screening, which has
expanded greatly in the past decade and is likely to increase
further as new screening technologies become available.
These instruments are available as paper forms or online
and can be administered on a tablet or laptop computer.
They can be administered by non-psychologists. They
extend across all age groups and exist in Spanish and other
languages as well as English. Reports can be generated
electronically, and scores can be entered into databases for
research purposes or tailored for feedback to patients,
families, and health-care providers.
Future studies are needed to evaluate the sensitivity of
the ABAS-II and BRIEF as pre- and posttests in medication
or other treatment trials. Additional studies are needed to
validate the other tests recommended in the Uniform
Assessment Method described by Waisbren and White
(2010), including the BASC, Beck Anxiety Inventory, and
Beck Depression Inventory to assess psychiatric and
emotional well-being.
In conclusion, the results of this study indicate that the
ABAS-II and BRIEF together can confidently be used as an
adjunct or supplementary method for clinical follow-up and
for research on functional status in infants, children, and
adults with metabolic disorders. This method can serve as
an “early warning” system to detect neuropsychological
deficits for which a full evaluation would be important.
Ideally, the ABAS-II and BRIEF can be administered as
part of regular follow-up for metabolic disorders to monitor
treatment effectiveness and disease progression. While
comprehensive neuropsychological evaluations provide a
more differentiated picture of the types and severity of
deficits associated with these disorders, the expense, time
commitment, and limited access to such testing has
prohibited and probably always will prohibit its use as a
method for routine follow-up in clinical settings or for
measures of functional status in registries or large research
studies. The ABAS-II and BRIEF can fill this void.
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Abstract Glutaric acidemia I (GA I, #231670) is one of the
treatable, autosomal recessively inherited metabolic disor-
ders. Macrocephaly, acute encephalitis-like crises, dystonia
and characteristic frontotemporal atrophy are the hallmarks
of this disease. In this communication, we present the
clinical, biochemical and molecular profile of seventeen
GA I patients from 15 unrelated families from India and
report seven novel mutations in GCDH gene (c.281G>A
(p.Arg94Gln), c.401A>G (p.Asp134Gly), c.662T>C (p.
Leu221Pro), c.881G>C (p.Arg294Pro), c.1173dupG (p.
Asn392G lu f s *5 ) , c . 1 238A>G (p .Ty r 413Cys )
and c.1241A>C (p.Glu414Ala)). Out of these, c.662T>C
(p.Leu221Pro) in exon 8 and c.281G>A (p.Arg94Gln)
allele in exon 4 were low excretor alleles, whereas
c.1241A>C (p.Glu414Ala), c.1173dupG and c.1207C>T
(p.His403Tyr) in exon 11 were high excretor alleles. We
conclude that c.1204C>T (p.Arg402Trp) is probably the
most common mutant allele. Exons 11 and 8 are the hot
spot regions of GCDH gene in Indian patients with GA I.
An early diagnosis and timely intervention can improve the
underlying prognosis. Molecular confirmation is helpful in
providing genetic counselling and prenatal diagnosis in
subsequent pregnancy.
Introduction
Glutaric acidurias are a group of autosomal recessively
inherited metabolic disorders that are characterized by
abnormal excretion of glutaric acid due to a defect in
amino acid or fatty acid metabolism pathways. Glutaric
acidemia type 1 or glutaric aciduria type 1 (GA I) occurs
due to the deficiency of glutaryl-CoA dehydrogenase
(GCDH) enzyme (EC 1.3.8.6, old number EC 1.3.99.7), a
member of the acyl-CoA dehydrogenase family and a key
enzyme in the catabolic pathways of the amino acids
tryptophan, lysine and hydroxylysine. Deficiency of GCDH
causes increased organic acid excretion of glutaric acid,
3-hydroxyglutaric acid and glutaconic acid in urine and
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elevated glutarylcarnitine (C5DC) in plasma. The estimated
worldwide frequency of GA I is 1 in 100,000 newborns
(Lindner et al. 2004), but increased frequency has been
reported in the inbred Old-Order Amish community of
Pennsylvania (Morton et al. 1991) and the Ojibway Indians
in Manitoba (Haworth et al. 1991). About ninety percent of
the affected children present classically between 2 and 37
months of age with extrapyramidal symptoms, predomi-
nantly dystonia superimposed on axial hypotonia after an
acute encephalopathic crisis precipitated by intercurrent
febrile illness, infection, fasting or immunization (Hoff-
mann et al. 1991; Kolker et al. 2006; Strauss et al. 2003).
About 75% of the patients have macrocephaly with soft
neurological signs such as head lag, irritability and feeding
difficulties. Extrapyramidal symptoms are due to bilateral
striatal injury during the acute episode. Early diagnosis and
prompt initiation of treatment can prevent the long-term
complications and mortality which have led to its inclusion
in conservative newborn screening programs (Heringer
et al. 2010; Kolker et al. 2007). GCDH enzyme is encoded
by GCDH gene, which is located on the chromosome
19p13.2 spanning about ~7 kb and contains 12 exons
(Transcript ID ENST00000222214) and encodes 438 amino
acid-long precursor protein. It is a genetically heteroge-
neous condition and is caused by different types of
mutations such as missense, nonsense and intronic varia-
tions in GCDH gene. Till date, 163 mutations have been
reported from different ethnic groups in HGMD (Goodman
et al. 1998; Busquets et al. 2000a; Zschocke et al. 2000).
Although there is some correlation between genotype and
the urinary excretion of glutaric acid, the correlation
between genotype and phenotype has been elusive (Kolker
et al. 2006). There is no published data from India on the
mutation spectrum of GA I. This retrospective study is
aimed to present clinical and molecular profile of Indian
patients and report seven novel mutations. In silico analysis
was performed to predict the role of these novel mutations
on protein function. The effects of novel missense
mutations on the structure of gene product have been
analyzed by computational modelling. Prenatal diagnosis
was offered in one family.
Materials and Methods
Patient Enrolment
Over a period of 5 years (June 2008 till June 2013), 17
patients of varying age from 15 unrelated families were
recruited from the Genetic Clinic and Pediatric Neurology
Clinic. The study was approved by the institutional ethics
committee, and written informed consent was taken from
all parents. Clinical details were filled in a predesigned
proforma for neurometabolic disorders. Diagnosis was
made based upon the clinical presentation, neuroimaging,
urinary organic acids and tandem mass spectrometry
results. Wherever possible, clinical outcome was assessed
through follow-up either clinically and by review of records
or through parents' interview where the child was not alive.
During follow-up assessment, patients were evaluated
mainly clinically and not biochemically for amino acids
due to lack of availability of amino acids and affordability.
Age-dependent developmental assessment tools were used
for the developmental delay. It included calculation of
developmental age and quotient using the Developmental
Assessment Scale for Indian Infants (DASII) for 0–30
months, Developmental Profile 3 (DP 3) for 0–12 years and
Malin’s Intelligence Scale for Indian Children (MISIC) for
6–15 years. No formal scoring for the severity of
movement disorder or morbidity was used.
GCDH Gene Analysis
Peripheral blood was collected in EDTA vacutainer, and
genomic DNA was isolated by salt method (Miller et al.
1988). Primers were designed by primer 3 software
(bioinfo.ut.ee/primer 3–0.4.0) (Supplementary Table 1),
and coding sequences were amplified in eight different
fragments by polymerase chain reaction (PCR). Amplified
PCR products were purified by enzyme treatment (ExoI &
SAP) and sequenced by ABI 3130 Genetic Analyzer
(Applied Biosystem, USA). Sequence analysis was per-
formed by using ChromasPro software (http://technelysium.
com.au) and NCBI blast. Nomenclature of novel mutations
was done according to the guidelines of Human Genome
Variation Society (http://www.hgvs.org/mutnomen). Novel
mutations were checked in the 1000 Genome Projects
database (http://www.1000genomes.org/), dbSNP database
(http://www.ncbi.nlm.nih.gov/snp/) and HGMD (Human
Gene Mutation Database, http://www.hgmd.org/).
In Silico Analysis of Novel Mutations
Multiple sequence alignments were performed to check the
conservation of amino acid across some other species.
PolyPhen2 (http://genetics.bwh.harvard.edu/pph2) and
SIFT (http://sift.jcvi.org) programs were used to assess the
qualitative effect of missense changes on the protein
function. Both these programs predict the effect of amino
acid replacement due to mutation on the function of protein.
PolyPhen2 predicts the effect based on physicochemical
properties of residue and comparative analysis, while SIFT
predicts on the basis of degree of conservation of residues
through PSI-BLAST sequence alignment.
Three-dimensional structure of the proteins is required to
understand the role of mutations on their structure and
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function at atomic level. Crystal structure of wild-type
human GCDH complexed with coenzyme FAD
(PDB: 1SIQ) (Fu et al. 2004) is available in PDB. Model
structure of protein with novel missense mutation was built
with the help of crystal structure of wild-type protein and
“Build Mutant” protocol incorporated in MODELLER 8.2
program (Sali and Blundell 1993) in the modelling environ-
ment of Discovery Studio (DS 2.0) (Discovery Studio 2006,
Accelrys Inc., San Diego, CA, USA). The “Build Mutant”
protocol changes the selected residue into the desired residue
and optimizes the conformation of mutated residue along
with neighbouring residues. Side chains of the residues in the
models were further refined to correct their conformation and
orientation using the modelling program “Chi Rotor”
(Spassov et al. 2007). The stereochemical quality of the
mutant models was verified by PROCHECK (Laskowski
et al. 1993). The generated models were energy minimized to
remove any steric clash between atoms, followed by short
MD simulations for the final refinement using CHARMm
force field simulation engine (Brooks et al. 1983; Momany
and Rone 1992).
Results
A total of fifteen unrelated families and seventeen patients
were recruited during the study period. The male/female ratio
was 1.4:1. The median age at onset of symptoms and final
diagnosis was 6 months (212 months) and 18 months
(3–192 months), respectively. Out of 15 families, 3 had
positive family history. Consanguinitywas seen in 8/15 (53%)
families with different religious backgrounds (5 Muslim, 1
South Indian, 2 Hindu). Twelve patients (70%) had precipitat-
ing illness like fever associated with seizure (4/12), fever
associated with/without gastroenteritis or pneumonia (4/12),
seizure alone (3/12) or after immunization (1/12). The main
presenting features were macrocephaly, developmental
regression mainly motor due to development of dystonia,
seizures or a combination of these. Table 1 shows the
distribution of clinical, biochemical and radiological abnor-
malities across various families. Patients were divided into
four developmental categories: patients with (1) normal
development, (2) developmental regression, (3) develop-
mental delay only and (4) developmental delay with
regression category. “Regression” in GA I essentially refers
to loss of intentional motor control due to development of
dystonia. Six patients (35.2%) had normal initial develop-
ment followed by regression and dystonia, two had normal
development without regression or dystonia but had asso-
ciated seizures and one had normal development with
dystonia. The rest of the eight patients (47%) had develop-
mental delay with or without regression with associated
extrapyramidal symptoms in all except one. Based upon the
developmental assessment by DASII, DP3 and MISIC at
different ages, all patients except F2, F10a, F12 and F15 had
delay in the physical and adaptive domain primarily because
of the development of dystonia. Patients F7, F9 and F15 had
mild global developmental delay, whereas patients F1, F3,
F4, F8 and F13 had severe to profound delay.
Macrocephaly, dystonia, choreoathetoid movements and
seizures were present in 70.5% (12/17), 64.7% (11/17),
0.05% (1/17) and 52.9% (9/17), respectively. Patients with
generalized tonic–clonic seizures had initial one or two
episodes followed by complete disappearance. Three
patients had myoclonic seizures. Both striatal (hyperinten-
sities in caudate and putamen) and extrastriatal (subdural
hygroma, wide sylvian fissure, frontotemporal atrophy,
hyperintensities in globus pallidus and thalamus) abnormal-
ities on neuroimaging were seen in all the patients. Majority
of the patients had feeding difficulties especially in
swallowing. Soon after diagnosis, all the patients were kept
on indigenous lysine- and tryptophan-restricted diet (pre-
dominantly a vegetarian Indian (native/local) diet in natural
form) and carnitine supplementation (50–100 mg/kg/day)
due to nonavailability and affordability of GA I-specific
diet. Lysine restriction was achieved by natural and locally
available diet. The amount of lysine varied depending upon
the different age groups with an average daily intake of
90–120 mg/kg body weight/day, the highest being in
infants. The total protein intake was 1–2 g protein/kg actual
body weight/day. All patients were also supplemented with
riboflavin (100–300 mg/day), calcium and other micro-
nutrients soon after the diagnosis, and none of them reported
to have any major deficiencies. These patients were on
naturally achieved lysine-restricted vegetarian diet, and
lysine-free, tryptophan-reduced amino acid supplements
were not given separately due to nonavailability of these
amino acid supplements. Baclofen (10–20 mg/day) was
used for dystonia. Two patients (F3 and F5) died at the age
of 1.6 and 2.6 years, respectively. Both these children had
severe feeding difficulties and were malnourished. They
died at home probably due to aspiration pneumonia.
GCDH Gene Mutations
A total of 15 different mutations were identified in
GCDH gene in different exons in 17 patients of 15
unrelated families. Seven novel (c.281G>A (p.Arg94Gln),
c.401A>G (p.Asp134Gly), c.662T>C (p.Leu221Pro),
c . 8 8 1 G >C ( p . A r g 2 9 4 P r o ) , c . 1 1 7 3 d u p G
(p.Asn392Glufs*5), c.1238A>G (p.Tyr413Cys) and
c.1241A>C (p.Glu414Ala)) and eight reported
(c.650C>T (p.Pro217Leu), c.769C>T (p.Arg257Trp),
c.764C>T (p.Ser255Leu), c.770G>A (p.Arg257Gln),
c.937C>T (p.Arg313Trp), 1173delG (p.Asn392Metfs*9),
c.1204C>T (p.Arg402Trp) and c.1207C>T (p.His403Tyr))
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mutations (Fig. 1, Table 2) were found only in five different
exons of GCDH gene. Mutation c.1207C>T (p.His403Tyr)
was initially thought to be novel in nature, but recently it
has been reported (Wang et al. 2013). Amongst the seven
novel mutations, one is frameshift and six are missense
mutations. Prenatal diagnosis was performed for one family
(F1). Upon counselling, pregnancy was terminated as the
foetus was affected.
In Silico Analysis
All the novel mutations were found in the highly conserved
region of the protein. Both PolyPhen2 and SIFT programs
predict the effect of observed novel mutation in this study to
have deleterious effect on the function of protein. Stereochem-
ical qualities of mutant models are good, and substituted
residues lie in the most favoured region of Ramachandran’s
plot. In silico study through the three-dimensional structure
of the model of the mutant proteins helps to understand the
effect of mutation on the structure of protein.
Genotype and Biochemical Phenotype
Patients were divided into high excretors and low excretors
based upon the criteria by Baric et al. (1999) and Kolker
et al. (2006). High excretors were defined as glutaric acid
excretion of >100 mmol GA/mol creatinine and low
excretors as <100 mmol GA/mol creatinine. Levels of
glutaric acids were available only in six patients with five
novel alleles. In our study, out of seven novel alleles,
two alleles, c.662T>C (p.Leu221Pro) and c.281G>A
(p.Arg94Gln), had almost no glutaric aciduria (F11a and
b) and hence were low excretors; however, c.1241A>C
(p.Glu414Ala) (F2), c.1173dupG (F12) and c.1207C>T
(p.His403Tyr) in Ex-11 (F13, F14) were found to be high
excretor alleles.
Discussion
There have been few reports of GA I in Indian patients, the
majority being on neuroimaging (Kamate et al. 2012; Sen
and Pillay 2011). This is the first report on clinical,
biochemical and molecular profile of Indian patients.
Clinical Spectrum
Glutaric aciduria type I is probably the second common
organic acidemia in India, the commonest being methyl-
malonic acidemia (unpublished data, personal communica-
tion). These patients have a variable course of illness, the
majority of patients presenting with loss of intentional
motor control due to development of dystonia precipitated
by an acute febrile illness, macrocephaly and extrapyrami-
dal symptoms. In our cohort, the median age at the onset of
symptoms was 6 months. The age at diagnosis was quite
variable and there was a gap of nearly 12 months between
the onset and diagnosis probably because of the variable
clinical spectrum of the disorder or due to the delayed
diagnosis. Twelve out of 17 (70%) had some precipitating
factor at around 6 months. Out of these three had normal
development, while others had developmental delay and/or
regression. In accordance with other studies (Wang et al.
2013; Mushimoto et al. 2011), a combination of macro-
cephaly, developmental regression, dystonia and seizures
emerged as the predominant presenting feature. Three out
of 17 had normal development (F2, F10a, F6) despite
having the precipitating event and radiological abnormal-
ities. Case F2 was diagnosed at 3 months and kept on
modified diet and carnitine supplementation. He has good
compliance and is developmentally normal. All patients
with or without crises had MRI abnormalities (Harting et al.
2009). Eighty two percent of the patients (14/17) were
already neurologically compromised (categories 2–4) at the
time of presentation. Category 2 patients had mainly motor
regression due to incapacitating dystonia. A correlation
between MRI findings and dystonia has been studied in
detail earlier by Harting et al. (2009) and Garbade et al.
(2014). These authors clearly showed that the severity of
striatal lesions on MRI did correlate with the severity of the
movement disorder. In contrast, extrastriatal MRI finding
did not correlate with the motor dysfunction. In our study,
5/17 patients did not develop dystonia at a mean age of 37
months (3–132 months). Two of these patients (F10a and
Fig. 1 Mutation distribution across GCDH gene
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F12) had only extrastriatal features, whereas F2, F4 and
F15 had both extrastriatal and striatal involvement. In our
study, we did not perform any follow-up MRI. It has been
shown (Heringer et al. 2010) that prompt vigorous
intervention during acute episodes with the provision of
glucose, fluids and electrolytes along with carnitine
supplementation can prevent striatal degeneration and has
improved outcome. Most of our patients had acute crises
prior to the diagnosis. They were diagnosed after routine
evaluation for either developmental delay, seizures or
macrocephaly. Hence no emergency regimen was given at
the time of acute precipitating factors. However, after initial
diagnosis, patients were explained about emergency home
treatment (Kolker et al. 2006, 2007, 2011).
An individualized long-term dietary treatment (Kolker
et al. 2011; Viau et al. 2012; Lee et al. 2013) includes a low
lysine diet through natural protein with or without lysine-
free and tryptophan-reduced amino acid supplements along
with L-carnitine supplementation for adequate growth (Boy
et al. 2013). Due to lack of availability of lysine-free and
tryptophan-reduced therapeutic formulae, the metabolic
maintenance treatment was tried mainly through locally
available protein-restricted diet with age-specific minimum
requirement of lysine and tryptophan, micronutrients,
riboflavin and carnitine supplementation. Baclofen was
given for dystonia.
Mutation Spectrum
GA I mutations are classified either as severe or mild
depending upon the residual enzyme activity and the
urinary excretion of glutaric acid. p.Arg402Trp mutation
in exon 11 is described as one of the severe and common
mutations that account for about 20% of the mutations in
Caucasians. Most of the patients are reported as compound
heterozygotes, but in our cohort, 80% of the family
mutations were in homozygous state including Arg402Trp
mutation.
Figure 1 shows the distribution of 15 different mutations
in five different exons of GCDH gene, in which seven of
them (c.1238A>G, c.1241A>C, c.1173dupG, c.881G>C,
c.401A>G, c.662T>C, c.281G>A) were novel and found
in seven unrelated patients. Three families were homozy-
gous for novel mutations, whereas five were compound
heterozygous. Mutation prediction software PolyPhen2 and
SIFT (Table 2) depicted that these missense mutations are
probably damaging/damaging the protein. Frameshift muta-
tions c.1173dupG (p.Asn392Glufs*5) and c.1173delG (p.
Asn392Metfs*9) were generated truncated proteins. Family
11 had two novel mutations in compound heterozygous
state, the father being a carrier of c.281G>A (p.Arg94Gln)
a n d t h e m o t h e r a c a r r i e r o f c . 6 6 2 T>C
(p.Leu221Pro). However, these mutations appear as leaky
or mild as both these sibs did not show urinary excretion of
glutaric acid.
In Silico Analysis of Effect of Mutation on Their Structure
GCDH is a member of acyl-CoA dehydrogenase family and
catalyses the oxidative decarboxylation of glutaryl-CoA
using flavoprotein as its electron acceptor. Structural
analysis reveals that the proper positioning of cofactor
FAD (flavin adenine dinucleotide) and glutaryl-CoA is
essential for decarboxylation reaction followed by dehydro-
genation (Fu et al. 2004). Sequence analysis shows that
residues Arg294, Tyr413 and Glu414 are highly conserved
amongst the dehydrogenase family. Residue Glu414 is an
active-site residue and functions as catalytic base. It is
responsible for proton abstraction. Hence, the position of
carboxylate group of Glu414 is extremely important and is
stabilized by two hydrogen bonds with side chain of
Arg294 (Fig. 2a). Therefore, Glu414Ala mutation will
abolish the catalytic function of proton abstraction. The
natural variant of Glu414 leads to loss of its enzymatic
activity (Keyser et al. 2008). In addition, replacement of
Glu414 by Ala also leads to a change in side chain
conformation of crucial residues Arg294 and Tyr413
(Fig. 2b). Hence, this substitution will hamper its function
severely. It clearly indicates that this mutation has a direct
and crucial role in the pathogenesis of GA I.
Tyr413 is essential for the stabilization of FAD position
through p–p aromatic interaction with phenyl ring of flavin
(Fig. 2a). It is present on the flexible loop region, and
conformation as well as the position of its aromatic side
chain is stabilized by hydrogen-bonded interactions with
another crucial residue Arg138. Arg138 plays an important
role in enzymatic function as its replacement by Gln or Gly
leads to manyfold increase in Km value for glutaryl-CoA
and decrease in its catalytic activity (Dwyer et al. 2001).
The conformation of Arg138 side chain is known to be
crucial for the enzymatic function as it acts as a hydrogen
bond donor to g-carboxylate of substrate glutaryl-CoA and
electrostatic catalyst to stabilize the negative charges during
catalysis (Keyser et al. 2008). Positively charged guanidi-
nium group of Arg138 in wild-type model complex was in
close proximity (3.0 Å) of carboxylate moiety of glutaryl-
CoA. Substitution of Tyr413 by Cys will lead to loss of a
crucial edge to face p–p interaction between Tyr and flavin;
this might lead to destabilization of FAD position (Fig. 2c).
Simultaneously this also alters the conformation of Arg138
as it is stabilized by hydrogen bond with Tyr413, and
important guanidinium group in mutant model complex
moves away from carboxylate group of glutaryl-CoA.
Therefore, Tyr413Cys mutation causes the double adverse
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impact and might lead to a significant decrease in the
enzymatic activity of GCDH.
The substitution of Arg294 by Pro causes loss of crucial
hydrogen bonds with Glu414, and this leads to a change in
the conformation of active-site residue Glu414 required for
proton abstraction (Fig. 2d). This also changes the loop
conformation on which another crucial residue Tyr413
resides. Moreover, residue 294 lies in the helical region,
and Pro is known to destabilize the helical conformation.
Hence, this mutation might also adversely affect its
enzymatic activity.
The rest of the three novel missense mutations
(Arg94Gln, Asp134Gly and Leu221Pro) lie away from
the active site. Residue Arg94 is positively charged and
surface exposed. In mutant, Arg94 is replaced by Gln
which is neutral in nature. This change in nature of residue
can affect the interactions with the interacting partner. The
degree of effect of this mutation on its function will depend
on the importance of the interacting partner. Recently two
important proteins, dihydrolipoamide S-succinyltransferase
involved in glutaryl-CoA synthesis and b subunit of
electron transfer flavoprotein acting as electron acceptor,
have been identified as directly binding partners of GCDH
(Schmiesing et al. 2014). Another mutation site residue
Leu221 lies on the loop region and away from the active
site. It is nonpolar in nature and its side chain is buried.
Fig. 2 Cartoon representation of (a) crystal structure of wild-type
human mitochondrial GCDH and model structure of mutants (b)
Glu414Ala, (c) Tyr413Cys and (d) Arg294Pro. Side chain of
important residues are shown (ball and stick in green for wild type
and cyan for mutants), glutaryl-Co-A (ball and stick in magenta) and
cofactor FAD (ball and stick in orange) and hydrogen-bonded
interactions in black dotted lines. Glutaryl-CoA and FAD are shown
partially
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Its substitution by Pro does not affect the conformation of
the protein significantly. Hence, this mutation does not
appear to affect the enzymatic function of GCDH. Similarly
Asp134 is pointing away from the active site; however,
OD1 and OD2 of its side chain form hydrogen bonds with
residues present on the neighbouring helices and might be
assisting in the proper arrangement of those helices. Its
substitution by Gly which lacks any side chain will not be
able to form hydrogen bonds with residues on the
neighbouring helices and might be decreasing the stability
of helical arrangement. Though the role of this mutation on
the catalytic function cannot be directly linked, this may
lead to decreased enzymatic activity.
Biochemical, Genotype and Phenotype Correlation
The genotype and phenotype correlation has been elusive in
GA I; however, genotype often predicts the biochemical
phenotype in GA I. Severe mutations tend to have no
residual enzyme activity and have a typical urinary
metabolite pattern. Milder mutations have significant
residual enzyme activity, hence low or normal urinary
excretion of glutaric acids. Some of the mutations correlate
well with the excretion of glutaric acid and 3 hydroxyglu-
taric acids. Arg402Trp and Ala293Thr correspond to high
excretor group (Busquets et al. 2000a), whereas Arg227Pro
and Val400Met account for low excretor group (Christen-
sen et al. 1997). In our study, out of seven novel alleles,
two (c.662T>C (p.Leu221Pro) and c.281G>A (p.
Arg94Gln)) in exons 8 and 4, respectively, were low
excretor alleles, whereas c.1241A>C (p.Glu414Ala),
c.1173dupG and c.1207C>T (p.His403Tyr) in exon 11
were high excretor alleles.
In accordance with previous studies, we also did not observe
any genotype and phenotype correlation (Christensen et al.
2004; Mushimoto et al. 2011). Interestingly, in our cohort,
Arg402Trp (allele frequency 8/34, 23.5%) mutation emerged
as one of the common mutations in four unrelated Muslim
families. Two of these families had consanguinity. Haplotype
analysis could not be done on these families to examine the
founder effect. This mutation constituted about 23.5% of all
the mutant alleles followed by His403Tyr (alleles frequency 4/
34, 11.76%). Both these mutations were seen in unrelated
families and did not have a similar phenotypic effect,
suggesting a poor genotype–phenotype correlation and
interfamilial variability in GA I. Intrafamilial variability as
previously reported by Gregersen et al. (1977) and Kolker
et al. (2007) was also observed in one of our families; the
siblings in F10 and F11 (F10 showed presence of isolated
macrocephaly and seizure in one sib and severe dystonia with
regression in another sib) with the same mutation and genetic
background had different phenotypes, suggesting intrafamilial
variability in GA I. This intrafamilial and interfamilial
variability can probably be explained by the epigenetic factors
or complex interactions at tissue or metabolic levels and the
extent of neurological damage caused by the various
precipitating factors (Wang et al. 2013). In our cohort, exon
11 (in 53%; 18/34 alleles) followed by exon 8 (in 23.5%; 8/34
alleles) appear to harbour most of the mutations (Fig. 1).
Hence, we recommend that molecular testing for exon 11
should be done first followed by exon 8 in resource-
constrained settings. The combined diagnostic yield for these
two exons appears to be as high as 76.5%.
Although the clinical, radiological and biochemical
analyses are helpful in arriving at the diagnosis, molecular
confirmation of the diagnosis undoubtedly gives an
opportunity to the family for prenatal diagnosis in the
subsequent pregnancies. Prenatal diagnosis could be offered
in one family, and the pregnancy was terminated as the
foetus was found to be affected.
The limitations in our study include qualitative results of
urinary organic acids, because of which the exact correla-
tion between biochemical phenotype and genotype could
not be established. Secondly, after initiating the modified
indigenous diet, the effectiveness of the diet could not be
evaluated as the subsequent follow-ups for growth, bio-
chemical monitoring for various amino acids and repeated
follow-up MRI scans were not available.
In India, due to lack of uniformly available newborn
screening, the diagnosis of GA I is delayed. Other factors
for delayed diagnosis and poor final outcome could be lack of
awareness amongst physicians, distance to the appropriate
medical facility, lack of home management and poor patient
compliance due to illiteracy and socioeconomic status.
Excellent outcomes after early diagnosis and early dietary
intervention for favourable neurological outcome have led to
the inclusion of GA I in newborn screening panel across
various countries. In countries like India, where a national
newborn screening program is yet to start, authors would like
to recommend its inclusion in the expanded panel. Till that
time it would be plausible to have a high index of suspicion
for early diagnosis and timely dietary intervention and parent
education to prevent further progress of neurological damage
and birth of another affected child. Although no formal
biochemical follow-up evaluation has been done for the low-
cost, culturally acceptable and locally available Indian indige-
nous diets, it was observed that with good patient compliance,
patients on these diets did not further deteriorated neurologi-
cally. Biochemical evaluation with lysine and tryptophan
levels and evaluation of growth parameters of Indian patients
with GA I on indigenous diet are warranted to examine the
effectiveness of these diets before drawing any conclusions.
Conclusion
Recognition of modifiable inherited metabolic disorders
such as GA I requires high index of suspicion and timely
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referral for further management to an appropriate centre.
Early diagnosis and prompt management for acute illness
and initiation of indigenous diet and carnitine are likely to
have a beneficial effect on the neurological outcome.
Further studies and appropriate follow-up are required to
evaluate the effectiveness of Indian indigenous diets in the
growth and long-term outcome of patients with GA. In
accordance with the previous reports, our results also
showed that there is a lot of intrafamilial and interfamilial
variability even with the same mutation and there is no
genotype–phenotype correlation. Molecular confirmation
of the diagnosis is particularly helpful in prenatal diagnosis
in the next pregnancy. p.Arg402Trp mutation emerged as a
common mutation in Muslim families. Exon 11 and exon
8 are two hot spot exons and should be analyzed first in
Indian patients for molecular diagnosis. Confirmation by
molecular diagnosis aids in providing genetic counselling
and prenatal diagnosis in future pregnancy.
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Take-Home Message
Exons 11 and 8 of the GCDH gene seem to be the
mutational hot spot regions in Indian patients with GA I.
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Abstract Fabry disease (FD) is a lysosomal storage disorder
resulting from a deficiency of lysosomal enzyme a-galacto-
sidase A (a-gal A). Reduced or missing a-gal A enzyme
results in the storage of globotriaosylceramide (GL3) and
related glycosphingolipids in the cellular lysosomes through-
out the body. The majority of GL3 buildup occurs in the
body’s vasculature resulting in narrowed blood vessels and
an increased risk for strokes, transient ischemic attacks, and
deep vein thrombosis. Theoretical concerns have been raised
about increased pregnancy complications in women affected
by FD as glycosphingolipid storage has been found in both
maternal- and fetal-derived placental tissues. This retrospec-
tive study was conducted to better understand risks for
women with FD during pregnancy. Survey questions
included queries about prenatal medications, teratogenic
exposures, prenatal testing, common pregnancy complica-
tions, Fabry symptoms during pregnancy, obstetrical history,
and immediate neonatal history. In total, 41 affected women
completed the survey. Results indicate several Fabry-related
symptoms and features may worsen during pregnancy,
including gastrointestinal symptoms, acroparesthesias, pro-
teinuria, headaches, and postpartum depression. Although
no life-threatening complications were reported, a statisti-
cally significant increased frequency of hypertension was
observed when comparing data from this study to the
general population (p < 0.05) and previous publications
(p < 0.001). Limitations include sample size and recall
bias. Though this survey sampling of women was small and
required women to recall their past pregnancy experiences,
the findings suggest that when pregnant, women with FD
should be aware of potential worsening of FD symptoms
and may benefit from consulting with a maternal-fetal
medicine specialist.
Introduction
Fabry disease (FD) is an X-linked lysosomal storage disorder
with an estimated incidence in at least 1 in 10,000 women in
the United States (Desnick et al. 2001a, b; Kampmann et al.
2002; Laney et al. 2013). FD is caused by a deficiency or
lack of the lysosomal enzyme a-galactosidase A (a-gal A;
EC 3.2.1.22). Reduced amounts of a-gal A enzyme result in
the buildup of globotriaosylceramide (GL3) and associated
glycosphingolipids in the lysosome of cells throughout the
body. GL3 storage in the endothelial lining of blood vessels
leads to narrowing and constriction of cardiac, renal, and
central nervous system vessels over time causing progressive
damage of renal and epithelial cells, myocardial cells,
neuronal cells, endothelial, and smooth muscle cells (Eng
et al. 2006; Laney et al. 2013).
It has been conclusively shown that women with FD are
not simply asymptomatic carriers. Over 60% of female
heterozygotes suffer significant burden of disease and
reduced quality of life (Wang et al. 2007). Frequent
symptoms include hypertension prior to onset of worsening
renal disease, severe abdominal cramping, hypohidrosis,
central nervous system involvement with premature stroke,
and psychological issues (Whybra et al. 2001; Ries et al.
2003; Gupta et al. 2005; Deegan et al. 2006; Wang et al.
2007; Wilcox et al. 2008; Bouwman et al. 2012). As more
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than half of women with FD suffer from disease symptoms,
the importance of evaluating disease status during preg-
nancy has been stressed and requires further investigation.
Specific concerns associated with females with FD during
pregnancy include microvascular disease that could increase
the risk for clotting and worsening kidney function (Mac-
Dermot et al. 2001; Eng et al. 2006). GL3 storage has also
been documented in maternal- and fetal-derived placental
tissues, which heightens the risk of constriction of the
placental blood vessels (Vedder et al. 2006; Bouwman et al.
2010; Politei and Thurberg 2012). Additionally, worries have
been raised about the status of an affected fetus causing
pregnancy complications due to abnormal GL3 storage
(Politei and Thurberg 2012). There are concomitant con-
ditions that, when combined with preexisting FD, may
complicate pregnancy. These include preeclampsia, gesta-
tional diabetes, hypertension, and maternal age at delivery
(Macdonald-Wallis et al. 2011). Small-scale studies have
shown that traditional FD symptoms such as acroparesthesias
may worsen during pregnancy; however, no conclusive
evidence of worsening of symptoms during pregnancy was
seen in a previous large-scale review (Bouwman et al. 2012).
The purpose of this retrospective survey is to increase our
understanding of the actual risks in the previous pregnancies
of women affected by FD as compared to reported rates of
complications in the general population. Study objectives
addressed this by determining the incidence of proteinuria
onset and the rate of adverse events including transient
ischemic attacks (TIAs), strokes, and deep vein thrombosis
(DVTs) in pregnant females with FD as compared to
pregnant women in the general population.
Methods
Institutional Review Board Approval
This project has been approved by the Emory University
Institutional Review Board. All participants completed a
detailed consent process prior to participating in the study.
Documents approved for this study included recruitment
flyers, recruitment emails, consent form, survey, and
medical release form.
Participants and Recruitment
Recruitment for the study was a multifaceted effort. Survey
recruitment flyers were mailed out to patients within the
Emory University mailing lists who met inclusion criteria.
Notice of this study was also included in the Fabry Support
and Information Group (FSIG) monthly newsletter and on
the National Fabry Disease Foundation (NFDF) website.
The study investigators attended local and regional Fabry
meetings sponsored by the NFDF and FSIG. Recruitment
flyers were also distributed by genetic counselors working
in Lysosomal Centers of Excellence around the United
States to provide to qualified patients who may have an
interest in participating. Participating institutions included
Children’s Hospital of Pittsburgh, Children’s Hospital of
Wisconsin, Cincinnati Children’s Hospital, and
Massachusetts General Hospital.
Study Population
After receiving IRB approval, participants who completed
the informed consent process in person or via the
telephone were screened to determine if they met study
entry criteria. Inclusion criteria for participating in the
IFOP study required all participants be female, over the
age of 18 years, have a confirmed GLA gene mutation or
low a-Gal A level on plasma leukocyte analysis, and
have had a pregnancy within the past 25 years. Subjects
not meeting these criteria were excluded. The target
participant population was 100 pregnancies in at least
75 women.
Survey Design
In addition to providing consent, participants were asked to
complete a medical release of information form in order to
obtain medical records from the patient’s obstetrician,
gynecologist, and birth hospital. Study participants also
completed a self-response survey entitled “The Impact of
Fabry Disease on Pregnancy” (IFOP) about their pregnan-
cies. The IFOP questionnaire was divided into five parts:
demographic background, gynecological history, fertility,
pregnancy history, and postnatal issues (Table 1). A
sampling of patient survey questions are provided in
Table 1. In total, the survey included at least 76 questions.
Women were asked to complete the survey for each
individual pregnancy, and questions were repeated for each
subsequent pregnancy.
Statistical Analysis
Statistical support was provided by Emory University
Biostatistics Center. All raw data was obtained from self-
response queries and verified in the patient’s medical
record, if available. Data was then analyzed using compar-
ative t-tests. Survey responses were totaled and compared
to general population estimates of pregnancy complications
from the Centers for Disease Control and Prevention
Women’s Health Survey (Centers for Disease Control and
Prevention National Center for Health Statistics 2012) and
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previously reported literature values in woman affected by
Fabry disease by using paired comparison tests. All
statistical analyses were performed using SAS® software.
Results
Over 100 surveys were distributed to women affected by
FD who met the inclusion criteria for the IFOP study. A
total of 45 women were consented to participate, and
ultimately, 41 women completed the survey and provided a
medical records release for a response rate of approximately
45%. Records were obtained from physicians and hospitals
for 21 out of the 41 participants. From the records, the
investigators extracted clinic notes, laboratory values, and
postnatal discharge summaries. The average age of the
women at the time the surveys were completed was
43.5 years of age, and the average number of pregnancies
per woman was 2.49. Responses collected from the survey
are shown in Table 2.
The most commonly reported FD symptoms and features
experienced during the 100 pregnancies included protein-
uria (37.20%), acroparesthesias (31.3%), headaches
(22.5%), constipation (29.40%), and diarrhea (27.5%)
(Table 3). No life-threatening complications such as renal
failure, stroke, TIAs, or DVTs were reported during
Table 1 IFOP survey sections and sample questions
IFOP survey section Sample question asked
Pregnancy and gynecological history 1. “Have you ever been pregnant?” If yes, number of times.
2. “At what age did you begin having your periods?”
3. “Have you ever been evaluated for infertility concerns?”
Family history and pregnancy history 1. “Have you ever had a miscarriage?”
2. “How many children have you given birth to?”
3. “Did you know that you had Fabry disease before having children?”
Individual pregnancy history 1. “Did you smoke during your pregnancy?” If yes, how many cigarettes per day?
2. “Did you have any of the following:”
Gestational diabetes
Abnormal ultrasounds
High blood pressure
Preeclampsia
3. “Did you experience any of the following during pregnancy:”
Increased diarrhea
Constipation
Alternating diarrhea and constipation
4. “Did you have any heart problems during pregnancy:”
Heart palpitations
Atrial fibrillations
Other heart problems
5. “Did your doctor tell you had protein in your urine?”
Post-birth 1. “Was your baby born with any birth defects such as a heart defect or an extra toe?”
2. Did you experience any symptoms of postpartum depression or anxiety?
Questions were presented to be answered as self-response multiple choice, yes or no, and free-response answers
Table 2 Demographic information of participants in the IFOP study
Demographic
background
IFOP Participants
Ethnicity 34 Caucasian
3 African Americans
3 Hispanic
1 Asian
Average age range of
first pregnancy
11 women (12–21 years)
21 women (21–29 years)
8 women (30–35 years)
1 woman (36–40 years)
Average number of
pregnancies per
participant
2.49 pregnancies
Average age of
participants at time
survey was
completed
43.5 years
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pregnancy. Of the symptoms reported, proteinuria was
reported most often. Of the 41 women who completed the
survey, 4 were treated with enzyme replacement therapy
(ERT). No complications of ERT were reported.
Pregnancy complications queried in the survey included
preeclampsia, proteinuria, gestational diabetes, premature
delivery, pregnancy-induced hypertension, miscarriage, and
intrauterine death. As seen in Table 4, the incidence for
preeclampsia, gestational diabetes, premature delivery, and
miscarriage as compared to the general population rate was
not statistically significant. The rate for intrauterine death
was significant; however, both babies were affected by
chromosomal abnormalities and as such do not reflect an
increased incidence of intrauterine death related to FD.
The rate of proteinuria and pregnancy-related hyperten-
sion in reviewed FD cases was statistically significant and
presents at a higher rate as compared to the general
population rate. Protein levels were increased in 38/102
(37.2%) pregnancies. Analyzing the data for proteinuria
onset by subject rather than pregnancy, 17 women out of 41
women affected by FD were found to have proteinuria
during at least one pregnancy (Table 5). Within this cohort,
7/17 women had new onset of proteinuria in their initial
pregnancy with an additional 3/17 women experiencing
proteinuria onset not in their first pregnancy but in a
subsequent pregnancy.
Pregnancy-related hypertension was reported in 10.8%
(12/102) of the pregnancies. Some of these pregnancies
4.9% (5/102) were also complicated by preeclampsia.
However, none of the six women reporting pregnancy-
related hypertension were affected by hypertension prior to
their first pregnancy.
Although few complications were experienced in the
postpartum period, we did find that postpartum depression
was reported in a surprising 17.1% of this cohort of women
(Table 6). This value is not statistically significant as
compared to the general population incidence, but it did
affect a significant number of participants (7/41). Of the
Table 3 Most common symptoms and laboratory abnormalities of Fabry disease experienced during pregnancy by affected women
Most common Fabry symptoms during
pregnancy
Number of pregnancies with increased
symptoms
Total number of
pregnancies
Incidence
(%)
Proteinuriaa 38 102 37.20
Acroparesthesia 32 102 31.30
Headaches 23 102 22.50
Constipation 30 102 29.40
Diarrhea 28 102 27.50
a Proteinuria was not formally quantified
Table 4 Comparison of pregnancy complications in affected women with FD during pregnancy and the general population of pregnant women
Pregnancy
complication
Incidence this
cohort of
pregnancies
Literature values in Fabry patients from
Bouwman et al. (2012)a and Wang et al.
(2007)b
P value,
comparing to
literature
General
population
incidence
P value, comparing
to general population
Preeclampsia 4.9% (n ¼ 5/102) 9.4% (n ¼ 3/32)a 0.35a 3.4% 0.40
Proteinuria 37.2% (n ¼ 38/
102)
34% (n ¼ 11/32)a 0.76a 3.8% <2.2  1016
56% (n ¼ 10/18)b 0.14b
Gestational
diabetes
8.8% (9/102) – – 2–10% 0.002–0.86
Premature
delivery
18.8% (16/85) 19% (n ¼ 6/32)a 0.99a 11.9% 0.06
Hypertension 10.8% (12/102) 34% (n ¼ 11/32)a 0.001a 6% 0.05
43% (n ¼ 16/37)b 1.91  105 b
Miscarriage 11.8% (11/102) 25% (n ¼ 8/32)a 0.06a 9–12% 0.30
Intrauterine
death
2.3% (2/85)c 0.03% (n ¼ 1/32)a 0.81a 0.625% 0.09
Symbols denote literature comparisons, Bouwman et al. (2012)a and Wang et al. (2007)b . Population incidence of complications is from the CDC
(Centers for Disease Control and Prevention National Center for Health Statistics 2012)
c These pregnancies were affected by chromosomal abnormalities
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seven women who reported postpartum depression, only
one participant reported having a prior history of depression
and anxiety (Table 5).
Discussion
Retrospective investigation into pregnancies in women
affected by FD found an increased prevalence of several
specific pregnancy complications as compared to the
general population of pregnant women. Results indicate
several FD symptoms may worsen during pregnancy,
including gastrointestinal symptoms, acroparesthesias, pro-
teinuria, headaches, and depression during the postpartum
period. This study also confirms that females with FD
report a significant incidence of proteinuria and hyperten-
sion during pregnancy; however, there was no increased
incidence of strokes, end-stage renal disease, or other
related life-threatening complications in this population.
Building on the current FD guidelines, this survey supports
the recommendation that pregnant women with FD be
evaluated and, in some cases, monitored throughout
pregnancy by a maternal-fetal specialist in addition to
standard prenatal care (Laney et al. 2013).
The survey results can assist providers caring for women
with FD during pregnancy. Although progression of renal
Table 5 Individual participant responses to pregnancy complications (proteinuria, hypertension, and depression/anxiety)
Women with significant pregnancy complications
Pregnancy
complication
Symptoms before
pregnancy
First
pregnancy
Affected pregnancies
per participant
Total number of women reporting
complications (n ¼ 41)
Affected
pregnancies
(n ¼ 102)
Proteinuria Yes Yes 2/2 17/41 38/102
No No 1/2
No Yes 2/2
No Yes 2/4
Yes Yes 2/2
No Yes 1/2
No Yes 2/2
Yes Yes 2/3
No No 2/4
No Yes 4/4
Yes No 2/2
Yes Yes 2/2
No No 3/4
No No 2/4
No Yes 2/2
Yes Yes 2/4
Yes Yes 5/5
Hypertension No No 2/2 6/41 11/102
No Yes 2/2
No Yes 1/1
No Yes 2/2
No Yes 2/2
No Yes 2/4
Depression/
anxiety
No Yes 1/1 7/41 10/102
No No 1/2
No Yes 2/2
No No 1/2
Yes Yes 1/2
No Yes 1/2
No Yes 3/5
This table shows reported responses for women prior to pregnancy, first pregnancy, and total pregnancies
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disease could not be determined from the dipstick analysis
data in our study, urinary protein levels should be
monitored in women with FD throughout the entire
duration of their pregnancy and addressed using established
clinical guidelines (Laney et al. 2013). The reported
incidence of hypertension in the pregnancies of participants
compared with literature and the general population also
suggests that women with FD should have their blood
pressure monitored when pregnant and should also be
recognized that unlike in the general population of pregnant
patients, the increased rate of pregnancy-related hyperten-
sion in our study seems unrelated to an increase in
preeclampsia or preexisting obesity.
Although not found to be a statistically significant risk as
compared to the general population rate, signs and symptoms
of postpartum depression should still be monitored in
prenatal and postpartum period. The risk for depression and
anxiety in women affected by FD is increased and is
experienced by half of affected women, even when they
are not postpartum (Wang et al. 2007; Bouwman et al. 2012;
Laney et al. 2013; Bolsover et al. 2014).
The increased Fabry-related symptoms such as acropar-
esthesias in hands and feet, headaches, constipation,
proteinuria, and diarrhea should be monitored and treated
in pregnancy to optimize patient comfort and prevent
disease progression. Of course, these women may require
a change in therapeutic regime and consultation with a
genetic counselor or teratogen service as some medications
used to treat symptoms may have a teratogenic effect.
The use of ERT during pregnancy to treat the root enzyme
deficiency in FD has only been evaluated in limited studies.
Accordingly, the decision to start or continue therapy must
be made on an individual basis in cooperation with a team
experienced with treatment of FD (Deegan et al. 2006;
Vedder et al. 2006; Parent et al. 2010). This is further
supported by established recommendations from the
National Society of Genetic Counselors which recommends
that women with FD be placed on ERT as soon as symptoms
are first experienced and use discretion on whether to
continue during pregnancy (Laney et al. 2013). In this study,
4 out of 41 women received ERT infusions throughout the
duration of the pregnancy.
There are several limitations to this study. The use of a
small sample size may have obscured statistical significance
that may be discovered in larger studies. Also, the
questionnaire used was created by the investigators and has
not been formally validated. The retrospective nature of the
study might have led to recall bias although use of medical
records to validate findings sought to avoid this issue. In
future studies, the investigators will likely change the
inclusion criteria to require a more recent pregnancy or
prospective enrollment to address the difficulties in obtaining
medical records on all patients. Although medical records
were requested to allow for verification of participant self-
responses, medical records were not received for all study
participants. Data analysis may be a limitation as the few
studies regarding pregnancy complications in FD all differ in
methods of data collection and sample size. This may limit
the ability to compare these studies. Data stratification based
on race or ethnicity was not included as the majority of
participants were Caucasian. We acknowledge that this
analysis may overrepresent the complications reported due
to the fact that multiple pregnancies were analyzed from the
same woman. The authors chose to analyze data collected
based on number of pregnancies due to the many uneventful
pregnancies reported. Additionally, the participants who had
problematic pregnancies may have been more eager and
willing to complete the survey thus creating participation
bias.
Results from this survey highlight a need for future
studies to inquire about complications and health concerns of
pregnant women affected with FD. Studying the quality of
life reported by women during pregnancy would assist in
determining how disease may affect pregnancy. In the future,
a multicenter prospective analysis of pregnant women with
FD may aid in providing more concrete information about
the specific risks of complications during pregnancy.
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who participated in completing the IFOP survey. We hope the data
collected from this survey will further benefit women with Fabry
disease.
Synopsis
Based on retrospective review, pregnant women affected by
Fabry disease do not have life-threatening complications but
may experience worsening of specific disease symptoms.
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Abstract Background: Implementation of guidelines and
assessment of their adaptation is not an extensively inves-
tigated process in the field of rare diseases. However, whether
targeted recipients are reached and willing and able to follow
the recommendations has significant impact on the efficacy
of guidelines. In 2012, a guideline for the management of
urea cycle disorders (UCDs) has been published.We evaluate
the efficacy of implementation, adaptation, and use of the
UCD guidelines by applying different strategies.
Methods: (i) Download statistics from online sources
were recorded. (ii) Facilities relevant for the implementation
of the guidelines were assessed in pediatric units in Germany
and Austria. (iii) The guidelines were evaluated by targeted
recipients using the AGREE instrument. (iv) A regional
networking-based implementation process was evaluated.
Results: (i) Download statistics revealed high access with
an increase in downloads over time. (ii) In 18% of hospitals
ammonia testing was not available 24/7, and emergency
drugs were often not available. (iii) Recipient criticism
expressed in the AGREE instrument focused on incomplete
inclusion of patients’ perspectives. (iv) The implementation
process improved the availability of ammonia measurements
and access to emergency medication, patient care processes,
and cooperation between nonspecialists and specialists.
Conclusion: Interest in the UCD guidelines is high and
sustained, but more precise targeting of the guidelines is
advisable. Surprisingly, many hospitals do not possess all
facilities necessary to apply the guidelines. Regional
network and awareness campaigns result in the improve-
ment of both facilities and knowledge.
Introduction
Medical decisions should ideally be based on firm data
obtained from well-designed studies. However, many fields
in medicine lack such information – especially when rare
diseases are involved – rendering the patient’s management
subject to individual doctors’ best knowledge and experi-
ence as well as to the advice of limited numbers of experts
(Arnold et al. 2008, 2009; Spiekerkoetter et al. 2009). In an
attempt to overcome such “eminence-based” approaches,
guideline projects have been initiated to collect, carefully
discuss, and weigh all available information on the basis of
standardized methodological strategies and finally propose
the highly needed recommendations and guidance for
medical decision making (Kishnani et al. 2010; K€olker
et al. 2011a). There has been some criticism addressing the
standardized methodological strategies applied because
those have been developed to evaluate large pharmacologi-
cal trials but not research in the field of rare diseases
(Vockley et al. 2013). While this criticism is appropriate for
the SIGN methodology (Scottish Intercollegiate Guideline
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Network, http://www.sign.ac.uk), the recently proposed
GRADE (short for Grading of Recommendations Assess-
ment, Development and Evaluation) approach aims at
ameliorating this shortcoming (http://www.gradewor-
kinggroup.org/).
The list of guidelines is currently steadily growing, and
according to the intention of such processes, this should
result in some benefit for the patients. First experiences in
the field of rare inborn errors of metabolism (IEM), e.g.,
with the guidelines addressing glutaric aciduria type 1,
support this assumption (Heringer et al. 2010). We have
recently proposed a guideline for the management of urea
cycle disorders (UCDs) (H€aberle et al. 2012), a group of
rare defects of ammonia detoxification. The process of this
guideline development involved the SIGN methodology as
of 2009 and a standardized nominal group discussion
approach. Target groups for the guidelines were metabolic
specialists and nonspecialists in the metabolic field. Aims
of the guidelines encompassed harmonization of diagnostic,
therapeutic, and disease monitoring strategies in expert
centers as well as raising awareness for the disease to
enhance the probability for early diagnosis and effective
treatment in the nonexpert field.
Targeted implementation of guidelines and the assessment
of their adaptation are a complex and not extensively
investigated process in the field of rare diseases. This study
investigates the general interest in the published guidelines
and addresses the following questions: Do the guidelines
reach the targeted readers? Do nonexperts consider under-
standable, reliable, and feasible in everyday practice what
experts have written? Do users of the guidelines have the
facilities and resources available to follow the recommenda-
tions? These are questions important to answer in order to
tailor future updates of existing guidelines or in the planning
of novel ones (Knai et al. 2012; Legido-Quigley et al. 2012).
Accordingly, we evaluated the efficacy of implementa-
tion, adaptation, and use of the UCD guidelines, and hereby
the “real-world” impact, within a proportion of the target
population by applying different strategies. The aim of this
publication is not only to document the current situation
with respect to the UCD guidelines, but in addition to
motivate colleagues to consider the evaluation and imple-
mentation of any planned guidelines already during their
development.
Methods
Download Statistics from Online Sources
Implementation strategies included publication of the full
guideline text as well as the method report from July 2012
on the website of the “Arbeitsgemeinschaft der Wissen-
schaftlichen Medizinischen Fachgesellschaften” (AWMF;
http://www.awmf.org/leitlinien/detail/ll/027-006.html), the
well-established German guideline server. The AWMF
follows a strict protocol to determine the classification of
guidelines. Downloads from this source are free of charge.
Generally, the AWMF guidelines are also accessed from
German-speaking physicians from Switzerland and Austria.
Additionally but with a different format and scope, the
UCD guidelines were published in an open access online
journal specially addressing rare diseases, the Orphanet
Journal of Rare Diseases (OJRD; http://www.ojrd.com/
content/7/1/32 (H€aberle et al. 2012)). To evaluate the
guidelines’ quantitative use, the frequency of downloads
from both online sources since publication at the AWMF
server on July 9, 2012 until May 31, 2014 (data missing for
months January and February 2014 due to technical
problems; total 632 days) and since publication at the
OJRD server on May 29, 2012, until May 21, 2014 (total
722 days) was counted.
Assessment of Facilities Necessary for the Practical
Implementation of the Guidelines in Pediatric Units
To estimate whether resources in pediatric units were
suitable to enable physicians to act on the basis of the
guidelines’ recommendations, a brief Internet-based survey
(Survey Monkey; https://de.surveymonkey.com/) was sent
out to all pediatric units in Germany (n ¼ 408) and Austria
(n ¼ 238). The survey addressed the following issues:
• Hospital category: primary, secondary, or tertiary care
center
• Availability of ammonia measurements: 24/7, only
during main working hours, or in an external lab only
• Time span between collection of sample and result:
<1 h, 1–3 h, 3–6 h, >6 h
• Mode of ammonia determination: bedside test, lab test
• Sample and preanalytical requirements (e.g., capillary
or venous blood, cooling of sample)
• Availability of emergency drugs (nitrogen scavengers,
L-arginine) in the hospital
Data presented are pooled from both countries.
Guideline Assessment Using the AGREE Instrument
For content and process evaluation of the guidelines, we
randomly selected 46 German and 26 Austrian target users
from an alphabetical list of the departments of pediatrics,
neurology, and neuropediatrics (Germany only). Heads of
departments were asked to complete the AGREE instru-
ment (http://www.agreetrust.org/resource-centre/the-origi-
nal-agree-instrument/) or to delegate this task to one of
their coworkers. The AGREE instrument is a standardized
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tool, developed in 2003 to “advance the science of
guidelines,” and has since then become the “international
gold standard for practice guidelines evaluation and
development” (Burgers et al. 2004).
Regional Implementation of Guidelines
Finally, we implemented the guidelines following a
regional networking approach in Vorarlberg, the most
western province of Austria. Due to the geographical
structure of the area, medical care for patients from the
region is offered mainly by regional medical services. The
implementation strategy focused on the three pediatric
departments in the region. The implementation process
encompassed the following phases:
1. Stakeholder consent: setup of a first contact to the
heads of the three pediatric departments to obtain
consent and support for the implementation.
2. Awareness raising for UCDs and the guidelines: a short
presentation of the main basic topics covered by the
guidelines was given to the medical staff of the three
departments.
3. Discussion of practical questions in every department,
such as facilities for ammonia measurement, clinical
symptoms which should prone immediate assessment
of ammonia, availability of emergency medications,
triage settings for (potentially) affected patients, etc.
4. Provision of assistance concerning practical issues
(ordering of drugs, laboratory facilities, which forms
to fill, how to get access to specialist advice, etc.).
5. Interactive elaboration of triage and decision trees for
each department.
The following outcome parameters for the evaluation of
the implementation strategy were measured before and after
the intervention:
1. Availability of laboratory facilities
2. Number of ammonia measurements/department (mean
per 6 months)
3. Availability of and knowledge about emergency drugs
(interview medical staff)
Results
Download Statistics from Online Sources
Download numbers for both online available versions of the
UCD guidelines are shown in Table 1.
Remarkably, there was an increase in downloading over
the time indicating an ongoing and even growing interest in
the guidelines (Fig. 1). However it was impossible by
limitations of the method to differentiate between first and
repeated downloads from single users.
Assessment of Facilities Necessary for the Practical
Implementation of the Guidelines in Pediatric Units
The overall response rate to the Internet-based survey was
10.4%; response rates were 14% in Germany (57 responses
from 408 addressants) and 4.2% in Austria (10 responses
from 238 addressants). Respondents represented primary
care hospitals in 30%, secondary in 9%, tertiary in 46%,
and tertiary at university in 15%. Detailed results are
summarized in Table 2.
Remarkably, emergency drugs were not available in 12
of 31 tertiary nonuniversity hospitals (39%) and in 10 of 20
primary care hospitals (50%).
Guideline Assessment Using the AGREE Instrument
After sending out the request to complete the AGREE
instrument to a total of 72 colleagues (46 in Germany, 26 in
Austria), we did not receive any response from 64
addressants. Two colleagues returned the completed form
without queries. Six addressants expressed that they
considered themselves not competent to fill the survey
Table 1 Numbers of downloads from OJRD and AWMF
Time
Orphanet Journal of Rare
Diseases (OJRD) AWMF server
Last 30 days 1,070 328
Last 365 days 10,896 2,882
Total 18,817 3,894
Total per daya 26.1 6.2
a Total days 722 and 632 for OJRD and AWMF, respectively
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Fig. 1 Number of downloads per quarter from the German AWMF
guideline server is shown for the period from July 2012 until May 2014
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because of not being an expert in the metabolic field.
Nevertheless, two of these colleagues agreed to fill in the
AGREE instrument after having being reassured that the
status of being a metabolic expert was not conditionary.
The low number of only four completed surveys
hampers systematic evaluation of the results but is in full
agreement with the AGREE research group recommending
“that each guideline is assessed by at least 2 appraisers and
preferably 4” (http://www.agreetrust.org/about-the-agree-
enterprise/introduction-to-agree-ii/preparing-to-use-the-
agree-ii/). However, although being in agreement with the
AGREE research group, we consider the small number of
responses a limitation. Nevertheless, there were two points
raised by all respondents: the views and wishes of the
patients were said to be not ascertained to their full extent
by the guideline developers (question 5; score 2 on a scale
of 4 to 1 with 4 being best). In addition, costs that possibly
result from use of the guidelines were supposedly not taken
into account (question 20; score 2 on a scale of 4 to 1 with
4 being best).
Regional Implementation of Guidelines
In the region of Vorarlberg, 52 ammonia measurements had
been carried out during 6 months before implementation of
the guidelines in two of the three regional departments. In
the first 6 months following the intervention, number of
ammonia measurements increased to 106.
In the third department, ammonia measurement had not
been available in-house but had to be sent to an external
laboratory with a turnaround time of >24 h. To the memory
of the medical staff, ammonia measurement had “very
rarely to never” been ordered. Following the intervention,
measurement of ammonia within 1 h time (24/7) has been
established in the hospital lab.
Before the intervention, medical staff in all pediatric
departments was not familiar with emergency drugs for the
treatment of hyperammonemia, and access to the drugs was
not regulated. In the context of the intervention, a list with
drugs, details of drug preparation, and dosages to be used in
hyperammonemic patients has been established on the basis of
the guideline recommendations. Drugs have subsequently
been stored in one hospital pharmacy and are available on
request 24/7 with a maximal delay of two hours for all three
departments. On all intermediate and intensive care units, in-
house storage of basic emergency drugs has been instituted.
With regard to triage and patient pathways, regional resources
were discussed, and it was agreed that since the most effective
extracorporeal detoxification technology was not available in
the region, patients with persistent or progressive hyper-
ammonemia must be referred to a tertiary institution in due
time. In addition it was agreed that advice from a metabolic
expert should be obtained as early as possible in the process,
and contact details were made available for the clinicians.
In the 6 months before the intervention, one child with
neonatal hyperammonemia had been diagnosed on day
three after admission. Since implementation of the guide-
lines, one neonate with acute neonatal hyperammonemia
has been identified. Ammonia measurement has been
conducted within two hours after admission, and subse-
quently metabolic specialist advice has been obtained.
Treatment has been initiated according to the guidelines,
and the patient was transferred to a tertiary center due to
progressive hyperammonemia.
Table 2 Survey on resources in pediatric units (pooled data from the 67 responding hospitals)
Availability of ammonia
measurements
24/7 Only during main working
hours
In an external lab only
82% 9% 9%
Time to result after sample
collection
<1 h 1–3 h 3–6 h >6 h
63% 27% 9% 1%
Mode of ammonia
determination
Bedside test Lab test Lab test during the day but bedside test outside normal working
hours
1% 96% 3%
Sample requirementsa Capillary Venous
9% 94%
Preanalytics Cooling of
sample
Fast
transport
Lab
informed
Special
tubes
Special
sampling
Special sample
transport
60% 88% 36% 25% 16% 9%
Availability of emergency drugs On the ward Available within 1 h Not available Unknown
44% 13% 34% 9%
a Some labs accept both types of samples
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Discussion
Guidelines are produced in the intention to guide medical
decisions in patient care. Readers ideally expect positive
effects of specific recommendations on clearly defined
(outcome) parameters. In children with glutaric aciduria
type 1, a significant benefit is seen when treatment during
acute illness adheres to the guideline recommendations
(Heringer et al. 2010). Such an evaluation requires detailed
knowledge of the natural course of the disease and patients’
perspectives and the formulation of relevant and meaning-
ful outcome parameters. Examples of possible outcome
parameters include the survival rate of patients with
neonatal presentation, the frequency of hyperammonemic
crises during the course, the delay in diagnosis, or the long-
term intellectual outcome. Respective data are so far only
randomly available for the UCD population. The lack of
data underlines the importance of currently ongoing UCD
registry projects in the USA, Europe, and Japan intending
to pool data from large patient populations systematically
(K€olker et al. 2011b; Tuchman et al. 2008).
On the basis of the frequency by which the UCD guideline
paper was accessed and downloaded from the open access
available online sources, the paper was and still is categorized
as “highly accessed” in the Orphanet Journal of Rare
Diseases. In the case of the AWMF guideline server,
download numbers constantly increased during the first two
years after publication (Fig. 1) indicating that the knowledge
about the availability of the UCD guidelines was (and still is)
growing. Nevertheless, given the rarity of UCDs, the strong
and ongoing interest in the guidelines indicated by high and
constant download numbers is remarkable. However, it must
be kept in mind that repeated downloads from single users
could not be differentiated from first downloads. In addition,
we cannot infer from these data whether download resulted
in any practical consequences. Likewise, it remains open
whether readers belong to the expert or nonexpert groups.
The survey sent to pediatric hospitals revealed some
remarkable results concerning the availability of ammonia
measurements and emergency drugs as well as preanalytical
standards. In only 82% of the hospitals, ammonia measure-
ment can be performed at all times, while 9% of the
hospitals offer this service only during working hours, and
another 9% need to send the sample to an external lab. This
seems to be a critical issue since a relevant proportion of
acutely hyperammonemic patients will in these circum-
stances not receive timely analysis of plasma ammonia.
This fact automatically results in a delay in diagnosis and
treatment initiation. In addition, there seems to be wide
variation of preanalytical procedures in use with cooling of
the blood sample and requirement to beforehand inform the
lab in 60% and 36% of institutions, respectively (Table 2).
Another finding from this nonrepresentative survey is even
more worrying: in 34% of the hospitals, emergency drugs
(nitrogen scavengers and L-arginine) for the treatment of
hyperammonemia are not available. Among the hospitals
without in-house drug availability, 39% are tertiary nonuni-
versity hospitals and thus by definition dedicated to care for
patients with complex, severe disorders such as UCD. It
should be noted however that this survey does not represent
a pre- versus post-guideline evaluation. We like to highlight
this shortcoming mainly as a suggestion for future guideline
groups when authors could (and should) perform a true pre-
versus post-evaluation.
Implementation of guidelines into clinical practice
resulting in the induction of behavioral change is challeng-
ing to achieve (Gross et al. 2001; Legido-Quigley et al.
2012). Publishing guidelines – even on open access
platforms – is one of the least effective interventions in
that respect (Gross et al. 2001). If enhancement of
awareness toward the value of ammonia measurements in
a variety of clinical conditions is the target, guidelines only
available by searching actively for the term “hyperammo-
nemia” will not be effective. Connecting the guideline to
more clinical, symptom-oriented search terms (e.g.,
impaired consciousness, coma) might help to ameliorate
this shortcoming in the future.
Presentation by expert talks likewise often fails to induce
changes in clinical practice (Gross et al. 2001). Along this,
a recent suggestion to improve surveillance for hyper-
ammonemia by introducing “an electronic medical record-
based tool to assist physicians in the detection of hyper-
ammonemia” deserves attention (Vergano et al. 2013). The
implementation of such warning systems may prove
superior efficacy if compared to education-based strategies
classically intended by expert talks.
Our experience in implementing the UCD guidelines in a
regional medical system underlined the finding that imple-
mentation of guidelines by networking activities and interac-
tive approaches is the most effective strategy to induce
behavioral change in everyday practice. This can be attributed
to the active involvement of target groups and to the potential
to adapt methods to local resources or local resources to yet
unmetmedical needs aswell as to the lowering of thresholds to
seek expert advice (Gross et al. 2001).
Conclusion
The data obtained by our evaluation indicate that interest in
the UCD guidelines is generally high and sustainable.
Nevertheless, more precise targeting of the guidelines is
advisable. In the future, registry data may develop into a
sound basis for significant outcome parameters the guide-
lines attempt to change. With regard to implementation of
guidelines for a group of rare diseases, our experience
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suggests that a regional network and awareness campaign
approach improve medical care. Sustainability of improved
awareness, patient care, and outcome are parameters of
interest for future research in this field.
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Abstract We studied the role of autophagy in a series of
10 infantile-, juvenile-, and adult-onset GSDII patients and
investigated autophagy blockade in successive biopsies of
adult cases during disease natural history. We also
correlated the autophagosome accumulation and efficiency
of enzyme replacement therapy (ERT) in four treated cases
(two infantile and two juvenile-adult onsets).
The autophagic flux was monitored by measuring the
amount of p62-positive protein aggregates and compared,
together with fibre vacuolisation, to fibre atrophy.
A blocked autophagic flux resulted in p62 accumulation,
increased vacuolisation, and progressive atrophy of muscle
fibres in biopsies collected from patients during natural
history. On the contrary, in the GSDII cases early treated
with ERT, the autophagic flux improved and muscle fibre
atrophy, fibre vacuolisation, and acid phosphatase activity
decreased.
The functionality of the autophagy-lysosome system is
essential in GSDII muscle, which is characterised by the
presence of swollen glycogen-filled lysosomes and auto-
phagic build-up. Defining the role of autophagy and its
relationship with muscle loss is critical for understanding
the disease pathogenesis, for developing new therapies, and
for improving ERT efficacy in GSDII.
Introduction
Glycogenosis type II (GSDII, MIM# 232300) is an autoso-
mal-recessive disorder caused by the deficiency of the
lysosomal enzyme acid a-glucosidase (GAA), which catal-
yses the hydrolysis of a-1,4 and a-1,6 links of glycogen
(Angelini and Engel 1973; Hirschhorn and Reuser 2001;
van der Ploeg and Reuser 2008). The enzyme deficiency
leads to a spectrum of clinical phenotypes ranging from an
infantile and rapidly fatal form (Pompe disease) to a slowly
progressive late-onset form (Laforet et al. 2000). The slow
progression of the disease and the variable organ involve-
ment complicate the prognosis and the efficacy of therapy
of adult GSDII cases. Untreated adult GSDII patients have
a poor quality of life (Hagemans et al. 2004).
The first successful trials with enzyme replacement
therapy (ERT) were done on selected infantile Pompe
patients, because of the severity of the disease and the
rather homogeneous natural course (Kishnani et al. 2007).
Recombinant human a-glucosidase (rhGAA) treatment was
demonstrated to be effective in reducing left ventricular
mass and improving survival in infantile patients. In adults,
treatment efficacy is variable (Angelini et al. 2012). We aim
to describe morphological changes and autophagy bio-
markers in muscle biopsies from both infantile and adult
forms of GSDII.
Material and Methods
Patients
We selected ten patients (three Pompe, seven adult onset)
with molecular diagnosis of GSDII (Table 1), who under-
went clinical examination, muscle biopsy, measurement of
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GAA activity in muscle or lymphocytes, and identification
of mutations in the GAA gene (Nascimbeni et al. 2008). Of
the ten patients studied (Table 1), four cases (two Pompe,
two adult onset) underwent ERT treatment before the only
(patient 3) or a second muscle biopsy was obtained
(patients 2, 4, 10), and three untreated adult-onset cases
(patients 5, 6, 7) underwent two biopsies during the natural
course of the disease.
Muscle Morphology, Immunohistochemistry, and
Immunoblot
Muscle biopsy sections were stained using a panel of ten
different routine stains (including the lysosomal acid
phosphatase), to analyse fibre size and the degree of
vacuolisation. We studied muscle autophagy markers and
atrophy at different times of the disease progression. For
immunohistochemical analysis, muscle sections were incu-
bated with primary antibodies against caveolin-3, p62, LC3,
according to methods previously reported (Nascimbeni
et al. 2008, 2012). The percentage of vacuolated fibres
and p62-positive fibres was defined as those presenting
either diffuse or scattered intracytoplasmic vacuoles or
staining, respectively. Fibre cross-sectional area (CSA) was
measured in at least 200 fibres in each biopsy using ImageJ
software.
Results
Patients in Natural History (Table 1)
Patient 1. This child was born from consanguineous parents
and has a first-degree cousin also affected. At 3 months, he
presented delayed psychomotor development, high CK
(1,260 U/L), axial and limb hypotonia, and poor motility.
At age 7 months, he underwent muscle biopsy and
molecular diagnosis was obtained. Patient 8. This 28-
year-old man was the brother of case 9. He had stepping
gait and proximal weakness. CK was 3,318 U/L and muscle
CT scan showed atrophy in paraspinal and gluteus muscles.
Spirometry showed moderate respiratory insufficiency.
Muscle GAA activity was 15%. Patient 9. This 32-year-
old woman had myalgia and elevated CK (825 U/L).
Muscle biopsy showed a vacuolar myopathy and GAA
activity was 17%. Spirometry revealed slight respiratory
insufficiency, and muscle CT showed moderate atrophy of
gluteus.
Patients in ERT Treatment (Table 1)
Patient 2. This female child at 5 months had severe
hypotonia, growth retardation, hepatomegaly, and cardio-
megaly. Echocardiography showed cardiac hypertrophy and
Table 1 Clinical and genetic data of GSDII patients
Pt. No. Biop.
No. Phenotype
ERT
duration Onset
Age at
biopsy
Disease
duration
Ventilator
use GAA gene mutations
1 8475 Infantile
onset
– 3 months 7 months 4 months – c.2015G>A, p.R672Q,
homozygote
2 8484 Infantile
onset
– 3 months 5 months 2 months – c.1564C>G, p.P522A,
homozygote8946 18 months 2 years 21 months
3 8668 Infantile
onset
17 months 2 weeks 18 months 18 months – c.1933G>A, p.D645N,
homozygote
4 8557 Juvenile
onset
– 18 years 18 years 0 – c.546+1G>T; n.d.
8868 6 months 19 years 1 years
5 4512 Adult onset – 40 years 56 years 16 years – c.-32-13T>G; c.307T>C,
p.C103G7786 65 years 25 years
6 5638 Adult onset – 34 years 54 years 20 years 50 years c.-32-13T>G; c.2219delTG,
p.V740fsX557774 60 years 26 years
7 5639 Adult onset – 41 years 42 years 1 years – c.-32-13T>G; c.546+1G>T
7797 48 years 7 years
8 6373 Adult onset – 27 years 28 years 1 years – c.-32-13T>G;
c.2066_2070duplAGCCG,
p.A691fsX6
9 6374 Adult onset – 32 years 32 years 0 – c.-32-13T>G;
c.2066_2070duplAGCCG,
p.A691fsX6
10 7340 Adult onset – 50 years 59 years 9 years 59 years c.-32-13T>G; c.2530_2541del,
p.A844_L847del9045 36 months 64 years 14 years
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wall motion abnormalities. CK was 575 U/L. Muscle
biopsy showed massive vacuolisation (Fig. 1), and GAA
gene mutations were identified. She was ERT treated
(20 mg/kg every 3 weeks) only after 8 months. At age
2 years, following aspiration pneumonia, she was not able
to sit unassisted. A second muscle biopsy at age 2 years
showed marked vacuolisation and increased fibrosis
(Fig. 2). This patient was a nonresponder to ERT treatment.
Patient 3. This female child was born at 41 g.w. by
caesarean section due to foetal bradycardia. Echocardiogra-
phy showed bilateral ventricular hypertrophy. CK was
elevated. EMG showed myotonic discharges. High levels
of urinary Glc4 were found. GAA activity in lymphocytes
was reduced. Mild hypotonia and macroglossia were noted.
ERT (20 mg/kg every 3 weeks) was started at 20 days of
life. Gradual improvement in left ventricular hypertrophy
was observed. At 18th month follow-up, a muscle biopsy
showed relatively mild myopathic changes with 10% of
vacuolated fibres. At 2 years, echocardiography was normal
as well as psychomotor development, except for a mild
speech delay. Patient 4. This 17-year-old boy complained
of generalised asthenia and cramps after intense exercise,
but was virtually asymptomatic (except for MRC in
iliopsoas 4/5). CK was 1,012 U/L. Spirometry showed
FVC ¼ 91%, FEV1 ¼ 83%, and pO2 ¼ 93%. Echocardi-
ography showed mild left ventricular and septal hypertro-
phy, and ejection fraction was 49.7 %. Muscle biopsy
showed glycogen storage with 50% vacuolated fibres
(Fig. 1). Muscle GAA was 20%. He had a second biopsy
after 6 months of ERT treatment, showing decreased
vacuoles and acid phosphatase (Fig. 1). The patient
improved after ERT, presenting less fatigue and increased
6-minute walking test. He is a good ERT responder. Patient
5. This 40-year-old woman complained of progressive
difficulty in climbing stairs, walking, and rising from the
floor. At 43 year, she walked with a cane and had marked
weakness of iliopsoas and quadriceps muscles and hypo-
trophy of thighs. ECG was normal. Spirometry showed a
slightly restrictive pattern with FVC ¼ 79%. Muscle CT
scan showed hypotrophy of gluteus, quadriceps, and
posterior thigh muscles. Muscle biopsy at age 56 showed
1% of vacuolated fibres (Fig. 2). Muscle GAA activity was
5%. A second biopsy at age 65 was done, and then, ERT
treatment was started. Her 6-minute walking test improved
from 80 to 160 m. FVC was 1.8 and 1.6 L after 6 months
(Angelini et al. 2009). After 4 years of ERT, she still
presented a stable condition. Patient 6. This woman had
difficulty walking, climbing stairs, and rising from the floor
since 34 years of age. Since 50 years, she had progressive
respiratory insufficiency and FVC decreased 13% every
year. She then used overnight oxygen and had dyspnea at
rest. At age 54, a first muscle biopsy showed 20%
vacuolated fibres (Fig. 2). Muscle GAA activity was 7%.
Muscle CT scan showed marked proximal atrophy in
posterior thigh muscles. At age 60, a second biopsy was
done. Then, ERT was started. At age 64, she had lordotic
gait, was able to climb stairs and to rise from a chair, but
could not lift legs. MRC on deltoid was 3/5, on triceps 4/5,
external shoulder rotators 3/5, and iliopsoas and quadriceps
3/5. Her 6-minute walking test was 120 m before ERT,
160 m. after 6 months ERT, and returned to 110 m after
12 months. FVC was initially 0.5 L and remained stable
after 12 months ERT (Angelini et al. 2009). Patient 7. This
43-year-old woman, since 7 years complained of weakness,
could rise from the floor only using two hands and climb
stairs only using the rail. A first muscle biopsy showed 3%
of vacuolated fibres (Fig. 2). Muscle GAA activity was
12%. A second muscle biopsy was done at age 48 before
ERT was started. She had an allergic reaction during ERT
treatment, consisting of erythematous thoracic rash, and had
to discontinue ERT. Patient 10. This 59-year-old woman
had onset at age 50, with weight loss and muscle weakness.
She needed ventilator since 59 years of age, when she
underwent the first muscle biopsy that showed 5% of fibres
with vacuoles. Muscle GAA activity was virtually absent.
At age 64 years, a second muscle biopsy was done after
36 months of ERT treatment, showing decreased vacuoles
and acid phosphatase reaction (Fig. 1). ERT resulted in
stabilisation of motor functions, and only nocturnal ventila-
tor support was required (Vianello et al. 2013).
Disease Progression and Autophagy Impairment
Infantile and late-onset patients have different levels of
autophagic flux and accumulation of p62-positive protein
aggregates. Infantile patients show impaired autophagy,
whereas late-onset patients display a correlation between
autophagic block and muscle atrophy with disease progres-
sion (Fig. 2). The comparison of three adult patients who
underwent two biopsies during natural history (Table 1,
Fig. 2) showed a different degree of autophagy impairment
as revealed by accumulation of p62 protein aggregates.
Cross-sectional area (CSA) decreased in all patients in the
second biopsy. Patient 7 showed a time-dependent increase
of abnormalities: in the first biopsy, she had an almost
normal fibre morphology, and in the second biopsy, there
was a 60% decrease in CSA, which correlated strikingly
with the increase in p62-positive aggregate and vacuolated
fibres (from 2 to 40%) (Fig. 2).
Early ERT Treatment Restores Autophagy
One infantile patient (patient 2) and two adult patients
(patient 4, 10) were ERT treated for 16, 6, and 36 months,
respectively, and after treatment, a second biopsy was
taken.
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Fig. 1 Comparison of pre-ERT (a, c, e, g) and post-ERT muscle
biopsies (b, d, f, h) stained for acid phosphatase (a–d) and
immunolabelled for p62 protein aggregates (e–h) in adult early-
treated patient 4 (a, b, g, h), in late-onset patient 10 (c, d), and in
74 JIMD Reports
The juvenile patient 4 showed a low level of mature
GAA that increased after ERT. ERT treatment in this patient
greatly reduced the number of p62-positive and vacuolated
fibres from 60 to 34% and from 44 to 35%, respectively
(Fig. 1), which remained atrophic. MRC of iliopsoas
muscle increased from 4 to 5 and his 6-minute walking
test also improved. The adult patient 10, after ERT, had less
degree of fibre vacuolisation and acid phosphatase reaction
(Fig. 1). Consistently, with morphology, therapy in adult
patients resulted in less fatigue and better exercise
performance.
The infant patient 2 started therapy at 8 months old, an
age probably too late for successful recombinant GAA
uptake. Indeed, the second biopsy suggested a persistent
autophagic impairment despite ERT treatment: p62-positive
aggregate fibres increased from 70 to 98%, while vacuo-
lated fibres were 94% before ERT and 98% after ERT
(Fig. 1). This patient had no detectable GAA mature forms
and instead elevated levels of the inactive 110 kDa
precursor (Nascimbeni et al. 2012). ERT induced the
appearance of mature 76 kDa GAA even if at very low
level. The p62-positive aggregate accumulation and number
of vacuolated fibres were increased, possibly contributing
to the poor ERT response.
Another early-treated infantile patient (patient 3), who
underwent only one biopsy after 18 months of ERT,
showed normal CSA value and only few fibres with p62
aggregates (6%) or vacuoles (3%). Also in this case, we can
conclude that early treatment, prior to massive autophagy-
build-up onset, is effective in restoring the autophagy flux.
Discussion
Autophagy is a highly conserved homeostatic process for
lysosome-mediated degradation of cytoplasmic compo-
nents, including damaged mitochondria and toxic protein
aggregates. In infantile Pompe patients, the enormous
build-up of glycogen-filled lysosomes appears to cause
the muscle damage (Raben et al. 2007). Recent studies
showed that autophagy impairment contributes to both
disease progression and fibre atrophy (Nascimbeni et al.
2012). A residually functional autophagic flux is important
for an efficient ERT delivery in muscle lysosomes, since
mature GAA forms were found in our ERT-responsive
juvenile case. The maturation steps of GAA, from the
synthesis of the immature protein in the endoplasmic
reticulum to the final cleaved active protein in lysosomes,
are complex and require a functional system of vesicle
trafficking.
A limited number of ERT trials and observational
studies have been published on late-onset patients (van der
Ploeg 2010; Strothotte et al. 2010; Angelini et al. 2012;
Regnery et al. 2012). An observational study (Deroma et al.
2014) in eight juvenile GSDII cases reported marked
decrease of CK after ERT and stabilisation of disease
course. According to treating clinicians, not all patients
respond to therapy to the same extent and in the same time
frame (Angelini et al. 2012; Strothotte et al. 2010; Regnery
et al. 2012). A number of prognostic factors were observed
or suspected, including patient gender, age, body composi-
tion, genotype, disease duration, and clinical conditions.
Good clinical condition and short disease duration seem to
be the most important predictors of good response
(Angelini et al. 2012; Regnery et al. 2012; Deroma et al.
2014). The majority of infantile patients in whom ERT was
started before the age of 6 months and before the need of
ventilator support improved and showed longer ventilator-
independent survival, reduced cardiac mass, and acquisition
of motor skills. Infants who started treatment before the
occurrence of extensive muscle damage had better motor
outcomes than patients who began treatment at more
advanced stages. The same parameters seem to apply to
early-treated juvenile cases, where often the main feature is
hyperCKemia. At the same time, ventilatory-dependent
patients fail to achieve independence from ventilation.
Effectiveness of ERT seems to be more limited in advanced
cases, even if clinical stabilisation in motor and respiratory
function was observed in some advanced cases (Regnery
et al. 2012).
The muscle structure is more severely affected in the
infantile form, whereas the degree of vacuolisation is
variable in late-onset patients. A further difference between
infantile and late-onset form is vacuolar compartmentalisa-
tion by membranes with sarcolemmal proteins, as shown by
caveolin-3 staining (Nascimbeni et al. 2008); this additional
feature could be important in determining response to ERT.
An important pathological feature is failure of autophago-
somal turnover and massive autophagic build-up in fibres.
This contributes to myofiber atrophy that increases during
natural history in late-onset GSDII (Nascimbeni et al.
2012).
Our data suggest that functional autophagy might protect
myofiber from disease progression and muscle atrophy in
Fig. 1 (continued) late-treated infantile patient 2 (e, f). The early ERT
treatment resulted in a reduction of fibre vacuolisation and lysosomal
acid phosphatase reaction, suggesting a lower degree of lysosomal
impairment. When started early, before autophagy block onset, ERT is
efficient and restores the autophagy block, as evidenced by a reduced
number of p62-positive fibres in patient 4, but not in patient 2.
Bar ¼ 40 mm
◂
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late-onset patients. The problem of autophagy and fibre
atrophy remains to be addressed. Non-pharmacological
therapies and drug therapies promoting cellular clearance
(or preventing autophagic build-up) might be a future
strategy in GSDII management.
Acknowledgments This paper was supported by grants from
Telethon (GUP13013), Association Francaise contre les Myopathies
(AFM), the Eurobiobank Network, and the Biobanking and Biomo-
lecular Resources Research Infrastructure (BBMRI).
Synopsis
Muscle fibre atrophy and autophagy are linked in the
progression of glycogenosis type 2; ERT might reverse
such features.
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Abstract Background: 3-Methylcrotonyl-CoA carboxylase
deficiency (3-MCCd) is an autosomal recessive disorder in
the catabolism of leucine. In the present study, we
investigated the current and prior medical condition of
patients with 3-MCCd in the Faroe Islands and their
carnitine levels in blood, urine and muscle tissue with and
without L-carnitine supplementation to evaluate the current
treatment strategy of not recommending L-carnitine supple-
mentation to Faroese 3-MCCd patients.
Methods: Blood and urine samples and muscle biopsies
were collected from patients at inclusion and at 3 months.
Eight patients received L-carnitine supplementation when
recruited; five did not. Included patients who received
supplementation were asked to stop L-carnitine, the others
were asked to initiate L-carnitine supplementation during
the study. Symptoms were determined by review of hospital
medical records and questionnaires answered at baseline
and after the intervention.
Results: The prevalence of 3-MCCd in the Faroe Islands
was 1:2,400, the highest reported worldwide. All patients
were homozygous for the MCCC1 mutation c.1526delG.
When not administered L-carnitine, the 3-MCCd patients
(n ¼ 13) had low plasma and muscle free carnitine levels,
6.9 (SD 1.4) mmol/L and 785 (SD 301) nmol/g wet weight,
respectively. L-Carnitine supplementation increased muscle
and plasma carnitine levels to a low-normal range, 25.5 (SD
10.9) mmol/L and 1,827 (SD 523) nmol/g wet weight,
p < 0.01, respectively. Seven of the thirteen 3-MCCd
subjects suffered from self-reported fatigue with some
alleviation after L-carnitine supplementation.
Conclusion: 3-MCCd is common in the Faroe Islands.
Some symptomatic 3-MCCd patients may benefit biochem-
ically and clinically from L-carnitine supplementation, a
more general recommendation cannot be given.
Introduction
3-Methylcrotonyl-CoA carboxylase deficiency (3-MCCd)
(OMIM 210200 and 210210) is a defect in the degradation
pathway of leucine. 3-MCCd leads to abnormally high
levels of 3-methylcrotonylglycine in urine and 3-hydrox-
yisovalerylcarnitine in the blood. Increased renal excretion
of 3-hydroxyisovalerylcarnitine is a natural way of excret-
ing toxic intermediary metabolites that interfere with
normal metabolism at the cost of low plasma carnitine
levels (Roschinger et al. 1995). Among organic acidurias,
3-MCCd is the most frequently diagnosed disorder at
neonatal tandem mass spectrometry (MS/MS) screening
(Koeberl et al. 2003; Schulze et al. 2003; Wilcken et al.
2003; Stadler et al. 2006; Lam et al. 2013). The 3-MCC
enzyme consists of two subunits, a and b, encoded by the
MCCC1 and MCCC2 genes, located at 3q25–q27 and
5q12–q13, respectively (Baumgartner et al. 2001; Gallardo
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et al. 2001; Holzinger et al. 2001). Mutations in either gene
can lead to 3-MCCd, and more than 130 mutations have
been reported (Grunert et al. 2012). 3-MCCd in the Faroe
Islands is, to the best of our knowledge, caused by
homozygosity for a single mutation in the MCCC1 gene,
the c.1526delG deletion.
Patients with 3-MCCd have low blood carnitine levels
(Arnold et al. 2008; Grunert et al. 2012). The most severe
forms of 3-MCCd have onset in infancy and include lethal
cases (Baykal et al. 2005). Some patients suffer episodes of
vomiting, lethargy and muscle weakness. These episodes
can lead to metabolic decompensation with seizures, coma
and death (Gallardo et al. 2001; Baykal et al. 2005). A
variety of other symptoms, mostly neurological, have been
reported but most patients are asymptomatic. The clinical
picture may show extensive intrafamiliar variation (Visser
et al. 2000; Baumgartner et al. 2004; Darin et al. 2007;
Dirik et al. 2008; Eminoglu et al. 2009; Grunert et al.
2012). However, most children detected through newborn
screening remain asymptomatic (Stadler et al. 2006; Lam
et al. 2013; Koeberl et al. 2003).
A population-based voluntary screening programme was
initiated in 2009 on the Faroe Islands to detect individuals
with abnormally low blood carnitine levels caused by
primary carnitine deficiency (PCD) from 2009 to 2011;
26,462 participated (Rasmussen et al. 2014). The screening
programme also revealed individuals with secondary
carnitine deficiency, including 3-MCCd.
The objective of the present study was to investigate the
prior and current health status of Faroese 3-MCCd patients
and to quantify blood, urine and muscle levels of carnitine
and to investigate the effect of L-carnitine supplementation.
We know of no prior studies performed to determine the
level of carnitine in muscle tissue in patients with 3-MCCd,
nor studies that determine the effect of L-carnitine supple-
mentation in this group of patients.
Currently there are no uniform treatment recommenda-
tions for 3-MCCd patients – including whether or not to
give L-carnitine supplementation (Arnold et al. 2008).
L-Carnitine supplementation of patients with 3-MCCd in
the Faroe Islands has generally not been recommended, the
rationale being that although the patients have low blood
carnitine levels, only few seem to suffer symptoms or are at
an increased risk of severe medical complications.
Methods
All seventeen registered adult Faroese 3-MCCd patients
were invited to participate. A total of thirteen patients were
enrolled (see flowchart in Fig. 1). Ten patients were
diagnosed with 3-MCCd in the population screening
programme. P3 and P8 were diagnosed as parents to
heterozygous children detected through newborn screening.
P6, a sibling of P3, was diagnosed through family testing of
P3’s direct relatives.
The design of the study included baseline evaluation,
an intervention and an end of study evaluation after
3 months. Blood, urine and muscle tissue were collected
at inclusion and at 3 months. Included participants were
divided into two groups – depending on whether they
received L-carnitine supplementation. Eight patients were
on L-carnitine supplementation when included. They were
asked to stop L-carnitine intake after the baseline samples
had been collected. These patients had received L-carnitine
supplementation for at least 2 years, doses ranging from
1.33 to 6 g daily corresponding to 19–87 mg/kg/daily. A
second set of samples were obtained after 3 months without
L-carnitine supplementation.
Five participants did not receive L-carnitine at baseline
evaluation. These L-carnitine-naive 3-MCCd patients
received a fixed oral L-carnitine dosage of 1 g three times
daily for 3 months, doses ranging from 33 to 46 mg/kg/
daily, which was the time we estimated it would take to
reach steady-state levels of carnitine in muscle tissue. New
samples were collected at 3 months.
Patients 1, 4, 8 and 9 refused to discontinue L-carnitine
supplementation, patient 9 due to pregnancy, and patients 1,
4 and 8 were concerned about negative health consequen-
ces. Patient number 11 stopped L-carnitine supplementation
before we were able to obtain new samples from him due to
miscommunication. Patients 2, 3, 5, 6, 7, 10, 12 and 13 are
represented in both groups.
Diagnosis was confirmed by DNA analysis performed in
the Centre for Inherited Metabolic Diseases (CIMD), Depart-
ment of Clinical Genetics, Rigshospitalet, Copenhagen
(Denmark). Subjects were also genetically analysed for PCD.
All available hospital medical records were systemati-
cally reviewed for admissions and outpatient contacts, and
the reasons for referral were grouped into the following
groups: symptoms from the central nervous system,
cardiopulmonary, gastrointestinal, urogenital and endocrine
systems as well as gynaecological, obstetrical and ortho-
paedic complaints.
All patients answered during baseline evaluation a
questionnaire. The questionnaire had six main sections:
(1) perceived prior and current health status, (2) possible 3-
MCCd symptoms (more often ill than others and/or more
sick than others when ill, tendency to vomit when ill with a
fever, unexplained fainting spells or cardiovascular symp-
toms), (3) physical capability (feeling reduced physical
capability compared to peers, participation in strenuous
physical activities, and participation in strenuous organised
sport on a national level), (4) dietary habits (craving for
meat), (5) L-carnitine supplementation (dosage, effects and
adverse effects), and (6) other medications (dosage and
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indication stated in free text field). Following the interven-
tion, another questionnaire was answered, which focused
on the perceived physical effect of initiation or discontinu-
ation of L-carnitine supplementation. Available answer
options were yes, no and unknown except for other
medications. Questionnaires were completed by the
patients. Symptoms at the time of diagnosis were collected
from medical records.
Routine blood samples were analysed in the National
Hospital (Faroe Islands) (haemoglobin, mean cell volume,
mean cell haemoglobin concentration, leucocytes and
leucocyte differential count, thrombocytes, sodium, potas-
sium, creatinine, urea, uric acid, lactate dehydrogenase,
creatine kinase, creatine kinase MB isoenzyme, alanine
aminotransferase, total cholesterol, high-density lipopro-
tein, low-density lipoprotein, c-reactive protein), while
plasma/urine acylcarnitines and urine 3-hydroxyisovaleric
acid were determined at CIMD, Denmark. Electrocardio-
grams (ECG) were analysed using the Minnesota ECG
criteria (Prineas 1982). Echocardiography was performed
initially in all patients according to current guidelines (Lang
et al. 2005).
Muscle biopsies were taken from the medial part of the
m. vastus lateralis using the Bergstrom technique (Berg-
strom 1975). The procedure was performed under con-
trolled conditions by a trained biopter. Biopsies were taken
with local anaesthesia from the thigh. One elderly male
subject on carnitine supplementation had highly atrophic
thigh muscles probably due to old age. The subject was
biopted thrice, but the samples contained only fat and
connective tissue, which is not an uncommon finding in
biopsies at old age. The samples were analysed at CIMD,
Denmark, to determine the muscle content of carnitine.
Analyses of acylcarnitines and carnitine in plasma, muscle
and urine were performed using stable-isotope dilution com-
bined with ultra-performance liquid chromatography–tandem
mass spectrometry, using a Quattro Micro triple quadrupole
mass spectrometer (Waters, Milford, Massachusetts). d3-Carni-
tine, d3-acetylcarnitine, d3-propionylcarnitine, d3-butyryl-
carnitine, d9-isovalerylcarnitine, d3-octanoylcarnitine,
d3-tetradecanoylcarnitine and d3-hexadecanoylcarnitine
(Hermen ten Brink, Vrije Universiteit, Amsterdam, the
Netherlands) were added to samples before extraction/homo-
genisation. Carnitine and acylcarnitines in all three matrices
- Excluded due to age < 18   n=4
Receiving
n=8
Naive
n=5
Disconnued
n=4
Refused
n=4
Iniated
n=4
No sample
n=1
L-carnine supplementaon status at 
inclusion, ﬁrst set of samples obtained. 
L-carnine supplementaon status 
aer intervenon*.
Data was pooled into two groups: Supplemented with L-carnine or not. Total number of samples on L-carnine 
supplementaon, n=12. Total number of samples without L-carnine supplementaon n=9
*Intervenon was performed right aer inclusion. Second set of samples were obtained aer three months. 
All known Faroese cases of 3MCCd
n=21
Eligible for inclusion in this study
n=17
Parcipated in this study
n=13
- Could not parcipate, were living
 abroad, n=3
- Could not parcipate, working on a 
ﬁshing vessel, n=1
Fig. 1 Inclusion of patients presented in a flowchart
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were quantified using external spiked plasma calibration
curves.
Quantitative urine analysis for 3-hydroxyisovaleric acid
was performed by stable-isotope dilution combined with
GC–MS (HP 6890 GC coupled to a HP5973 mass selective
detector) using a d6-3-hydroxyisovaleric acid (Hermen ten
Brink, Vrije Universiteit, Amsterdam, the Netherlands).
Statistics and Analysis
Data are presented as mean and standard deviation in
parenthesis. Two-tailed Student’s t-test was used when
analysing differences in mean values of routine blood
samples and plasma, urine and muscle carnitine values in
two groups, with (n ¼ 9) and without (n ¼ 12) L-carnitine
supplementation. Level of significance was p < 0.05. The
method of Bonferroni was used to correct for repeated
testing, the Bonferroni critical value was 0.05/24 ¼ 0.0021,
corrected p-value, p < 0.002. Correlation between plasma
and muscle free carnitine values was calculated with
Pearson’s test for correlation. Results were computed with
Statistical Package for the Social Sciences (SPSS).
Informed consent was obtained from all patients for
being included in the study and the study was approved by
the Faroese Ethical Committee.
Results
Plasma and muscle free carnitine levels increased signifi-
cantly when oral L-carnitine was given, p < 0.01. Mean
plasma free carnitine increased from 6.9 (1.4) to 25.5 (10.9)
mmol/L and mean muscle free carnitine increased from 785
(301) to 1,827 (523) nmol/g wet weight after L-carnitine
supplementation (Table 1).
There was a significant positive correlation between
plasma and muscle free carnitine irrespective of L-carnitine
supplementation, R2 ¼ 0.657, p < 0.01 (Fig. 2).
Table 1 Blood, plasma, urine and muscle data
Sample site Sample Unit Carnitine supplementation No carnitine Stud. t-testa
Mean (SD) Mean (SD) p-values
Blood Haemoglobin mmol/L 8.1 (0.8) 8.5 (0.6) 0.19
Potassium mmol/L 3.8 (0.3) 3.7 (0.2) 0.41
Creatinine mmol/L 71.8 (10.9) 78.2 (19) 0.34
Urea mmol/L 4.3 (1.1) 4.1 (1.2) 0.73
ALAT U/I 22.2 (9.7) 24.2 (17) 0.34
Random blood glucose mmol/L 4.9 (0.8) 5.2 (0.5) 0.84
LDL mmol/L 3.58 (1.2) 3.5 (1.2) 0.74
Plasma Free carnitine mmol/L 25.5 (10.9) 6.9 (1.4) <0.002
Acetylcarnitine mmol/L 5.3 (3.8) 0.8 (0.2) <0.002
3-HIV-carnitine mmol/L 17.3 (3.8) 10.1 (4.8) <0.002
Total carnitine mmol/L 49.6 (15.9) 20.1 (9.4) <0.002
Free/total % 49.6 (8.9) 41.7 (5.4) 0.029
Urine Creatinine mmol/L 12.7 (7.4) 14.7 (6.2) 0.52
Free carnitine mmol/mmol creatinine 24.2 (32) 2.3 (0.8) 0.056
Acetylcarnitine mmol/mmol creatinine 5.3 (7.5) 0.1 (0.03) 0.053
3-HIV-carnitine mmol/mmol creatinine 155.5 (68.5) 52.2 (14.7) <0.002
3-HIVA mmol/mmol creatinine 2.2 (0.9) 1.9 (0.5) 0.37
Total carnitine mmol/mmol creatinine 184.7 (81) 57.1 (13.7) <0.002
Free/total % 7.8 (8.9) 4.4 (2.2) 0.29
Muscleb Free carnitine nmol/g wet weight 1,827 (523) 785 (301) <0.002
Acetylcarnitine nmol/g wet weight 195 (55) 86 (26) <0.002
3-HIV-carnitine nmol/g wet weight 2,112 (746) 1,152 (593) <0.002
Total carnitine nmol/g wet weight 4,288 (1,161) 2,117 (800) <0.002
Free/total % 43 (8) 38 (9) 0.18
a Student’s t-test. At p < 0.05, difference between groups was significant
ALAT alanine aminotransferase, LDL low-density lipoprotein, 3-HIVA 3-hydroxyisovaleric acid, 3-HIV-carnitine 3-hydroxyisovalerylcarnitine
Carnitine supplementation group, all patients except P11; b no relevant muscle biopsy obtained from P1. No supplementation group: P2, P3, P5,
P6, P7, P10, P11, P12 and P13
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Changes in levels of urine free carnitine and acetyl-
carnitine demonstrated a tendency towards significance,
p ¼ 0.056 and p ¼ 0.053, respectively, while levels of
3-hydroxyisovalerylcarnitine and total carnitine increased
on oral L-carnitine supplementation, p < 0.01 (Table 1).
Routine blood samples did not differ before and after
L-carnitine supplementation (Table 1). Quantitative urine
analysis demonstrated no difference between groups regard-
ing levels of 3-hydroxyisovaleric acid, p ¼ 0.37 (Table 1).
Review of hospital medical records revealed largely
unremarkable medical histories, including 18 live births,
three spontaneous abortions and admissions with vertigo,
pneumonia, pulmonary embolism, heart palpitations and an
extrauterine pregnancy (Table 2). Furthermore, P1 is
followed regularly for non-insulin-dependent diabetes mel-
litus and gout. Baseline characteristics including blood
pressure, heart rate, routine blood samples, ECG (electro-
cardiogram) and transthoracic echocardiography were unre-
markable (Tables 1 and 2). Symptoms at the time of
diagnosis ranged from none to fatigue and palpitations
(Table 2). Mean BMI (body mass index) was 23 and 22 kg/
cm2 and mean age was 49 and 38.3 in male and female
3-MCCd patients, respectively (Table 2).
Six of 13 patients reported chronic fatigue that was
alleviated by L-carnitine supplementation. One patient, who
did not perceive fatigue at baseline, reported feeling more
fit when given L-carnitine. Three patients reported fatigue
from childhood. Four patients reported heart palpitations.
Two patients stated a tendency to vomit when ill with a
fever both in childhood and as adults. Six patients reported
participation in strenuous physical activities on a regular
basis. Four patients reported a stronger than normal craving
for meat. Few side effects of L-carnitine supplementation
were reported – one though experienced weight gain and
developed an unpleasant body odour (Table 2).
A total of 21 patients, including children and adults,
have been diagnosed with 3-MCCd in the Faroe Islands.
All were homozygous for a single deletion, c.1526delG, in
the MCCC1 gene. On January 1, 2014, the population of
the Faroe Islands was 48,308 (Faroese Board of Public
Health 2010). In the screening period from 2009 to 2011,
11 3-MCCd patients were diagnosed from the 26,462
samples collected. Thus, the prevalence of 3-MCCd is
1:2,400. A total of 34,000 live births were recorded in the
Faroe Islands from January 1970 until December 2012.
During this period, 13 patients with 3-MCCd were born –
giving an incidence of 1:2,615 live births.
Subject number 13 was found to be a carrier for the PCD-
related c.95A>G (p.N32S) mutation in the SLC22A5 gene.
The patient cohort includes three sib pairs, P3 and P6, P4
and P8 and P7 and P11.
Discussion
The incidence of 1:2,615 and prevalence of 1:2,400 of 3-MCCd
in the Faroe Islands are far greater than reported elsewhere:
1:41,676 in California (Schulze et al. 2003; Wilcken et al.
2003; Lam et al. 2013), 1:64,000 in North Carolina (Koeberl
et al. 2003) and 1:84,700 in Bavaria in South Germany
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(Stadler et al. 2006). The listed prevalences and incidences are
conservative estimates, because we only report on carnitine-
deficient 3-MCCd cases and not everyone in the Faroe Islands
participated in the voluntary screening programme. The
Faroese population stems from a genetic isolate and expanded
rapidly during the last three centuries with an almost tenfold
increase, from 5,000 to 48,308 individuals, making a founder
effect a probable cause of the high prevalence of 3-MCCd in
the population (Jorgensen et al. 2002).
We found that all Faroese 3-MCCd patients were carnitine
depleted when not treated with L-carnitine, with values of
free carnitine in plasma ranging from 4 to 8.2 mmol/L. Free
carnitine in plasma increased, p < 0.01, when 3-MCCd
patients were supplemented with oral L-carnitine, indicating
that oral L-carnitine supplementation of 3-MCCd patients can
restore levels of free carnitine in plasma to lower range
normal values.
We have demonstrated that mean muscle free carnitine
increased from 785 to 1,827 nmol/g wet weight of muscle
tissue when the patients were supplemented with L-carnitine.
Reference mean levels in normal subjects were reported by
Opalka et al. (2001) and Madsen et al. (2013) to be 2,400
(800) and 2,914 (249) nmol/g wet weight of muscle tissue,
respectively. The difference in reported mean values by
Opalka et al. and Madsen et al. might have been caused by
an age difference between the cohorts – as mean muscle free
carnitine levels reportedly decrease with age (Opalka et al.
2001). The levels of mean muscle carnitine in 3-MCCd
patients treated with L-carnitine are in the lower range of the
normal reference interval reported by Opalka et al., but
below that found by Madsen et al. Mean muscle carnitine
reported by Madsen et al. was quantified by the CIMD as in
the present study, but on a younger study population
(age 19–31), which may explain the lower values in our
older cohort compared to the reference interval. We conclude
that a significant increase in muscle free carnitine to a low
to low-normal level can be obtained by administration of
L-carnitine when given for 3 months or more.
We have demonstrated that rising plasma values of free
carnitine are an indicator of rising intramuscular free
carnitine levels in 3-MCCd patients (Fig. 2) as there was
a significant positive correlation between increasing plasma
carnitine levels and an increase in the level of carnitine in
muscle – the principal store of carnitine in the body.
Patients with a secondary carnitine deficiency such as 3-
MCCd have a normally functioning carnitine transporter
and are thus able to transport more carnitine into the
intramuscular compartment when plasma carnitine levels
increase. We conclude that plasma levels of free carnitine
reflect the intramuscular levels and can be used as a marker
for intramuscular levels of free carnitine.
Review of hospital medical records and questionnaires
revealed unremarkable present and past medical histories
concerning serious illnesses or diseases. Furthermore,
routine blood samples did not differ before and after L-
carnitine supplementation. Baseline ECGs, blood pressures
and transthoracic echocardiograms were unremarkable as
well. The reported clinical picture in the literature is
heterogeneous, ranging from fatal cases (Gallardo et al.
2001; Baykal et al. 2005) to asymptomatic adult cases
(Gallardo et al. 2001) including mothers diagnosed due to
abnormal newborn screening results in their infants
(Grunert et al. 2012). Clinical presentation varies even
within families (Visser et al. 2000; Eminoglu et al. 2009).
Neurological abnormalities have been reported (Baykal
et al. 2005) including one case of multiple sclerosis (Darin
et al. 2007). The mother of siblings P4 and P8 suffered
multiple sclerosis – however, the patients and their brother
did not present or complain of neurological deficits.
Carnitine depletion in PCD has been linked to sudden
death (Rasmussen et al. 2012). In PCD, the organic cation
transporter 2 (OCTN2) is deficient and leads to intracellular
carnitine depletion in contrast to the situation in patients
with 3-MCCd who have a normal OCTN2 activity that will
probably secure a sufficient intracellular carnitine level and
prevent sudden death.
Though their medical histories were unremarkable, some
patients reported mild but long-lasting symptoms. Fatigue
was the main symptom reported by 54% of the patients.
Given the small sample size and the difficulties in grading
fatigue even in large populations, the research group chose
not to include a formal grading of the self-reported
symptoms of fatigue. Grunert et al. (Grunert et al. 2012)
reported that among 88 patients, only one patient (#87) or
1.1% reported suffering from chronic tiredness – patient
#87 was Faroese and also included in our study as P8. The
prevalence of fatigue was thus much higher in our cohort.
Reasons for the difference might include different inter-
view/reporting procedures between the studies, cultural
differences in feeling fatigued and reporting it as a
diagnosis and a possible association between the Faroese
MCCC1 mutation c.1526delG and fatigue.
Two patients described consistent vomiting when ill with
a fever, which could indicate a tendency to slight metabolic
decompensation. Metabolic decompensation with vomiting
during illness is well described in cases of organic aciduria
(Pasquali et al. 2006).
3-MCCd patients seem slender; mean BMI was 23 and
22 kg/cm2 for males and females, respectively. A Faroese
population health survey from 2010 showed that mean BMI
for men and women aged 40 to 70 was 28 and 26,
respectively (Statistics Faroe Islands 2014). Thus, the
3-MCCd patients seem to have a normal BMI, though
lower than the national average. Our sample size is small and
only 8 of 13 patients fall into the sampled age group
(Table 2). Lower than national average BMI has not been
reported for 3-MCCd by other research groups, but the
reason for the finding is unclear and might be due to chance.
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The enzymatic activity of 3-methylcrotonyl-CoA car-
boxylase was not quantified in the present study. It has been
reported previously by Grunert et al. (2012) for patient P3,
labelled patient #73c, and patient P8, labelled patient #87,
as being severely reduced. All cases are homozygous for
the MCCC1 mutation c.1526delG and therefore we expect
reduced enzymatic activity in all subjects.
The patients in this study are enzymatically and
molecularly homogenous concerning 3-MCCd, which may
be a strength when evaluating the clinical consequences of
the disease. However, though generally mild, the phenotype
varies between the patients, which has also been demon-
strated previously within families (Eminoglu et al. 2009),
making general conclusions and treatment recommenda-
tions less viable and might instead call for future individ-
ualised treatment strategies.
Grunert et al. (2012) described 88 3-MCCd patients with
varying mutations in either MCCC1 or MCCC2. They
found no indication for dietetic treatment (except for maybe
an emergency regimen during intercurrent illness) and
recommended supplementation with L-carnitine if free
carnitine levels are low or patients are symptomatic. Arnold
et al. (2008) recommend L-carnitine supplementation for
carnitine-deficient cases regardless of symptomatology.
Faroese 3-MCCd patients were all carnitine depleted at
diagnosis and some had minor symptoms. Based on the
treatment strategies proposed by Grunert et al. and Arnold
et al. and our finding that some patients experience
alleviation of fatigue when treated with L-carnitine, it may
be discussed whether L-carnitine supplementation should be
recommended to Faroese 3-MCCd patients. However, the
symptoms experienced by these patients are not severe –
rather these patients have been feeling well for extended
periods. Data from other patient groups with secondary
carnitine depletion (as opposed to those with PCD) are not
conclusive concerning a beneficial effect of L-carnitine
supplementation, e.g. as in MCADD (medium-chain acyl-
CoA dehydrogenase deficiency) patients (Madsen et al.
2013). Supplementation in patients with LCHADD (long-
chain 3-hydroxyacyl-CoA dehydrogenase deficiency) on
the other hand may cause increased production of toxic 3-
hydroxyacylcarnitines (Spiekerkoetter et al. 2009). Possible
consequences of long-term L-carnitine supplementation are
not to date sufficiently documented, and some data may
raise concerns – Koeth et al. suggest a linkage between
ingestion of L-carnitine supplementation and cardiovascular
disease (Koeth et al. 2013). Furthermore, levels of
3-hydroxyisovaleric acid in urine did not differ between
those on and those without L-carnitine supplementation,
p ¼ 0.37, arguing against an effect of detoxification of the
L-carnitine given. It may be reasonable to supplement
symptomatic patients, but it seems premature at present to
give any more general recommendations.
Limitations
L-Carnitine was administered in a fixed dosage of 1 g three
times daily, when provided by the research group. One
could argue that doses based on body weight would render
a more true reflection of the effect of L-carnitine on
intramuscular carnitine levels. Fatigue, the dominating
symptom reported in questionnaires, is difficult to score
and represents a subjective feeling experienced by patients
– however self-reported fatigue that alters quality of life
must be taken into consideration and treated as a genuine
symptom. In the examined patient category, the patients
have had a lifelong state of secondary carnitine depletion.
Quantification of fatigue in the presence of this baseline
state is inherently difficult, as demonstrated in this study by
the fact that a patient upon L-carnitine supplementation
reported alleviation of fatigue, which the person had not
been conscious of and had not reported previously.
Conclusion
3-MCCd due to the MCCC1 c.1526delG mutation is
common in the Faroe Islands compared to the rest of the
world because of a probable founder effect. Levels of free
carnitine in muscle tissue and blood were low in patients
without L-carnitine supplementation and increased signifi-
cantly to low–low-normal levels upon L-carnitine supple-
mentation. Plasma levels of free carnitine and intramuscular
levels are highly correlated regardless of carnitine level;
therefore plasma carnitine levels can be used as an indicator
for intramuscular levels. Seven of 13 investigated patients
presented with a subjective feeling of fatigue that was
alleviated after L-carnitine supplementation. Taking into
consideration the newly raised concern regarding the safety
of L-carnitine supplementation, the absence of dangerous
symptoms and the significant but mild subjective feeling
of fatigue reported by some patients, a general recommen-
dation about supplementing all 3-MCCd patients with
L-carnitine cannot be given. However, since L-carnitine
supplementation can alleviate fatigue suffered by some
patients, one could argue for an L-carnitine supplementation
trial for these selected patients.
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Synopsis
Intramuscular levels of free carnitine correlate with plasma
levels of free carnitine and can be restored to near-normal
levels with oral L-carnitine supplementation in 3-MCCd
patients.
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Abstract Background: Classical homocystinuria due to
cystathionine b-synthase (CBS) deficiency (OMIM
236200) is a recessively inherited condition caused by
mutations in the CBS gene. The founder mutation p.R336C
accounts for almost all CBS deficiency in Qatar, affecting
approximately 1 in 1,800 births, making it the most
prevalent monogenic disease among the Qatari population.
Untreated patients can have severe intellectual disability
(ID), devastating multisystem complications and premature
death. Current treatment is based on pharmacology therapy
and life-long methionine-restricted diet, which is difficult to
maintain particularly in late diagnosed individuals. Data on
the neurodevelopmental and psychological impact of the
disease on outcomes among Qatari patients are generally
lacking and have not been studied.
Objectives: To examine the cognitive, educational and
psychological outcomes of classical homocystinuria on
Qatari patients.
Subjects and Methods: Thirty-two cases with classical
homocystinuria and 25 sibling controls were recruited to
evaluate the neurodevelopmental and cognitive outcomes.
We reviewed the subjects’ medical record and collected
pertinent clinical and educational data from parents.
Stanford–Binet Intelligence Test (Arabic translation – 4th
ed.) was used for cognitive (IQ) testing.
Results: The mean age for the subjects was 11.2 years
(range 0.6–29) with 56% males. The majority of cases
(93%) carried the mutation (p.R336C), and parental
consanguinity was 84%. There were no differences between
the two groups in the fine motor, expressive language,
behavioural and visual skills. However, cases have much
lower total IQ particularly in the domains of short memory,
quantitative reasoning and visual–spatial domains. A
significant number of adolescents and adult cases had
medical co-morbidities as well as behavioural and emo-
tional problems.
Conclusion: Individuals with classical homocystinuria
have many developmental and cognitive difficulties with
significant number of cases having learning disability and
lower IQs (cf. sibling controls) with adolescents and adults
more affected. Those diagnosed by newborn screening have
better developmental and cognitive outcomes compared to
late diagnosed cases. Psychological and psychiatric refer-
rals should be part of the standard of care for those cases
Introduction
Classical homocystinuria (CHU) due to CBS deficiency
(OMIM 236200) is caused by mutations in the CBS gene.
Although this disease is the most frequent disorder of
sulphur and methionine metabolism, it is still considered a
rare inborn error of metabolism with estimated prevalence
between 1/20,000 and 344,000. However, in Qatar, its
prevalence is extremely high, the highest in the world, of
approximately 1/1,800 births (Mudd et al. 1964; Mudd
1985; Naughten et al. 1998; El-Said et al. 2006; Zschocke
et al. 2009; Gan-Schreier et al. 2010; Yap 2012). Clinically,
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CBS-deficient patients may present with ectopia lentis,
osteoporosis, and skeletal deformities often associated with
Marfanoid features, but most importantly with intellectual
disability and life-threatening complications of the vascular
system leading to premature death (Mudd 1985; Mudd
et al. 1985; Yap 2012). Therapy of homocystinuria usually
includes administration of high doses of pyridoxine, the
cofactor of CBS; however, only less than 50% of affected
subjects show a substantial plasma homocysteine reduction
(Mudd 1985; Lindner et al. 2007; Yap 2012). The
homocystinuria patients in Qatar are known to be pyridox-
ine nonresponsive with more severe phenotype and com-
plications (El-Said et al. 2006; Zschocke et al. 2009; Gan-
Schreier et al. 2010).
Human CBS is a pyridoxal 50-phosphate (PLP)-containing
enzyme (E.C. 4.2.1.22), and it is the enzyme involved in the
first step of the methionine transsulphuration pathway, where
Hcy is combined with serine forming cystathionine, which in
turn is the precursor of cysteine. Consequently, an impaired
CBS activity leads to hyperhomocysteinaemia and homo-
cystinuria, hypermethioninaemia and hypocysteinaemia
(Mudd 1985; Yap 2012). The human CBS gene, mapped to
chromosome 21q21-3, encompasses 30 kb of genomic DNA,
and a total of 23 exons have been reported (Lindner et al.
2007). However, only exons 1–14 and 16 encode the
CBS protein. More than 140 different disease-causing
mutations have been identified in the CBS gene, and
although scattered along the entire gene length, mutations
in exons 3, 8 and 10 are most prevalent (Schiff and Blom
2012). Most of these mutations are missense, and only three
nonsense mutations have been reported. In addition, several
splicing mutations as well as deletions and insertion
mutations have been found (Kraus et al. 1999; Schiff and
Blom 2012).
The founder mutation p.R336C (c.1006C>T) can cause a
severe B6 nonresponsive phenotype. If untreated, homozy-
gous patients for this mutation (the usual situation in Qatar)
are clinically affected with severe intellectual disability as the
most prominent feature, in addition to devastating multisys-
tem complications and premature death (El-Said et al. 2006;
Zschocke et al. 2009; Gan-Schreier et al. 2010).
Furthermore, p.R336C mutation exhibited an activity lower
than 4% of the wild-type protein (Urreizti et al. 2006). This
disease imposes a huge clinical, financial and psychosocial
overall burden on the population of Qatar (Gan-Schreier
et al. 2010).
Treatment of patients with CHU whether diagnosed early
by newborn screening or later is based on a combined life-
long methionine-restricted diet and pharmacological therapy.
Dietary treatment includes low methionine diet with cysteine
enriched methionine free amino acid supplement. The use of
dietary control and medications is an effective intervention to
reduce the mean homocysteine and methionine levels.
However, dietary control is rather difficult to maintain, in
particular for late diagnosed patients and during puberty,
adolescence and adulthood. Pharmacological therapy
includes betaine, in addition to vitamin B6, vitamin B12
and folate supplementation. In our cohort of cases with
CHU, the overall disease control (measured by homocysteine
and methionine levels) is significantly better among those
diagnosed through newborn screening than those diagnosed
clinically. This is attributed mainly to poor compliance with
both diet and medications (Table 1).
In this study, we prospectively assessed the neuro-
developmental and cognitive outcomes in 32 children and
adults with CHU and compared them with 25 sibling
controls using standardized assessments.
Methodology
Between April 2011 and March 2013, a total of 32 cases
with CHU who attended the Metabolic Clinic at Hamad
Medical Corporation (HMC), Doha, Qatar, were invited to
participate in the study. We also recruited one (the
immediate older or younger) unaffected sibling of the same
sex to serve as control for the subject. Sibling controls were
used as the neurodevelopmental and cognitive outcomes
assessed in this study may be affected by family circum-
stances and genetic makeup.
The diagnosis was achieved in late diagnosis/symptom-
atic patients by measuring plasma total homocysteine.
Table 1 Mean homocysteine and methionine pre- and posttreatment levels among CHU cases diagnosed by NBS and those of late diagnosis
Diagnosed by NBS Late diagnosis
Mean homocysteine level (umol/L)
Pretreatment 141.6 130.5
Posttreatment 40.8 115.2
Mean methionine level (umol/L)
Pretreatment 468.9 770.6
Posttreatment 256.1 928.2
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The diagnosis is further supported by simultaneously high
or borderline high plasma methionine. Confirmation of the
diagnosis is by mutation analysis of the CBS gene
(common Qatari mutations). For newborn babies (identified
by NBS), we measure total homocysteine in dried blood
spots by LC/MS/MS. Then, in positive cases, confirmation
of the diagnosis is achieved by measuring plasma total
homocysteine, plasma methionine and mutation analysis of
the CBS gene.
A detailed medical assessment including history, physi-
cal examination and medical records review was conducted
by the study investigators to collect pertinent data on
demographic factors, medical, laboratory, neurodevelop-
mental, psychosocial and educational attainment. Direct
questioning of parents and or adult cases was used to
collect pertinent data that was not available in the medical
records.
Cognitive assessment was conducted using Stanford–Binet
Intelligence Scale – 4th ed. (Arabic translation) by a trained
clinical psychologist. The test yields a total mental processing
composite based on subtests that measure verbal reasoning,
quantitative reasoning, visual–spatial processing, working
memory and total IQ. For children under 3 years of age at
testing, cognitive assessment was not done.
T-test or Fisher’s exact test was used for normally
distributed data, and for non-normally distributed data, non-
parametric tests were used. Matched and unmatched
analysis for all variables was used to adjust for the use of
sibling controls.
Differences in baseline characteristics were assessed
using McNemar’s test for comparing dichotomous variables
and chi-square and Fisher’s test for higher-order categorical
variables. Two-tailed significance test was used with a p-
value of <0.05 as significance level. Statistical analyses
were conducted in STATA 13.
All procedures followed were in accordance with the
ethical standards of the responsible committee on human
experimentation (institutional and national) and with the
Helsinki Declaration of 1975, as revised in 2000.
Results
Thirty-two cases and 25 sibling controls were available for
evaluation. The mean age for the study’s subjects (cases
and controls) was 11.2 years (range 0.6–29) and 32 (56%)
were males. The mean age at diagnosis of all cases was 66
months (range 1–240), and 9 (28%) were diagnosed in the
first month of life through the national expanded newborn
screening programme that was established in early 2006.
The mean age of the 14 (44%) cases that were diagnosed
prior to 2006 was 92 months (range 14–240) compared
with a mean age of 100 months (range 56–142) for those
diagnosed on or after 2006 excluding cases diagnosed by
newborn screening (p ¼ NS).
Parental consanguinity was positive in 27 (84%) of the
cases. Interestingly, all cases carry the founder mutation
p.R336C, except one child who had the G347S mutation.
Developmental Domains
In 25 (78%) of cases, the parents reported one or more
concerns about their children’s development. Table 2 shows
developmental difficulties among cases and controls.
Parents reported more difficulties in the domains of fine
motor skills and coordination, and expressive language, but
only the vision and behavioural/emotional problems were
statistically significant when compared with their sibling
controls. All cases were able to walk independently;
however, three cases needed help to climb stairs or to run.
None of them had cerebrovascular insult; however, one
child had white matter changes in his brain MRI. There
were no significant differences in developmental domains
among boys and girls in the study.
There were no parental concerns regarding daily living
activities (eating, personal care skills and independent use
of toilet), but four cases aged 10, 13, 22 and 29 years have
major coordination and handwriting difficulty skills.
Seven cases had both receptive and expressive language
difficulties, and in four cases expressive language difficul-
ties were only reported. At the time of enrolment, two
children were getting private speech therapy sessions.
A significant number (13/32) of cases were reported by
their parents to have behavioural and emotional difficulties.
The mean age for those cases was 14.6 years (range 9–29)
and six were females. Eight (61%) of the cases had a mean
total IQ < 70. According to the families, none of their
children had a formal psychiatric assessment or an explicit
diagnosis.
Over half of the cases reported to regularly attending the
ophthalmology clinics because of their visual difficulties
and two needed eye operation. Four cases were labelled as
visually impaired and attend a special school for children
with visual impairment.
Education Attainment
Table 3 shows the educational attainment history as
reported by parents. At the time of enrolment, a significant
number of cases were attending or previously attended
special needs school or needing extra help in the classroom
to access the mainstream education curriculum. A number
of parents reported that their child’s school performance
was average or below what is expected especially in
arithmetic and language. Overall, cases and controls had
good school attendance record.
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Cognitive Function
The cognitive data was obtained from 28 cases and 24
controls. Cognitive testing was not available in the
remainder of cases and controls due to young age and
refusal to conduct the test. Total IQ score as well as three of
the four subset scales (quantitative reasoning, visual–spatial
processing, working memory) for the Stanford–Binet
Intelligence Scale – 4th ed (Arabic translation) were
significantly lower among cases compared with controls
(P < 0.001) (Fig. 1).
Figure 2 shows the classification of cognitive levels
according to the total IQ score. Unlike the controls whom
the majority (19/24) were classified to have average or high
average cognitive level, only 9 (32%) cases had total IQ in
the average or high average (p < 0.001). Moreover, more
than a third of the cases (10/28) had total IQ < 70 and were
classified as mental retardation but none of the controls
(p ¼ 0.001). There were no significant differences in IQ
among boys and girls in the study.
Newborn Screening and Outcomes
Table 4 shows the developmental and cognitive outcomes
among cases stratified by age at diagnosis. Nine cases were
diagnosed within the first month of life by newborn
screening, whereas the remainder of the cases were
diagnosed at different ages according to their presentation.
None of the nine cases had visual problems compared with
18 (78%) in the late diagnosed group. This is a significant
difference between the two groups. One child in the
newborn screening group has receptive and expressive
language difficulties at the time of enrolment; however, his
total IQ was 116 (high average).
The differences in language domains, attendance at
special school and access to extra support in class were not
statistically significant between those diagnosed soon after
birth and cases detected/diagnosed later in life. Nonethe-
less, it is apparent that the “late detection” group had more
reported difficulties. In addition, the late diagnosed group
Table 2 Developmental difficulties among cases and controls as reported by parents
Domain Cases (n ¼ 32) Controls (n ¼ 25) p-value
Gross motor skills 3 (9%) 0 (0%) NS
Fine motor skills + coordination 4 (12.5%) 0 (0%) NS
Receptive language 7 (22%) 3 (12%) NS
Expressive language 11 (34%) 3 (12%) NS
Self-care skills 2 (6.2%) 0 (0%) NS
Behavioural/emotional 13 (40.6%) 1 (4%) 0.002
Vision problems 18 (56%) 3 (12%) < 0.001
Hearing problems 0 (0%) 1 (4%) NS
NS not significant
verbal
visual
spatial
Quantitative
reasoning
short
memory
Total IQ
cases 43.17 37.21 37.76 37.69 74.45
controls 47.13 55.83 46 50.46 99.88
p-value 0.088 <0.001 0.002 <0.001 <0.001
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Fig. 1 Total and subscale IQ scores among cases and controls
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total mean IQ was significantly lower when compared with
the newborn screening group (p < 0.001) (Table 4).
Discussion
We conducted a case–control study to report on the
neurodevelopmental, educational and cognitive outcomes
of cases with CHU. To our knowledge, only a limited
number of studies have reported on these outcomes in
subjects with CHU. We used siblings as control to adjust
for genetic, environmental (protective or risk) factors and
socioeconomic status that may affect the outcomes in
question especially the IQ which could be highly heritable
(Bailey and Revelle 1991; Devlin et al. 1997; Dickens and
Flynn 2001; Turkheimer et al. 2003). The use of sibling
controls in this study is not novel, as a number of previous
studies have used siblings as controls possibly for the same
reasons mentioned above (Koch et al. 1984; Eldridge et al.
1989; Yap et al. 2001).
In 2003, Qatar has established an expanded newborn
screening (NBS) programme for a number of metabolic and
endocrine conditions including CHU (by using methionine)
(Lindner et al. 2007; Zschocke et al. 2009; Gan-Schreier
et al. 2010). In 2006, NBS for CHU performed by
measuring total homocysteine. The introduction of the
screening programme has clearly helped in the early
detection of newborn cases. All cases bar one were
homozygous for the founder p.R336C mutation, and
considering the high consanguinity rate among the families,
this explains the high prevalence rate of CHU in Qatar
(El-Said et al. 2006; Zschocke et al. 2009; Gan-Schreier
Fig. 2 Classification of IQ scores among cases and controls
Table 3 Education variables among cases and controls as reported by parents
Variable Cases (n ¼ 27) Controls (n ¼ 21) p-value
Attends education 26 (96.3%) 20 (95.2%) NS
Attends special needs school or centre 6 (22%) 0 (0%) 0.028
School performance rated by parents as average or below 16 (59%) 9 (43%) NS
Extra help in class 10 (37%) 3 (14.3%) NS
> 3 days off school in 3 months 4 (15%) 2 (9.5%) NS
NS not significant
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et al. 2010). It is interesting that cases reported from a
neighbouring country (Saudi Arabia) had different common
mutations for CHU (Al-Essa et al. 1998).
Our study showed a large number of families had raised
concerns about one or more domains of their child’s
development, and clearly there was a trend of difficulties
among the cases; nonetheless, the data did not show
statistical differences between cases and controls in the
gross or fine motor skills or the language domains. This
could be attributed to the small sample size.
Forty percent of our cases were reported by their parents
to have behavioural and emotional difficulties. Our study
concurs with previous studies that reported similar or even
higher rates of psychiatric/behavioural disorders among
cases of homocystinuria (Abbott et al. 1987). Another
significant finding is that all those cases bar one had total
IQs that are low average or below 70. The association
between psychiatric/behavioural problems and low IQ in
CHU has been reported previously (Abbott et al. 1987).
However, it is not clear from our study if those cases have
behavioural/emotional issues secondary to their low cogni-
tive abilities or they have primary behavioural/emotional
problems that are independent of their IQ; particularly the
parents have denied any formal diagnosis or follow-up of
psychiatric illness among the cases. This may be explained
by cultural factors or more family support particularly
among female patients. A recent systematic review has
reported difficulty in assigning causality association of
metabolic disorders with psychiatric illnesses in adults
(Bonnot et al. 2014).
Visual problems were very prevalent among our cases
and clearly represent a long-term morbidity. However, it
was reassuring that the majority of cases are regularly
followed up and closely monitored in the Ophthalmology
Clinic. A significant number of cases have low cognitive
abilities as highlighted by their low total and subset IQs.
The high prevalence of visual problems may have con-
tributed further to their lower score. Low IQs in the subset
of short-term memory and reasoning negatively impact on
the child’s learning ability.
Our study is susceptible to biases common to
case–control studies. It was not possible to blind the study
team to the subject’s status. Another limitation is the
relatively small sample size which could be the reason why
many of the differences between cases and controls did not
achieve statistical significance; however, CHU is still a rare
condition and most of the studies that addressed the
neurodevelopmental and cognitive outcomes have pub-
lished similar number of subjects or even less (Yap et al.
2001; Weisfeld-Adams et al. 2013). Another important
limitation is that we relied on parent/subject report and
recall on some of the developmental and educational
domains. It is not clear if those reports have over- or
underestimated the prevalence of difficulties in those
domains. Further studies with larger sample size and using
assessment tools that have been translated and validated
into Arabic language may help to control this limitation.
Conclusion
It is clear that current treatment for CHU in early-treated
children, particularly in those detected by NBS, has
eliminated severe intellectual and cognitive impairment.
More support is needed for cases attending mainstream
schools especially those with low cognitive abilities and
those with visual problems as they may need extra support
in class or individual educational plans that take into
account their overall difficulties. Future research assessing
intellectual and neurocognitive outcome in CHU will
enhance the development of new treatment strategies.
Long-term follow-up studies are needed to explore the
behavioural/emotional difficulties especially among adoles-
cents and adults with this condition. Psychological and/or
Table 4 Age at diagnosis and developmental, educational and cognitive outcomes among the cases as reported by parents
Variable Newborn screening (n ¼ 9) Late detection (n ¼ 23) p-value
Mean (SD) age at enrolment 4.2 (1.7) 14.0 (6.2) <0.001
Vision problems 0 18 <0.001
Receptive language difficulties 1 6 NS
Expressive language difficulties 1 10 NS
Special school 0 (n ¼ 4) 6 NS
Extra help in class 1 9 NS
Mean (SD) total IQ 101 (14.2) 66 (19.8) 0.002
NS not significant, SD standard deviation
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psychiatric referrals should be part of continuing care of
those cases especially for those with low cognitive (IQ)
abilities who may be at greater risk.
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Abstract Background: Omega-3 long-chain polyunsatu-
rated fatty acids (n3LCPUFA) levels are reduced in
phenylketonuria (PKU). Recent care guidelines recommend
essential fatty acid status is monitored in patients with PKU
but access to such testing is limited. We hypothesized that
information obtained on diet history would identify PKU
adults with suboptimal levels of n3LCPUFA.
Methods: A 12-month single site prospective study was
completed including 35 adults (age 18–46) attending a
clinic for adults with inborn errors of metabolism. Levels of
n3LCPUFA were correlated with estimated intake using a
published food frequency questionnaire. n3LCPUFA levels
were tested at a commercial laboratory and values > one
SD below the laboratory mean value were considered
suboptimal.
Results: Mean levels of docosahexaenoic acid (DHA)
were lower and levels of eicosapentaenoic acid (EPA) and
alpha-linoleic acid (ALA) higher in subjects with PKU than
in laboratory controls. n3LCPUFA levels correlated with
estimated intake (p <0.002). Diet history had a positive
predictive value of 93% and negative predictive value of
90% to identify subjects with suboptimal n3LCPUFA
levels.
Conclusions: Diet history is sufficient to predict adult
subjects who may have low DHA levels and can be used to
target testing or supplementation to those at risk. DHA
levels are low despite high levels of ALA suggesting that
supplementation, if indicated, should be with preformed
DHA rather than with its precursors.
Introduction
Suboptimal levels of omega-3 long-chain polyunsaturated
fatty acids (n3LCPUFA) have been documented in patients
with phenylketonuria (PKU) (Lohner et al. 2013) related
both to dietary restriction of sources of preformed
n3LCPUFAs and possibly due to an inhibitory effect of
phenylalanine metabolites on the endogenous synthesis of
docosahexaenoic acid (DHA) (Infante and Huszagh 2001).
Suboptimal levels of n3LCPUFA may be related to
neurologic (Agostoni et al. 2003) and bone (Lage et al.
2010) outcomes, and supplementation may improve subtle
surrogate markers of neurologic function in patients with
PKU (Gutierrez-Mata et al. 2012). There are several studies
which suggest a possible benefit of n3LCPUFA supple-
mentation on neurological outcomes in children with PKU.
For example, fish oil supplementation in children with PKU
has been shown to improve n3LCPUFA levels and motor
skills (Beblo et al. 2007) and visual evoked potential
latencies (Koletzko et al. 2009; Beblo et al. 2001). In a
study of female patients over the age of 12, Yi et al. found a
positive relationship between red blood cell (RBC)
DHA levels and performance on a verbal ability task
(Yi et al. 2011).
Unfortunately, most of the data available on n3LCPUFA
status in PKU are for children. A recent meta-analysis on
this topic (Lohner et al. 2013) reviewed 15 studies, only
two of which included patients over the age of 25 (Lage
et al. 2010; Moseley et al. 2002) for a total of 47 patients
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over the age of 25 years. Despite the paucity of data on
n3LCPUFA status in PKU adults, recent consensus guide-
lines (Singh et al. 2014) suggest that all patients given fat-
free medical foods should have essential fatty acid status
monitored. Some literature suggests that suboptimal
n3LCPUFA status in adults may not be the same as seen
in children (Moseley et al. 2002; P€oge et al. 1998),
questioning the need for screening in adults and its
associated costs. Recent work has also documented that
adult patients with PKU have very limited access to expert
care (Berry et al. 2013) so specialized laboratory testing
may be even more restricted. Thus, it would be useful to
identify standard nutrition screening tools to assess risk for
suboptimal n3LCPUFA levels in order to reduce the need
for specialized laboratory testing.
Methods
The University of British Columbia Clinical Research
Ethics Board approved the study protocol and all subjects
provided informed consent. Adults with PKU followed at
our site and able to provide informed consent were invited
to participate over a 12-month period. Plasma total fatty
acid profiles are included in the VGH Adult Metabolic
Clinic’s annual laboratory assessment of PKU patients as
this is a recommended component of the nutrition manage-
ment for PKU (Singh et al. 2014). This blood work was
sent to a commercial laboratory (Kennedy Krieger Institute,
Baltimore, Maryland, USA), and other laboratory parame-
ters including phenylalanine (PHE) levels were done locally
using standard methods. The Kennedy Krieger laboratory
has derived its normal range for plasma total fatty acids
from 52 controls who reside in North America, but details
of the ethnic makeup of the control population are not
known (Dr. Richard Jones Ph.D., Administrative Labora-
tory Manager, Genetics Laboratory Kennedy Krieger
Institute, personal communication, November 5, 2014).
Data on docosahexaenoic acid (DHA), eicosapentaenoic
acid (EPA), a-linolenic acid (ALA), and arachidonic acid
(ARA) are included here. Levels within one standard
deviation of the mean for laboratory controls were
considered normal. Although the usual threshold for
defining laboratory values as being “low” is 2 SD below
the mean of healthy controls, we selected a higher threshold
of 1 SD given our primary goal was to see if diet history
could be used to define an at-risk population to allow
appropriate targeting for n3LCPUFA screening. This lower
threshold would reduce the chance that patients who might
benefit from n3LCPUFA measurement and/or supplemen-
tation would be missed.
A nutrition history was obtained from each subject using
the Omega-3 PUFA Food Frequency Questionnaire
(Sublette et al. 2011) modified by asking additional
questions about ALA, DHA, and EPA intake from PKU
medical food products and adherence to the subjects’
prescription of medical food products as shown in question
5 and 6 of the Appendix. The daily amount of n3LCPUFA
consumed in the diet from food, supplements, and actual
(not prescribed) formula intake was used based on these
patient self-reports.
The normality of plasma level distributions was tested
using the Shapiro–Wilk test. Student’s t-test was used to
compare data showing normal distribution, and the Man-
n–Whitney U test was used for data which were not
normally distributed. Correlations were calculated with the
Pearson correlation test. All conclusions were based on a
significance level of P < 0.05.
Results
In a 12-month period, 53 adult subjects with PKU had plasma
total fatty acid profiles drawn. Of these, 10 subjects were
diagnosed with PKU before newborn screening and unable to
provide informed consent, 1 was pregnant, 2 consented but
did not have the blood work done, 2 declined consent, and 5
could not be contacted for consent so were excluded from
analysis, leaving a total of 35 subjects for inclusion in the
study. Clinical characteristics and laboratory parameters of
the study participants are shown in Table 1.
Plasma DHA levels in study subjects were significantly
lower (p < 0.0001) and plasma EPA (p ¼ 0.021) and ALA
(p < 0.001) significantly higher than laboratory normal
controls. ARA levels in study subjects did not differ from
control values (p ¼ 0.2). Estimated dietary intake of DHA
and EPA using the modified questionnaire correlated with
plasma levels for DHA ( p < 0.001) and for EPA
(p ¼ 0.002). Blood PHE levels did not correlate with
DHA ( p ¼ 0.74), EPA ( p ¼ 0.4), ALA ( p ¼ 0.2), or
ARA (p ¼ 0.1) levels in study subjects.
Fifteen subjects had normal levels of DHA, and 14 of
these subjects had normal levels of DHA, EPA, and ALA.
Of the 15 subjects with normal levels of DHA, 10 were
consuming DHA through supplements or a supplemented
PKU medical food product. Three of the 5 subjects with
normal DHA levels who did not obtain DHA from medical
food products or supplements reported eating fish. There
were two patients were on medical food product supple-
mented with DHA but had DHA levels <1 SD below the
laboratory control range. Both subjects routinely consumed
less than 50% of the DHA supplemented medical food
product prescribed indicating limited compliance.
Predictive values were calculated from these data. If a
subject was predicted on history to have adequate intake of
DHA, then 93% of those subjects actually did have a
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normal plasma value of DHA, and measurement of
n3LCPUFA levels in this group would be of low yield. If
a subject was predicted on history to have low intake of
DHA, then 90% of those subjects did have a low DHA and
supplementation (with or without measurement of
n3LCPUFA levels) could be considered on the basis of
the diet history.
Discussion
Consistent with other authors, we have identified that levels
of DHA are lower in PKU subjects although we did not
identify deficiencies of other n3LCPUFA. Our intention,
however, was to focus on findings useful from a patient
management perspective. Firstly, information on
n3LCPUFA intake obtained simply by diet history is
sufficient to identify adult subjects at risk of suboptimal
n3LCPUFA levels, suggesting this information can be used
to target laboratory analysis or supplementation of
n3LCPUFA levels only to those at risk.
Suboptimal DHA status is evident despite more than
adequate levels of the precursor ALA. EPA levels were
elevated, which differs from previous studies (Lohner et al.
2013), consistent with the findings of Infante and Huszagh
(2001), suggesting that PHE metabolites may inhibit later
stages in the pathway for DHA synthesis. This has
relevance to current nutritional guidelines (Singh et al.
2014) which suggest that supplementation with the precur-
sor ALA or with preformed DHA is appropriate in patients
with low levels of n3LCPUFA. Our subjects have low
levels of DHA despite elevated levels of ALA, suggesting
that precursor supplementation would not be sufficient to
normalize DHA levels in our adult population.
In our study of adult patients, we did not identify a
relationship between blood PHE levels and n3LCPUFA
status which is contrary to reports in children (Agostoni
et al. 1997) and other reports in adults (Moseley et al.
2002). We are not sure of the reason for this discrepancy
but speculate that it is related to the factors underlying poor
control in our population. Dietary indiscretions in our
patient population tend to be related to excessive intake of
carbohydrate-rich foods, dairy, and meat rather than due to
intake of n3LCPUFA protein sources such as fish, so
noncompliance with dietary recommendations in our
patients does not mean that their intake of DHA will
increase.
Our study has limitations. Subject numbers are limited
although this is the one of the largest data sets to date on
n3LCPUFA levels of adult patients with PKU. We used lab-
based normal values as a reference rather than our own
controls. However, as the purpose of our study was not to
repeat the work of other authors documenting n3LCPUFA
deficiency in subjects with PKU but rather to identify ways
we could target our screening to individuals at risk, we feel
the use of lab-based normal ranges is reasonable. We also
defined patients at risk of n3LCPUFA deficiency as being
below 1 SD of the mean which is higher than the usually
accepted thresholds of 2 SD of the mean. The predictive
values of diet history in determining subjects at risk of
Table 1 Demographics, phenylalanine, and n3PUFA levels of adult subjects with PKU
Parameter Subject values Comment
N (male:female) 22:13 Data not available on sex of controls
Age (mean  SD) 28.5  7.5
BMI (mean  SD) 28.7  6.6
Blood PHE (mmol/L; median (range)) 703 (range 103–1,721) N ¼ 33 as two subjects did not have PHE levels
at the time of PUFA analysis
Subjects on supplemented formula 10 N ¼ 4 on formula supplemented with ALA alone; N ¼ 5 on
formulas supplemented with DHA and EPA, and N ¼ 1 on
formula supplemented with DHA alone
DHA – (%total; mean  SD) 1.65  0.61 p < 0.0001 versus laboratory control rangea
EPA – (%total; mean  SD) 0.79  0.31 p ¼ 0.021 versus laboratory control rangea
ALA – (%total; mean  SD) 0.96  0.32 p < 0.001 versus laboratory control rangea
ARA – (%total; mean  SD) 7.12  1.67 p ¼ 0.2 versus laboratory control rangea
PHE phenylalanine, n3LCPUFA omega-3 polyunsaturated fatty acids, DHA docosahexaenoic acid, EPA eicosapentaenoic acid, ALA alpha-linoleic
acid, ARA arachidonic acid
aP value compared with laboratory normal control values: control range was determined from 52 North American subjects aged (mean  SD)
44  13.8; range 18–75 years (Dr. Richard Jones Ph.D., Administrative Laboratory Manager, Genetics Laboratory Kennedy Krieger Institute,
personal communication, November 5, 2014). The mean values (%total) of DHA, EPA, ALA, and ARA for the 52 controls used were 2.655%,
0.664%, 0.742%, and 6.751%, respectively, with a standard deviation of 0.968%, 0.366%, 0.307%, and 1.374%, respectively
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having low levels of n3LCPUFAs reported in this study are
expected to change if the threshold to define a low level
changes. However, in the absence of data which demon-
strate clinical benefits of DHA supplementation in adults,
we cannot comment on what threshold level of DHA is
appropriate and choose a higher threshold to minimize the
risk of failing to identify patients who might benefit from
supplementation. Plasma levels of n3LCPUFA were used
rather than measurement of tissue levels such as in RBC
membranes which may be a more reliable measure of
cellular availability of n3LCPUFA (Vilaseca et al. 2010).
However, as assessment of membrane lipid content is not
available clinically to most centers caring for adults with
PKU (due to the practicality of sample handling in that
samples have to be received at the lab within 24 h of
collection), we feel the information on plasma levels is still
useful to clinicians. Finally, geographic differences in
dietary n3LCPUFA intake which have been described in
other European countries (Acosta et al. 2001) may not
make our results applicable to other centers.
Conclusions
Use of a modified diet history looking at sources of
n3LCPUFA intake can be used to target screening of fatty
acid levels to at-risk individuals with PKU. If supplemen-
tation is considered, preformed DHA may be the most
appropriate form of supplementation. Further research is
required to determine the optimal dose range for DHA
supplementation and the effects of such supplementation, if
any, on clinical outcomes in patients with PKU.
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Appendix
Questions useful in assessing DHA intake and predicting
DHA status (Questions 1–4 selected from Sublette et al.
2011):
1. How many times have you eaten fish or shellfish in any
form?
(1) Never
(2) Less than 1 time each month
(3) 1 time each month
(4) 2–3 times each month
(5) 1 time each week
(6) 2 times each week
(7) 3–4 times each week
(8) 5–6 times each week
(9) 1 time each day
(10) 2 or more times each day
2. Each time you ate fish or shellfish, how much did you
eat?
(1) Less than 2 ounces or less than one fillet or less
than 4 pieces of sushi
(2) 2–7 ounces or about 1 fillet or 4–14 pieces of
sushi
(3) More than 7 ounces or more than 1 fillet or more
than 14 pieces of sushi
3. In the past 6 months, about how often did you use cod
liver oil?
(1) Never
(2) Less than 1 time each month
(3) 1 time each month
(4) 2–3 times each month
(5) 1 time each week
(6) 2 times each week
(7) 3–4 times each week
(8) 5–6 times each week
(9) 1 time each day
(10) 2 or more times each day
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4. In the past 6 months, have you used an omega-3 fatty
acid or fish oil supplement at least once each week?
(1) No
(2) Yes – What type of an omega-3 fatty acid or fish
oil supplement did you take?
Please write the name of the supplement below:
(3) Is the omega-3 fatty acid or fish oil supplement in
pill or capsule form?
(1) No
(2) Yes – How much did you take?
(1) 1 pill or capsule each week
(2) 2 pills or capsules each week
(3) 3–4 pills or capsules each week
(4) 5–6 pills or capsules each week
(5) 1 pill or capsule each day
(6) 2 pills or capsules each day
(7) 3–4 pills or capsules each day
(8) 5 or more pills or capsules each
(4) Is the omega-3 fatty acid or fish oil supplement
(besides cod liver oil) in liquid form?
(1) No
(2) Yes – How much did you take?
(1) Less than 1 tablespoon each week
(2) 1 tablespoon each week
(3) 2 tablespoons each week
(4) 3–4 tablespoons each week
(5) 5–6 tablespoons each week
(6) 1 tablespoon each day
(7) 2 tablespoons each day
(8) 3–4 tablespoons each day
(9) 5 or more tablespoons each day
(5) Please write down the dosage of omega-3 fatty
acids or fish oil supplement if you know it:
Dosage:
Pills or Capsules: _____mg DHA and ______mg
EPA per pill/capsule
Liquid: _____mg DHA and ______mg EPA per
tablespoon
Do not know dosage
5. Do you take a PKU Medical Food Product?
No
Yes
Please write down the name of your PKU Medical
Food:
6. On average, how much of this PKU Medical Food do
you take each day (please write down what you are
actually taking, not what would be ideal):
Scoops/packages: I take ______scoops/packages
of formula each day
Grams of powder: I take _______grams of powder
per day
Tetra’s/pouches: I take _______pouches of for-
mula per day
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Abstract We present the positive outcome of a pregnancy
in a woman with severe classic maple syrup urine disease
(MSUD). Maintaining the maternal plasma levels of leucine
between 200 and 300 mmol/L allowed normal development
of the foetus. Tolerance of protein and leucine increased
continuously from the 16th gestational week until delivery.
The patient was able to increase protein and leucine intake
from 5 g to nearly 30 g and 300–3,000 mg/day,
respectively. Weekly measurement of branched-chain
amino acid (BCAA) concentrations and the assessment of
dietary intake were used to adjust protein intake. After
41 weeks of pregnancy, she gave birth to a healthy baby
girl and was able to breastfeed her daughter for 6 months
during which time, the protein and leucine intake were
lower than during pregnancy, but higher than with her usual
pre-pregnancy diet. The development of the girl is normal
at the age of 3 years.
Introduction
MSUD or branched-chain alpha-ketoaciduria is an
autosomal recessive disorder of branched-chain amino acid
(BCAA) catabolism first described in 1954 (Menkes et al.
1954). It is caused by a deficiency of branched-chain alpha-
ketoacid dehydrogenase, which leads to an accumulation
of the BCAAs leucine, isoleucine and valine and their
toxic metabolites (Barbara 2010). Five distinct clinical
phenotypes have been described in patients with MSUD,
with 80% suffering from the severe classic type with
0–2% of normal enzyme activity (Chuang and Shin 2001).
Untreated MSUD leads to severe mental and physical
disabilities or death (Treacy et al. 1992). In 1964 adminis-
tration of a diet restricted in BCAA was reported
in seven patients with MSUD demonstrating that neuro-
logical manifestations could be prevented if nutritional
management was instituted early (Snydermann et al. 1964),
thereby establishing the basis for long-term nutritional
management of patients with MSUD. In severe classical
MSUD the nutritional therapy consists of strict protein
restriction in combination with daily supplementation
of a precursor-free amino acid mixture. Since then
the outcome of patients with MSUD has gradually
improved. Progress in newborn screening, early diagnosis
and medical treatment, as well as an improved nutritional
management, has resulted in normal growth and mental
development in many of these patients (Hoffmann et al.
2006). As a result, an increasing number of women
with MSUD reach child-bearing age. Since protein require-
ment increases during pregnancy, the management of such
patients is a considerable challenge. Successful pregnancy
outcomes in women with MSUD have been reported
(Tchan et al. 2013; Gr€unewald et al. 1998; Van Calcar
et al. 1992).
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Case Report
The patient is a 31-year-old Caucasian woman who suffers
from severe MSUD, diagnosed within the first week of life.
She received dietary treatment with strictly reduced intake
of protein and branched-chain amino acids. She only had
one significant metabolic decompensation at the age of 18
months. Physical and mental development remained nor-
mal. Also during adolescence – often a difficult period to
keep patients motivated to follow the diet – leucine levels
were most of the time within the target range. Higher
BCAA levels were usually attributed to short episodes of
illness such as influenza. The normal mental development
and her decision to become a nurse were surely helpful in
comprehending the particular features of MSUD and were
supportive for dietary compliance. The patient’s usual diet
in adulthood includes a very low protein diet with about 5 g
natural protein per day derived from fruits and vegetables.
This corresponds approximately to 300–500 mg leucine. To
keep the protein and leucine intake that low and to reach an
adequate energy intake, she consumes medical dietary
products such as low protein pasta, bread, cereals or sweets.
To ensure an appropriate protein intake, she daily takes
70 g of a BCAA-free, micronutrient-enriched amino acid
mixture (ILV-AM®, SHS). She is aware of the importance
of covering the energy requirements to avoid leucine
increase from protein breakdown, i.e. she eats about five
to six meals per day and she avoids catabolic fasting
conditions. According to the regular laboratory results
(leucine between 400 and 600 mmol/L), she consistently
adhered well to her diet.
At the age of 29 she married an unrelated Caucasian man
and became pregnant at the age of 30 years.
Pre-pregnancy anthropometric measures were height
153 cm, weight 58 kg and BMI 24.7 kg/m2. Her calculated
resting energy requirement was 1,350 kcal, total energy
expenditure 2,000 kcal (38 kcal/kg), which corresponds to
the recommended daily energy intake for adults with
MSUD (Barbara 2010). Energy need for pregnancy was
derived from requirements for healthy women plus approx-
imately 250 kcal/day for the entire pregnancy. She
presented in the seventh gestational week to the metabolic
team. Based on the experience of the University of
Wisconsin, Madison, United States, the goal was to keep
plasma leucine concentration during pregnancy between
200 and 300 mmol/L which was slightly lower than usual.
During the first 8 weeks, she followed her usual diet
containing 300–500 mg leucine per day. First dietary
counselling was set up after the first trimester of pregnancy.
At this time the intake of leucine was around 1,000 mg/day.
Plasma leucine concentrations were between 200 and
300 mmol/L, and she gained 1 kg in weight. She did not
suffer from pregnancy sickness or vomiting.
Plasma leucine concentrations were measured weekly,
and the patient maintained a food diary. Based on the plasma
concentrations of BCAA, the intake of natural protein was
increased. To keep plasma leucine concentrations in the
target range, natural protein requirement continuously
increased from the fourth month of gestation (Fig. 1). In a
first step the low protein products were replaced by normal
products. The daily intake of natural protein was increased
to 15 g, corresponding to approximately 1,500 mg leucine,
and the amino acid mixture was increased to 80 g. During
the second half of pregnancy, a further increase to 30 g of
natural protein was required to reach the target plasma
BCAA values. This corresponded to approximately
3,000 mg leucine per day and was clearly much more than
she had ever consumed before. In order to meet these
increased protein needs, she had to consume more natural
proteins. She disliked meat and fish, so that she ate more
milk products and eggs. The maximal protein and leucine
intake was in the eighth month of pregnancy. For a while
she enjoyed this extraordinary situation; however, during
the last month of pregnancy, she had no more appetite for
those foods and she decreased the intake of natural protein
to approximately 20 g/day. Despite this, the BCAA levels
were maintained within the defined range (Fig. 2). During
the whole pregnancy weight gain was about 10 kg.
After 41 weeks of gestation our patient gave birth to a
healthy baby girl (weight 3,430 g, height 48 cm, head
circumference 33.5 cm). To avoid catabolism during labour,
she received intravenous glucose (220 g/24 h) from the
moment the birth process started. The infusion was
continued for the next 2 days. The maternal BCAA levels
5 h after birth were valine 205 mmol/L, isoleucine 63 mmol/
L and leucine 174 mmol/L. The baby’s BCAA levels were
checked on day two after birth and were below the normal
range: isoleucine 14.9 mmol/L, leucine 43.8 mmol/L and
valine 85.2 mmol/L. For the first few days after delivery, the
mother followed her pre-pregnancy diet with about 500 mg
leucine per day. The postpartum goal for the BCAA levels
of the mother was the same as those before pregnancy.
Breastfeeding was instituted successfully at day two after
birth. It was possible to discharge mother and baby after
5 days. The patient continued breastfeeding for the next 6
months. The BCAA levels were controlled approximately
every third week. Three weeks after birth we found rather
low levels of leucine (118 mmol/L) and valine (148 mmol/
L). At this point the mother’s intake of natural protein was
5–10 g/day. Based on the measured levels, the protein
intake was increased to almost 15 g/day, and this was the
average intake of natural protein per day during breastfeed-
ing period. After stopping breastfeeding, she returned to her
usual MSUD diet. The baby thrived very well, and at the
age of 3 years she appeared to be normal in all aspects. The
parents are planning a further pregnancy.
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Fig. 2 Plasma leucine concentration (mmol/l) during pregnancy
Conception
Birth
Fig. 1 Intake of total protein, aminoacid-mixture and normal protein (g). Intake of leucine (mg)
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Discussion
This is the sixth case of a successful pregnancy in a woman
with classical MSUD documented in the literature (Tchan
et al. 2013; Gr€unewald et al. 1998; Van Calcar et al. 1992).
Remarkable in our case is the patient’s excellent compli-
ance with the diet. In order to maintain her compliance and
motivation, we involved her in every possible process. This
included the calculation of protein requirements and leucine
intake as well as frequent regular follow-up visits with the
metabolic team (physician, dietician and laboratory staff).
Successful outcomes of pregnancies in MSUD patients
were presented by Tchan et al. (2013), Gr€unewald et al.
(1998), and Van Calcar et al. (1992). Compared to the cases
of Van Calcar and Tchan, our patient had a much lower pre-
pregnancy protein intake (29, 15–35 and 30–50 g, respec-
tively, versus 5 g natural protein in our patient). This was
because of higher leucine tolerance or suboptimal compli-
ance of the patient(s). While Van Calcar found a very high
leucine tolerance of 8,600 mg/day at the end of the
pregnancy suggesting a mild form of MSUD, Gr€unewald’s
patient’s highest leucine tolerance (2,100 mg leucine per
day) just before giving birth in the 36th week was closer to
that to our patient. We found a progressive increase of
leucine tolerance up to 3,000 mg of leucine per day and a
maximal natural protein intake of approximately 30 g/day
around week 30. As with Gr€unewald et al., we assume the
increased tolerance of natural protein during pregnancy
reflects enhanced protein synthesis in the fetomaternal
compartment because of the capacity for branched-chain
amino acid metabolism in the foetus that partially compen-
sated the mother’s metabolic deficit. In contrast to other
cases, we found no increase in leucine level postpartum.
Those high leucine levels were thought to be the result of
protein breakdown due to postpartum uterine involution
and perhaps also poor dietary compliance (Tchan). In order
to avoid a postpartum rise of leucine, we therefore decided
to attempt to avoid the catabolic state during labour and
birth by giving an infusion of 10% glucose (3.3 g/kg/day).
We also reduced leucine intake to pre-pregnancy values
immediately postpartum until breastfeeding was success-
fully instituted. Since one hundred ml of mother’s milk
contains about 1.5 g protein and 300 mg leucine, we
expected an increase of protein and leucine requirement
during the breastfeeding period.
Our case and the described examples clearly
demonstrate that careful and close monitoring of MSUD
patients is very important during pregnancy and the
experience gained is helpful to handle further cases.
Although it is clear that it remains essential to treat every
case individually, this needs to be based on the careful and
detailed documentation of management and outcome of
pregnancies in women with MSUD as reported here.
Finally a metabolic team with experience of patients
with inherited metabolic diseases, with close collaboration
of physicians, laboratory staff, dietician and the patient,
is essential for successful outcome in pregnancy of MSUD
and related disorders.
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Abstract Defects in the mitochondrial respiratory chain
can induce a heterogeneous range of clinical and biochemi-
cal manifestations. Hepatic involvement includes acute
fulminant hepatic failure, microvesicular steatosis, neonatal
non-alloimmune haemochromatosis and cirrhosis. Recently
pathogenic mutations in tRNA 5-methylaminomethyl-2-
thiouridylate methyltransferase (TRMU) gene (OMIM
610230) have been demonstrated to cause transient infantile
liver failure (OMIM 613070). The human TRMU gene
encodes a mitochondrial protein, 5-methylaminomethyl-2-
thiouridylate methyltransferase, whose molecular function
is that of mitochondrial tRNA modification.
We report an infant who presented with acute liver
failure, in whom we observed hepatic copper intoxication
and cirrhosis on liver biopsy. We postulate that the hepatic
copper intoxication observed in our patient is most likely a
secondary event associated with cholangiopathy. Periportal
copper accumulation has been implicated in causing
secondary mitochondrial dysfunction; the impact of copper
accumulation in patients with TRMU mutations is unclear
and warrants long-term clinical follow-up.
Introduction
The mitochondrial respiratory chain (MRC) is an essential
component of normal cellular activity. Mitochondria are
double-membraned intracellular organelles whose main
function is to generate the high-energy phosphate molecule
ATP via the process of oxidative phosphorylation
(OXPHOS) (Lee and Sokol 2007). In order to achieve
OXPHOS, the MRC is constructed into five separate
complexes in which the subcomponents are encoded by
both nuclear and mitochondrial DNA (mtDNA), with
Complex II being the only complex without mtDNA
contributions to its structure or maintenance.
The clinical features of a mitochondrial disorder are
protean, in which “high-energy requirement” organs are
more likely to produce a measurable disease burden.
Hepatic involvement can occur as part of a single-organ
or multi-organ clinical phenotype. The hepatic involvement
of MRC disorders is common and demonstrates heteroge-
neity in clinical presentations and age of onset and is often
fatal especially in the neonatal-infantile period. The hepatic
features most commonly associated with MRC diseases
include cholestasis, coagulopathy, cirrhosis, non-alloim-
mune neonatal haemochromatosis and acute fulminant
hepatic failure (Lee and Sokol 2007; Fellman and Kotarsky
2011). Liver biopsy most commonly demonstrates hepatic
steatosis.
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In recent years nuclear-encoded genes that play a role in
the maintenance and translational efficiency of mtDNA
have been linked with hepatic phenotypes due to mitochon-
drial depletion. Nuclear-encoded genes associated with
mitochondrial depletion syndromes include POLG (OMIM
174736), MPV17 (OMIM 137960), SUCLG1 (OMIM
611224) and DGUOK (OMIM 601465) (Fellman and
Kotarsky 2011). Mutations in the tRNA 5-methylamino-
methyl-2-thiouridylate methyltransferase (TRMU) gene
(OMIM 610230) have recently emerged as a cause of
infantile-onset acute hepatic failure (Zeharia et al. 2009).
The TRMU gene product functions as a mitochondrial
tRNA modification and thus mitochondrial translation
(Sasarman et al. 2011). An encouraging feature of this
clinical presentation is that the hepatic failure can be
reversible with appropriate supportive treatment. However,
long-term neurological and hepatic outcomes are yet to be
defined. Our case differs to the reported cases with TRMU
mutations in that periportal hepatocyte copper loading was
evident on liver biopsy.
Case Report
Our previously well female infant presented in extremis in
hypovolaemic shock with acute hepatic failure at 4.5
months of age. There was no obvious precipitating infective
illness. She had a gastrointestinal haemorrhage secondary
to severe coagulopathy and was found to be profoundly
hypoglycaemic and acidotic from a high lactate. She
ultimately made a full systemic, hepatic and neurological
recovery with intensive respiratory, circulatory and liver
supportive therapy (N-acetylcysteine, carnitine and coen-
zyme Q10).
A primary mitochondrial defect was considered as part
of the differential diagnosis in view of the abruptness and
severity of clinical and biochemical presentation. Persistent
mild abnormalities in liver function combined with the
absence of an alternative diagnosis prompted the collection
of liver and muscle biopsies at 8 months of age.
Significant abnormalities were detected on histological
examination of the liver biopsy, most notably copper
loading. Copper staining with rhodanine was performed
revealing conspicuous copper and copper binding protein
deposition in hepatocytes in a periportal distribution with
no evidence of Mallory hyaline deposits (Fig. 1). Other
prominent histological findings included portal tract fibro-
sis, cholangiopathy and small droplet steatosis (Figs. 2 and
3). Electron microscopy of the liver tissue revealed
excessive numbers of mitochondria per cell, providing
ultrastructural morphology correlation of oncocytosis noted
on light microscopy with microvesicular steatosis and
normal mitochondrial morphology.
Fig. 1 Rhodanine staining revealing conspicuous copper and copper
binding protein deposition in hepatocytes in a periportal distribution
with no evidence of Mallory hyaline deposits
Fig. 2 Portal tract fibrosis, cholangiopathy and small droplet steatosis
Fig. 3 Portal tract fibrosis, cholangiopathy and small droplet steatosis
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The patient had no dietary history to suggest excess
copper ingestion and no wider clinical features associated
with known genetic defects in copper transportation. Serum
copper levels (16 mmol/L, reference range 13–26) and
ceruloplasmin levels (1.75 mmol/L, reference range
1.9–3.41) were within normal limits.
Mitochondrial respiratory chain (MRC) enzyme analysis
occurred via previously published methods (Bernier et al.
2002) with normal results in the muscle. Liver MRC chain
activity levels of Complexes I, III and IV were low
compared to citrate synthase, and Complex IV activity
was low compared to Complex II activity (see Table 1).
Mutation analysis for the common mitochondrial DNA
mutations and the three common POLG mutations yielded
normal results. The hepatic mtDNA/nDNA ratio was 1.02.
TRMU sequencing proceeded via previously published
methods (Zeharia et al. 2009) identifying compound
heterozygosity for two pathogenic mutations c.835G>A
and c.1037-1040 del TCAA.
Having identified periportal copper staining and hepatic
fibrosis, we instituted a hepatocellular carcinoma surveil-
lance programme involving yearly liver ultrasounds and
plasma alpha-fetoprotein levels. In the absence of a formal
diagnosis of Wilson’s disease, specific copper chelation
was avoided, but it was thought prudent to commence zinc
acetate to reduce enterocyte absorption of copper. Now 4
years later our patient continues to demonstrate normal
neurological developmental and hepatic function. Liver
synthetic function and transaminases, copper studies and
regular hepatobiliary ultrasound scanning are normal.
Discussion
The aetiology of acute infantile hepatic failure is heteroge-
neous in nature, and mitochondrial respiratory chain defects
are potentially under-recognised. Diagnosis is confounded
by non-specific clinical phenotypes, technical difficulties in
obtaining and interpreting mitochondrial respiratory chain
studies and molecular heterogeneity of mitochondrial
defects. An accurate and timely diagnosis for the hepatic
failure and of the molecular aetiology of mitochondrial
respiratory chain defects is of significant practical impor-
tance for the hepatologist in terms of liver transplantation
suitability. The reversible hepatic failure seen in patients
with TRMU mutations underscores the importance of
making this diagnosis and the value of aggressive support-
ive care. The clinical presentation and recovery of our
infant are similar to reported cases associated with TRMU
mutations (Gaignard et al. 2013; Schara et al. 2011;
Uusimaa et al. 2011; Zeharia et al. 2009). Our infant
presented with acute hepatic failure, had mild deficiency of
MRC Complex IVon liver samples and has made a full and
sustained clinical recovery. This case is unique in that the
histopathological findings revealed excessive periportal
copper deposition in the liver biopsy.
Copper is an essential trace element, and both excess and
deficiency are associated with clinically relevant pathology.
Once dietary copper is absorbed from the enterocyte, it is
transported to the liver via the portal venous system bound
to amino acids like histidine and serum proteins like
albumin. Delivery of copper into the hepatocyte occurs
via the copper transport protein, and once into the
hepatocyte, most copper is bound to caeruloplasmin, the
major transport protein for copper. Within the liver, there
are four potential routes for copper distribution, (1) joining
the copper/metallothionein pool, (2) binding to copper
chaperone protein for delivery to zinc superoxide mutase,
(3) attaching to cox17 for trafficking into the mitochondria
for MRC Complex IV assembly and (4) trafficking to the
trans-Golgi network (TGN) via human atox-1 homologue
(Shim and Harris 2003). Copper plays an essential role in
numerous crucial enzymatic pathways including neuro-
transmitter production, lysyl oxidase cross-linkage of
collagen, free radical savaging via superoxide dismutase
and metallothioneins and formation of MRC Complex IV
and clotting factors (Corkins 2011). Genetic diseases of
copper excretion and intracellular transport are associated
with varied clinical phenotypes. These genetic diseases are
associated with the TGN transportation of copper and are
Menkes disease (MD) (OMIM 309400) and Wilson’s
disease (WD) (OMIM 277900).
Under normal physiologic conditions 80% of copper is
excreted via the biliary system attached to bile acids and
Table 1 Mitochondrial respiratory chain enzymes – liver
Unit (nmol/min/mg) Activity (ref range) % Activity % CS ratio % CII ratio
Complex I 12 (8–11) 126 29 58
Complex II 134 (54–73) 220 49
Complex III 9.5(5.2–10.3) 125 28 57
Complex IV 0.45 (0.5–0.9) 63 14 29
Citrate synthase 122 (26–31) 436
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20% via the urine (Corkins 2011). Diseases associated with
copper excretion are caused by a primary genetic defect in
the excretion pathway, such as those associated with the
TGN or by the process of biliary obstruction (Corkins 2011;
Elmes et al. 1989; Evans et al. 1980; Goldfischer et al.
1980; Prohaska 2008). The periportal location of copper
staining in our patient is more in keeping with being
secondary to altered biliary excretion rather than from
dietary copper excess as seen in Indian childhood cirrhosis
(Pankit and Bhave 2002), endemic Tyrolean infantile
cirrhosis (Pankit and Bhave 2002) or a TGN-related copper
transport defect in which the copper distribution tends to be
pan-lobar (Goldfischer et al. 1980).
Our case raises unanswered questions regarding the role
of copper in the pathogenicity of liver failure secondary to
patients with TRMU mutations. The most likely reason for
the periportal copper staining in our patient is secondary to
abrupt biliary cholestasis secondary to severe mitochondrial
impairment. To our knowledge, the only reported functions
of the TRMU gene product have been of mitochondrial
2-thiolation of the wobble U in tRNAlys, tRNAGlu and
tRNAGln (Sasarman et al. 2011). A cytosolic role,
especially one associated with intracellular copper traffick-
ing, has not been postulated. MRC Complex IV is a critical
component of the OXPHOS pathway in which the catalytic
core contains three copper atoms (Horn and Barrientos
2008; Mehta et al. 2006). The TRMU gene product has not
been postulated to have a role as a cytosolic or an intra-
mitochondrial copper chaperone molecule or in that of
MRC Complex IV assembly. However, MRC Complex IV
deficiency has been described in patients with TRMU
mutations including our case (Gaignard et al. 2013; Schara
et al. 2011; Uusimaa et al. 2011; Zeharia et al. 2009).
Hepatic copper deposition does not equate to systemic
copper excess, as demonstrated in our patient. Cases of
symptomatic copper deficiency have been described in
patients with chronic cholestasis when copper has been
removed from total parenteral nutrition supplements (Cor-
kins 2011), highlighting the importance of copper for
normal cellular function.
Oxidative stress is implicated in the pathogenesis and
progression of specific liver diseases including biliary
cirrhosis (Sastre et al. 2007; Tiao et al. 2009). In chronic
cholestasis liver mitochondria have demonstrated increased
H2O2 production and GSH depletion and oxidation (Sastre
et al. 2007). Mitochondrial oxidative stress is a precursor to
apoptosis. Copper excretion from the TGN involves
interaction between MURR1/COMMD1 and the X-linked
inhibitor of apoptosis protein (XIAP), which is a potent
suppressor of apoptosis that directly inhibits specific
members of the caspase family of cysteine proteases
(Burstein et al. 2004). XIAP levels are greatly reduced by
intracellular copper accumulation in Wilson’s disease and
other copper toxicosis disorders (Mufti et al. 2006, 2007).
Elevated copper levels result in a profound, reversible
conformational change in XIAP, which accelerates degra-
dation and significantly decreases the ability of XIAP to
inhibit caspase-3 (Mufti et al. 2006, 2007). The observation
of periportal copper accumulation in our patient is likely to
be secondary to cholestasis; however, copper accumulation
has been associated with the initiation of apoptosis via
XIAP and mitochondrial oxidative stress. The TRMU gene
product functions in the mitochondrial matrix; what is
unclear from our case is if the copper accumulation will
induce long-term secondary mitochondrial oxidative stress
in an already abnormal mitochondrial system.
In conclusion, this case highlights the importance of
recognising TRMU mutations as a cause of reversible,
transient liver failure in infants and provides some insight
into the potential interaction of mitochondrial disorders and
intrahepatic copper accumulation. As the long-term out-
come from liver failure in infants with TRMU mutations, in
particular those with copper accumulation, has yet to be
defined, our case also highlights the need for long-term
follow-up of these patients.
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Abstract Few data exists regarding the clinical impact of
breastfeeding in infantile sitosterolaemic cases. We report
four Japanese infantile cases of sitosterolaemia, an
extremely rare inherited disease characterised by increased
serum levels of plant sitosterol, presenting with severe
hypercholesterolaemia and systemic xanthomas exacer-
bated by breastfeeding. In these four cases, genetic analyses
were performed for low-density lipoprotein (LDL) receptor,
proprotein convertase subtilisin/kexin type 9 (PCSK9),
LDL receptor adaptor protein 1 and ATP-binding cassette
(ABC) subfamily G member 5 and 8 (ABCG5 and
ABCG8) genes. We assessed their clinical manifestations,
including responsiveness to a variety of treatments, espe-
cially to weaning from breastfeeding and use of ezetimibe.
Two pairs of mutations in the ABCG5 gene in each case,
including two novel mutations (c.130C>T or p.Ser44Ala
and c.1813_1817delCTTTT or p.Pro558GlufsX14) and two
known mutations (c.1306G>A or p.Arg389His and
c.1336C>T or p.Arg446X), were identified. Significant
reductions in cholesterol levels were obtained by means of
weaning from breastfeeding alone. Substantial reductions in
sitosterol levels, without any apparent side effects, were
observed with ezetimibe. In conclusion, we have identified
infantile Japanese sitosterolaemic subjects with extreme
hypercholesterolaemia exacerbated by breastfeeding. Their
unique response to weaning from breastfeeding, as well as
to use of ezetimibe, could provide insights into the
metabolic basis of sterols in humans.
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Introduction
Sitosterolaemia (OMIM #210250) caused by mutations in
either of two genes, ATP-binding cassette (ABC) subfamily G
members 5 and 8 (ABCG5 and ABCG8), is an extremely rare
autosomal recessive disorder of sterol metabolism character-
ised by increased absorption and decreased biliary excretion
of plant sterols and cholesterol, resulting in prominently
elevated serum levels of plant sterols such as sitosterol and
campesterol (Shulman et al. 1976). Subjects suffering from
sitosterolaemia present primarily with tendinous and tuber-
ous xanthomas and premature coronary atherosclerosis
resembling familial hypercholesterolaemia (FH: Salen et al.
(2002), Bhattacharyya and Connor (1974)). Serum LDL
cholesterol (LDL-C) levels tend to vary more in sitoster-
olaemia than in other genetic or nongenetic hyperlipidae-
mias. Notably, LDL-C can be elevated significantly in some
cases with sitosterolaemia, especially in infantile cases, due
to unknown mechanisms (Yoshida et al. 2000). Thus, those
cases are sometimes misdiagnosed as homozygous FH.
We encountered four Japanese infantile cases initially
diagnosed as homozygous FH based on their clinical
manifestations of severe hypercholesterolaemia and sys-
temic intertriginous xanthomas. However, those manifes-
tations responded very well to a variety of treatments,
especially weaning from breastfeeding, which would not be
observed in homozygous FH. Therefore, the aims of this
study were (1) determining their molecular diagnosis,
including LDL receptor, proprotein convertase subtilisin/
kexin type 9 (PCSK9) and LDL receptor adaptor protein 1
(LDLRAP1) genes that have been described as causative
genes of Japanese FH (Mabuchi et al. 2014) as well as
ABCG5/8 genes as causes of Japanese sitosterolaemia
(Tsubakio-Yamamoto et al. 2010), and (2) evaluating their
responsiveness to a variety of treatments.
Materials and Methods
Study Subjects
The backgrounds of the study subjects are listed in
Supplemental Tables 1, 2, and 3. All of the probands
showed severe hypercholesterolaemia, and three of them
exhibited intertriginous xanthomas, but no subjects showed
tendon xanthomas. None of them were born from consan-
guineous marriages, and none of their parents exhibited any
sign of physical xanthomas. In all the study subjects, we
noted no evidence of secondary hypercholesterolaemia,
such as thyroid insufficiency or nephritic syndrome. The
families initially visited three different institutions (Kana-
zawa University Hospital, Gifu Prefectural General Medical
Center and Miyazaki University Hospital). And the families
from Gifu Prefectural General Medical Center and Miya-
zaki University Hospital were referred to Kanazawa
University Hospital because of the (initial) clinical diagno-
sis of homozygous FH.
Ethical Considerations
This study was approved by the Ethics Committee of
Kanazawa University and carried out in accordance with
the Declaration of Helsinki (2008) of the World Medical
Association. All procedures followed were in accordance
with the ethical standards of the responsible committee on
human experimentation (institutional and national) and with
the Helsinki Declaration of 1975, as revised in 2008.
Informed consents were obtained from all subjects or their
parents (if the subject was an infant) when they visited
Kanazawa University Hospital for being included in the
study.
Genetic Studies
Genomic DNA was isolated from peripheral white blood
cells according to standard procedures and was used for
polymerase chain reaction (PCR). Primers for the study
were designed as previously reported (Noguchi et al. 2010);
PCR products were purified by Microcon (Millipore Corp.,
Bedford, MA) and used as templates for direct sequencing.
DNA sequencing was carried out according to the manu-
facturer’s instructions, using a dye terminator method, ABI
PRISM™ 310 Genetic Analyzer (Applied Biosystems,
Foster City, CA). We analysed ABCG5/ABCG8 genes as
well as LDL receptor, PCSK9 and LDLRAP1 genes, as
previously reported (Mabuchi et al. 2014). In order to
precisely determine the deleted codons in Case 1, Case
2 and Case 4, we digested the PCR products using DraI,
which could recognise the 6-bp nucleotide TTTAAA and
consequently make a 28-bp and an 85-bp fragment in the
normal allele. Thus, we could discriminate the normal and
abnormal alleles in exon 12 of the ABCG5 gene after
electrophoresis through 2.5% polyacrylamide gels.
Biochemical Analysis
Blood samples were drawn for assays after overnight
fasting. Serum levels of total cholesterol (TC), triglycerides
(TG) and high-density lipoprotein cholesterol (HDL-C)
were determined enzymatically (Allain et al. 1974; Sugiura
et al. 1977; Kajikawa et al. 1981). Serum levels of LDL-C
were derived from the Friedewald’s formula (Friedewald
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et al. 1972). Serum cholesteryl ester transfer protein
(CETP) levels were determined by a specific enzyme-
linked immunosorbent assay (Kiyohara et al. 1998). Serum
levels of sterol, including those of sitosterol, lathosterol and
campesterol, were determined using gas–liquid chromatog-
raphy–mass spectrometry (Ahmida et al. 2006).
Results
Genetic Analysis (Fig. 1, Supplemental Fig. 1)
No mutation was identified in the three FH genes (LDL
receptor, PCSK9 and LDLRAP1) amongst any of the four
sitosterolaemic cases.
In Case 1, direct sequencing analysis for exon 12 of
ABCG5 gene showed abnormal overlapping after nucleo-
tide position 1813, suggesting deletion of several nucleo-
tides in this region (Fig. 1a). To clarify the supposed
overlapping sequence, we attempted to digest the PCR
products with DraI and found no fragmentation of PCR
products that would have suggested the existence of an
abnormal sequence (Fig. 1b). After direct sequencing of the
non-fragmented PCR products, we could confirm a novel
m u t a t i o n o f a 5 - n u c l e o t i d e d e l e t i o n
(c.1813_1817delCTTTT or p.Pro558GlufsX14) causing a
premature termination at codon 571 (Fig. 1c, d). In
addition, we identified another mutation in exon 9
(c.1306G>A or p.Arg389His, Fig. 1e), which is one of
the most common mutations in Asian sitosterolaemic cases
(Park et al. 2014). We confirmed the same mutations in
Case 2 (the younger sister of Case 1). In Case 3, another
novel substitution mutation in exon 1 of the ABCG5 gene
(c.130T>C or p.Ser44Ala, Fig. 1f) and the same mutation
in exon 9 as observed in Cases 1 and 2 (c.1306G>A or p.
Arg389His, Fig. 1e) were identified by direct sequencing
analysis, despite no apparent evidence of a familial
relationship with Case 1 and Case 2. In Case 4, the same
deletion mutation (c.1813_1817delCTTTT or p.Pro558-
GlufsX14) was detected in the ABCG5 gene, as observed
in Case 1, despite no apparent evidence of a familial
relationship with Case 1. In addition, another mutation was
found in exon 10 of ABCG5 (c.1336T>C or p.Arg446X,
Fig. 1g). The latter is also one of the most common
mutations in Asian sitosterolaemic cases (Wang et al.
2014). No other mutation was found in either the ABCG5
or the ABCG8 gene in any of the four cases.
Clinical Courses and Interventions (Fig. 2)
The decisions on the treatments of the four cases were
made based on their personalities, the policies of each
institution and the preferences of the parents, providing us
an opportunity to observe responsiveness to a variety of
treatments.
The original serum TC, LDL-C and sitosterol levels of
Case 1 were 523 mg/dl, 407 mg/dl and 101 mg/ml,
respectively. These levels were reduced to 151 mg/dl,
81 mg/dl and 46 mg/ml, respectively, with 10 mg ezetimibe
daily (gradually increased from 2 mg daily) and a low-
cholesterol (<200 mg daily) and low-plant-sterol diet
(avoiding vegetable oils, nuts and cereals), after weaning
(Fig. 2a). Intertriginous xanthomas (Supplemental Fig. 2a,
b) completely regressed in association with the reduction of
these sterol levels (Supplemental Fig. 2c, d).
In the initial blood test, the serum levels of sitosterol in
Case 2were lower than those of Case 1 (Case 2’s elder sister),
whereas the serum levels of TC were similar for Cases 1 and
2. Weaning from breastfeeding was effective in reducing the
TC levels of Case 2, but it increased her sitosterol levels; this
increase was probably also associated with increased
sitosterol intake. However, additional treatment with ezeti-
mibe further reduced her TC and sitosterol levels (Fig. 2b). In
this case, ezetimibe was introduced at 10 mg daily because
this dose was well tolerated in Case 1 (Case 2’s elder
sister). In Case 3, the original serum TC, LDL-C and
sitosterol levels were as high as 870 mg/dl, 796 mg/dl and
80 mg/ml, respectively. In a clinical course similar to that of
Case 1, these levels dramatically reduced to 228 mg/dl,
157 mg/dl and 64.5 mg/ml, respectively, with administration
of 10 mg of ezetimibe daily and a low-cholesterol
(<200 mg daily) and low-plant-sterol diet (avoiding
vegetable oils, nuts and cereals) after weaning (Fig. 2c).
Ezetimibe was introduced at 10 mg daily in this case, based
on discussions with her parents. Her intertriginous xantho-
mas (Supplemental Fig. 3) also successfully regressed (data
not shown). In a similar way to that of Cases 2 and 3, in
Case 4, weaning itself resulted in a great reduction in serum
TC and LDL-C levels (from 756 mg/dl and 589 mg/dl to
326 mg/dl and 115 mg/ml, respectively) (Fig. 2d). Interest-
ingly, his intertriginous xanthomas (Supplemental Fig. 4)
completely disappeared at the age of five (data not shown).
Ezetimibe at 10 mg daily, rather than colestimide, was
effective in reducing serum sitosterol levels.
It is noteworthy that whilst weaning itself was effective
in reducing TC and LDL-C levels and in promoting the
regression of intertriginous xanthomas, it was not sufficient
to reduce serum sitosterol levels (Table 1). Although the
impact on the degree of reduction was different in each
case, ezetimibe was effective in reducing serum sitosterol
levels in all four cases.
Although several papers have suggested the association
between sitosterolaemia and haematologic abnormalities, such
as macrothrombocytopaenia, haemolytic anaemia and spleno-
megaly (Park et al. 2014; Wang et al. 2014), none of our
cases exhibited any abnormal haematological manifestations.
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Clinical and Laboratory Characteristics of Infantile Cases
with Sitosterolaemia (Table 1)
We have summarised clinical and laboratory characteristics
of infantile cases with sitosterolaemia of ours and those
from the literature (Niu et al. 2010; Park et al. 2014; Rios
et al. 2010) in Table 1, focusing on the changes in clinical
manifestations before and after the weaning. Most of the
infantile cases with sitosterolaemia exhibited intertriginous
xanthomas associated with extremely high LDL cholester-
olaemia during breastfeeding, which decreased dramatically
after weaning.
Fig. 1 DNA analysis for ABCG5 gene. (a) DNA sequence data of
control and the proband, the latter of which showed an abnormal gap
of several nucleotides in the coding region of exon 12. (b) Restriction
enzyme analysis using DraI. Deletion of nucleotides in this region
protected from fragmentation by this enzyme. (c) Sequencing of the
non-fragmented PCR product revealed a novel mutation of a five-
nucleotide deletion in exon 12 (c.1813_1817delCTTTT). (d) Blue-
coloured nucleotides indicate those deleted in the proband. This
deletion mutation caused a premature termination at codon 571. (e)
DNA sequence data of the carrier which showed G to A substitution in
exon 9 of the ABCG5 gene (c.1306G>A). (f) DNA sequence data of
the carrier which showed T to C substitution in exon 1 of the ABCG5
gene (c.130T>C). (g) DNA sequence data of the carrier which
showed T to C substitution in exon 10 of the ABCG5 gene
(c.1336T>C)
118 JIMD Reports
Discussion
The main findings of the current study are as follows: (1)
we iden t i f i ed nove l ABCG5 gene muta t ions
(c.1813_1817delCTTTT or p.Pro558GlufsX14 and
c.130T>C or p.Ser44Ala) in Japanese cases with sitoster-
olaemia; (2) all four infantile cases with sitosterolaemia
exhibited severe hypercholesterolaemia, and three of them
showed intertriginous xanthomas resembling homozygous
FH; (3) weaning from breastfeeding was very effective in
reducing serum cholesterol levels; and (4) ezetimibe, not
colestimide, was effective in reducing serum sitosterol
levels.
Interestingly, all four cases, treated in three different
institutions, had been clinically misdiagnosed as homozy-
gous FH due to severe hypercholesterolaemia and/or
intertriginous xanthomas. Several subjects with sitostero-
laemia, especially infantile cases, have been described as
exhibiting clinical manifestations resembling homozygous
FH. Thus, they were sometimes diagnosed as having
“pseudo-homozygous FH” in the past (Yoshida et al.
2000). However, all four cases showed great reductions in
serum cholesterol levels immediately after weaning, which
would not have been observed in homozygous FH. Rios
et al. reported an 11-month-old girl with compound
heterozygous sitosterolaemia due to ABCG5 gene muta-
tions who showed extreme hypercholesterolaemia (serum
TC level, 1,023 mg/dl) (Rios et al. 2010). Her cholesterol
levels also dramatically decreased after weaning, as with
our cases. Park et al. also reported a similar case to ours, in
which a 15-month-old girl whose severe hypercholester-
olaemia (serum LDL-C level, 540 mg/dl) was also
complicated by intertriginous xanthomas during breastfeed-
ing; her hypercholesterolaemia disappeared two months
after the introduction of a low-fat/low-cholesterol diet and
cholestyramine. She was diagnosed with compound hetero-
zygous sitosterolaemia due to an ABCG5 gene mutation
(Park et al. 2014). Our findings of greatly reduced serum
cholesterol levels seen after weaning in four infantile
sitosterolaemic cases reinforce the previous findings
(Table 1).
However, the mechanism by which serum cholesterol
levels increase during breastfeeding in sitosterolaemia is
still unclear. Stigmasterol, the other plant sterol that
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accumulates in sitosterolaemia, inhibits the processing of a
transcription factor, sterol regulatory element binding
protein-2 which stimulates the transcription of hepatic
LDLR (Yang et al. 2004). Accordingly, the transcription
of hepatic LDLR is assumed to be inhibited, resulting in an
increase in circulatory cholesterol. Breast milk contains
around 100 mg/dl of sitosterol, which is independent of
plant sterol intake (Laitinen et al. 2009). Thus, the infantile
consumption of sitosterol is estimated at around 1,000 mg/
day if an infant ingests 1,000 ml of breast milk per day; this
amount of sitosterol intake is close to that of an adult but
greater in terms of proportion with body weight. The
accumulation of non-cholesterol sterols contributes to the
very low cholesterol biosynthesis in cases with sitoster-
olaemia (Yang et al. 2006), leading us to speculate that
severe hypercholesterolaemia observed in infantile sitoster-
olaemia during breastfeeding reflects the reduced catabo-
lism of LDL or excretion of cholesterol into the bile, rather
than an increase in cholesterol biosynthesis. Compared with
the dietary intake of cholesterol by adults, infants ingest
about 3 to 4 times the amount of cholesterol per kg body
weight through breast milk (Ohta et al. 2002; Ohlsson
2010), or the high content of saturated fatty acids in breast
milk (Ohlsson 2010), which may explain the extreme
hypercholesterolaemia of infants with sitosterolaemia.
Other possible factors could be increased absorption and
retention of sterols induced by ABCG5 deficiency itself.
Niu et al. described the effectiveness of ezetimibe in
reducing cholesterol levels in sitosterolaemic cases, includ-
ing infantile cases (Niu et al. 2010); we noted good results
with ezetimibe in the present study as well; however, our
serial assessment of the clinical courses of the current cases
revealed that a reduced intake of cholesterol (weaning from
breastfeeding) should be considered as an important cause
of the greatly reduced cholesterol levels. Although weaning
was effective in reducing serum cholesterol levels and
regressing intertriginous xanthomas, it was not sufficient to
reduce serum levels of sitosterol. Ezetimibe, not colesti-
mide, effectively reduced sitosterol levels by ~50%,
although there is a lack of evidence for its long-term safety,
especially in children. We therefore suggest weaning from
breastfeeding and a restriction of plant sterols or the
introduction of ezetimibe for the treatment of infantile
sitosterolaemia, rather than the introduction of bile acid-
sequestering resins.
A limitation of this study is that we could not elucidate
the exact mechanism of the reduction of cholesterol after
weaning from breastfeeding. However, it is difficult to
conduct a crossover clinical trial from breastfeeding to
weaning. Kinetic studies using stable isotopes could reveal
a detailed record of abnormalities in lipid metabolism (Tada
et al. 2012), but they are difficult to perform in infantile
cases.
In conclusion, we identified two novel mutations in the
ABCG5 gene in Japanese infantile sitosterolaemic cases, all
of whom exhibited great reductions in serum cholesterol
levels by means of weaning from breastfeeding. These
novel mutations should add new support to the molecular
heterogeneity of sitosterolaemia in the Asian population.
Additionally, their unique response to weaning from
breastfeeding, as well as to use of ezetimibe, could provide
insights about the metabolic basis of sterols in humans.
Acknowledgements We express our special thanks to Kazuko
Honda, Sachio Yamamoto (staff of Kanazawa University) and Tohru
Noguchi (former staff) for their outstanding technical assistance. This
work has been supported by the Japan Heart Foundation and Astellas/
Pfizer Grant for Research on Atherosclerosis Update.
Take-Home Message
Extreme hypercholesterolaemia is exacerbated by breast-
feeding in the infantile case with sitosterolaemia.
Compliance with Ethics Guidelines
We hereby certify that this paper, which consists of
unpublished original observations, is not under consider-
ation for publication elsewhere. This manuscript has been
read and approved by all coauthors. Atsushi Nohara and
Horoshi Mabuchi has received research grants from MSD
K.K., Sanofi K.K., Shionogi & Co., Ltd., Kowa Co., Ltd.,
Astellas Pharma Inc., AstraZeneca K.K., Keiai-Kai Medical
Corp. and Biopharm of Japan Co. Hayato Tada, Mutsuko
Takata, Kunihiro Matsunami, Atsushi Imamura, Misayo
Matsuyama, Hirotake Sawada, Hiroyuki Nunoi, Tetsuo
Konno, Kenshi Hayashi, Akihiro Inazu and Junji Kobayashi
have no financial or other relations that could lead to a
conflict of interest. Masa-aki Kawashiri has received pay-
ments for lectures from Shionogi & Co., Ltd., Daiichi-
Sankyo Co., Ltd., Astellas Pharma Inc., AstraZeneca K.K.,
Kissei Pharmaceutical Co., Ltd., Bayer Yakuhin, Ltd. and
Kyowa Hakko Kirin, Co., Ltd. Masakazu Yamagishi has
received research grants from MSD K.K., Astellas Pharma
Inc., Daiichi-Sankyo Co., Ltd. and Otsuka Pharmaceutical
Co., Ltd., and he has received payments for lectures from
Astellas Pharma Inc., Daiichi-Sankyo Co., Ltd., Shionogi &
Co., Ltd. and Kowa Co., Ltd. All coauthors agreed to submit
this article to the Journal of Inherited Metabolic Disease. All
JIMD Reports 121
procedures followed were in accordance with the ethical
standards of the responsible committee on human experi-
mentation (institutional and national) and with the Helsinki
Declaration of 1975, as revised in 2008. Informed consents
were obtained from all patients or their parents (if the
subject was an infant) when they visited Kanazawa
University Hospital for being included in the study.
Author Contributions
Hayato Tada: designed research and performed research
and wrote paper. Masa-aki Kawashiri: designed research
and wrote paper. Mutsuko Takata: collected data and
drafted paper. Kunihiro Matsunami: collected data and
drafted paper. Atsushi Imamura: collected data and drafted
paper. Misayo Matsuyama: collected data and drafted paper.
Hirotake Sawada: collected data and drafted paper. Hir-
oyuki Nunoi: collected data and drafted paper. Tetsuo
Konno: collected data and drafted paper. Kenshi Hayashi:
collected data and drafted paper. Atsushi Nohara: collected
data and drafted paper. Akihiro Inazu: collected data and
drafted paper. Junji Kobayashi: collected data and drafted
paper. Hiroshi Mabuchi: collected data and drafted paper.
Masakazu Yamagishi: designed research and wrote paper.
References
Ahmida HS, Bertucci P, Franzò L et al (2006) Simultaneous
determination of plasmatic phytosterols and cholesterol precur-
sors using gas chromatography–mass spectrometry (GC-MS)
with selective ion monitoring (SIM). J Chromatogr B Analyt
Technol Biomed Life Sci 842:43–47
Allain CC, Poon LS, Chan CS, Richmond W, Fu PC (1974)
Enzymatic determination of total serum cholesterol. Clin Chem
20:470–475
Bhattacharyya AK, Connor WE (1974) Beta-sitosterolemia and
xanthomatosis. A newly described lipid storage disease in two
sisters. J Clin Invest 53:1033–1043
Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the
concentration of low-density lipoprotein cholesterol in serum,
without use of the preparative ultracentrifuge. Clin Chem
18:499–502
Kajikawa T, Ishiki R, Nakao Y et al (1981) Determination of high-
density lipoprotein cholesterol by heparin-Ca2+ precipitation and
enzymatic measurement. J Jpn Atheroscler Soc 9:393–398
Kiyohara T, Kiriyama R, Zamma S et al (1998) Enzyme immunoassay
for cholesteryl ester transfer protein in human serum. Clin Chim
Acta 271:109–118
Laitinen K, Isolauri E, Kaipiainen L, Gylling H, Miettinen TA (2009)
Plant stanol ester spreads as components of a balanced diet for
pregnant and breast-feeding women: evaluation of clinical safety.
Br J Nutr 101:1797–1804
Mabuchi H, Nohara A, Noguchi T et al (2014) Genotypic and
phenotypic features in homozygous familial hypercholesterol-
emia caused by proprotein convertase subtilisin/kexin type 9
(PCSK9) gain-of-function mutation. Atherosclerosis 236:54–61
Niu DM, Chong KW, Hsu JH et al (2010) Clinical observations,
molecular genetic analysis, and treatment of sitosterolemia in
infants and children. J Inherit Metab Dis 33:437–443
Noguchi T, Katsuda S, Kawashiri MA et al (2010) The E32K variant
of PCSK9 exacerbates the phenotype of familial hypercholester-
olemia by increasing PCSK9 function and concentration in the
circulation. Atherosclerosis 210:166–172
Ohlsson L (2010) Dairy products and serum cholesterol levels. Food
Nutr Res 54:5124
Ohta T, Kiwaki K, Endo F, Umehashi H, Matsuda I (2002)
Dyslipidemia in young Japanese children: its relation to familial
hypercholesterolemia and familial combined hyperlipidemia.
Pediatr Int 44:602–607
Park JH, Chung IH, Kim DH, Choi MH, Garg A, Yoo EG (2014)
Sitosterolemia presenting with severe hypercholesterolemia and
intertriginous xanthomas in a breastfed infant: case report and
brief review. J Clin Endocrinol Metab 99:1512–1518
Rios J, Stein E, Shendure J, Hobbs HH, Cohen JC (2010)
Identification by whole-genome resequencing of gene defect
responsible for severe hypercholesterolemia. Hum Mol Genet
19:4313–4318
Salen G, Patel S, Batta AK (2002) Sitosterolemia. Cardiovasc Drug
Rev 20:255–270
Shulman RS, Bhattacharyya AK, Connor WE, Fredrickson DS (1976)
Beta-sitosterolemia and xanthomatosis. N Engl J Med
294:482–483
Sugiura M, Oikawa T, Hirano K et al (1977) A simple colorimetric
method for determination of serum triglycerides with lipoprotein
lipase and glycerol dehydrogenase. Clin Chim Acta 81:125–130
Tada H, Kawashiri MA, Ikewaki K et al (2012) Altered metabolism of
low-density lipoprotein and very-low-density lipoprotein remnant
in autosomal recessive hypercholesterolemia: results from stable
isotope kinetic study in vivo. Circ Cardiovasc Genet 5:35–41
Tsubakio-Yamamoto K, Nishida M, et al (2010) Current therapy for
patients with sitosterolemia–effect of ezetimibe on plant sterol
metabolism. J Atheroscler Thromb 17:891–900
Wang Z, Cao L, Su Y et al (2014) Specific macrothrombocytopenia/
hemolytic anemia associated with sitosterolemia. Am J Hematol
89:320–324
Yang C, Yu L, Li W, Xu F, Cohen JC, Hobbs HH (2004) Disruption of
cholesterol homeostasis by plant sterols. J Clin Invest
114:813–822
Yang C, McDonald JG, Patel A et al (2006) Sterol intermediates from
cholesterol biosynthetic pathway as liver X receptor ligands. J
Biol Chem 281:27816–27826
Yoshida A, Naito M, Miyazaki K (2000) Japanese sisters associated
with pseudohomozygous familial hypercholesterolemia and
sitosterolemia. J Atheroscler Thromb 7:33–38
122 JIMD Reports
RESEARCH REPORT
Molecular Characterization of QDPR Gene in Iranian
Families with BH4 Deficiency: Reporting Novel
and Recurrent Mutations
Hannaneh Foroozani • Maryam Abiri •
Shadab Salehpour • Hamideh Bagherian •
Zohreh Sharifi • Mohammad Reza Alaei •
Shohreh Khatami • Sara Azadmeh • Aria Setoodeh •
Leyli Rejali • Farzaneh Rohani • Sirous Zeinali
Received: 03 December 2014 /Revised: 08 April 2015 /Accepted: 10 April 2015 /Published online: 26 May 2015
# SSIEM and Springer-Verlag Berlin Heidelberg 2015
Abstract Newborn screening for PKU has been in practice
in Iran since 2007. Some hyperphenylalaninemia cases
have tetrahydrobiopterin (BH4) biosynthesis deficiency/
disorder. Several genes including QDPR (encodes DHPR
enzyme, the necessary cofactor for PAH activity) have been
associated with the BH4. Mutations have been previously
described in the QDPR gene. The incidence of BH4
deficiency is expected to be higher in Iran due to high rate
of consanguineous marriages.
We identified a total of 93 BH4-deficient families. A
multiplex set of STR markers linked to 4 genes responsible
for the BH4 deficiency (i.e., GCH1, PCBD1, PTS, and
QDPR genes) was used to quickly determine which gene
may be responsible to cause the disease. Mutation analysis
of QDPR gene revealed some known and novel mutations.
Our findings show that no common mutation predominates,
and they are scattered in the gene in our population.
Introduction
Hyperphenylalaninemia is presented either as a result of
phenylalanine hydroxylase (PAH, EC 1.14.16.1) deficiency
or rarely as a form of tetrahydrobiopterin (BH4) deficiency.
It is estimated that the overall prevalence of BH4 deficien-
cies is about 1 in 106 live births in the western population,
but this estimation is higher in some Mediterranean countries
(Blau et al. 2001). PAH is a hepatic enzyme that needs the
BH4 as a necessary cofactor for proper functioning.
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BH4 is also an essential cofactor for tyrosine and
tryptophan hydroxylases, the critical enzyme in monoamine
neurotransmitters (Wang et al. 2012). So BH4 deficiency
can also leads to defect in neurotransmitters. As a result,
BH4-deficient patients show neurological deterioration
when they are only treated with phenyl restricted diet
(Wang et al. 2006). So the differential diagnosis of the BH4
deficiency from phenylketonuria (PKU, MIM 261600) is
very essential and should be initiated as soon as possible to
reduce neurological impairment in the affected individuals.
BH4 deficiencies include heterogeneous disorders with
several genes involved in the etiology of the disease. BH4
is synthesized from guanosine triphosphate (GTP) by GTP
cyclohydrolase 1 (GTPCH; EC 3.5.4.16), sepiapterin
reductase (SR; EC 1.1.1.153), and 6-pyruvoyl-tetrahydrop-
terin synthase (PTPS; EC 4.3.2.12) and recycled from
pterin-4-a carbinolamin by pterin-4-a-carbinolamin dehy-
drogenase (PCD; EC 4.2.1.96) and dihydropteridine reduc-
tase (DHPR; EC 1.6.99.7) enzymes (Blau et al. 2005).
Therefore, five different genes have been identified in the
synthesis or recycling of BH4.
DHPR deficiency is one form of BH4 deficiency. This
deficiency is presented by psychomotor retardation, myo-
clonic epilepsy, microcephaly, febrile attacks, hypertonia of
the trunk with limb hypertonia, and fatal course because of
neurotransmitters. Patients also show defective folate
metabolism which recuperate by phe-restricted diet. Diag-
nosis is confirmed by measuring pterins and neurotransmit-
ter metabolites in urine and cerebrospinal fluid.
Measurement of the DHPR enzyme activity in dried blood
spot or fibroblast is also possible (Smith and Brenton
1996).
The mode of inheritance of the DHPR deficiency is
autosomal recessive. Therefore, a higher number of patients
are expected in the countries with high rate of consanguin-
eous marriage. In this study, 93 BH4-deficient families were
studied. All participants were subjected to homozygosity
mapping by linked STR markers. Twenty-four families were
homozygous for STR markers linked to QDPR locus. Full
gene sequencing was done for all 24 samples.
Materials and Methods
Sample Criteria
The samples were collected from families with hyper-
phenylalaninemia referred to Kawsar Human Genetic
Research Center and Department of Biochemistry, Pasteur
Institute of Iran since 2008.
Inclusion criteria were having at least two children
(either both or one being affected) born to consanguineous
parents or both parents coming from the same small village
and also showing autosomal recessive mode of inheritance.
All families completed a questionnaire and signed informed
consent.
Differential diagnosis between PAH- and BH4-deficient
patients was performed according to the published diagnos-
tic criteria (Blau et al. 2011).
Molecular Genetic Studies
Five milliliters of peripheral blood was collected from each
patient, parents, and relatives (if needed) in EDTA. DNA
was extracted from peripheral blood for all participants
using salting-out method (Miller et al. 1988). Homozygos-
ity mapping by the STR markers flanking the QDPR gene
was conducted to indirectly track the probable mutated
gene. Table 1 shows the STR markers used in this study
and their locations, for each gene. Primer sequences are
available upon request.
We carried out direct sequencing of QDPR gene by
using specific primers amplifying seven exons and the
exon/intron boundaries (Table 2).
PCR amplification was performed in a 25 mL reactions;
briefly, 1.7 mL of AMS 10X buffer (Cinnagen, Tehran,
Iran), 1U Taq DNA polymerase (Kawsar Biotech Co.,
KBC, Tehran, Iran; KBC) 0.24 mM of each primer, 0.66 mL
of MgCl2 (100 mM), 0.4 mL dNTP (40 mM), 12.3 mL
ddH2O, and 1.66 DMSO mL (Sigma, USA) were mixed.
The PCR conditions included an initial denaturation step
for 5 min at 95C, 1 min at 95C, 1 min at 64C (except for
exon 1 at 62C), and 1 min in 72C and a final extension
for 10 min at 72C for 28–30 cycles.
PCR products were directly sequenced using BigDye
Terminator kit (Thermo Fisher Scientific, Life Technologies,
USA, TS) according to manufacture protocol, and the
samples were run on an ABI3130XL Genetic Analyzer at
KBC facility. Sequences were compared with human
genomic and cDNA of the QDPR gene, and variations were
checked with NCBI reference sequence (NC_000004.12).
Result
From 93 investigated families, 24 affected probands
showed homozygosity to all STR markers linked to the
QDPR gene. This suggested high probability of disease
segregation with the QDPR gene. All seven exons and
exon/intron boundaries of the gene in the probands were
sequenced, and detected mutations were confirmed in the
parents. We identified different new and previously
reported mutations in the QDPR gene (Tables 3 and 4).
Sixteen different types of mutations were found. Ten of
them had not been reported previously. Most of the mutations
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were missense mutations and only two were homozygous
deletion of a nucleotide. We also found two nonsense
mutations. From 12 missense mutations, two would cause
termination of codon. Two different types of mutations were
seen for codon 115 (exon 4). One creates a termination
codon and the other causes substitution of leucine to serine.
p. [(Gly18Asp)] was found to be the most common mutation
which was seen in four different families. Types and
frequencies of mutations are shown in Tables 3 and 4.
The pathogenicity of identified mutations were checked
in related websites such as Polyphen-2 (Adzhubei et al.
2010), SIFT (Kumar et al. 2009), and also HOPE project
(Venselaar et al. 2010). Results and suggested effects are
shown in Table 4.
Table 1 STR markers used this study
STR marker Location Repeated seq Length of PCR product
D4QDPRSD0. 2 Chr4:17464963–17465289 TATC 327
D4QDPRSD2 Chr4:17281517–17281740 CTAT 224
D4SQDPRSD9. 6 Chr4:16519399–16519589 ATCC 191
D4QDPRSD10 Chr4:16483281–16483592 TAGA 312
D4QDPRSU13 Chr4:18845242–18845393 GATA 129–162
D4QDPRSU17 Chr4:19234187–19234517 TATAGA 314–342
Table 2 List of QDPR exon amplification primers and product sizes (bp)
Exon number Primer sequences Primer length (bp) Product size (bp)
1 F: 50-TTACACTTCACAAATTAATGCTCGT-30 25 605
R: 50-AAACAGGAATAGACGCGTAGACC-30 23
2 F: 50-CCCTCATTTCTATGTGTGACTCTT-30 24 247
R: 50-CAAAGGAAGAACATACAGCCAG-30 24
3 F: 50-TCTTCCGTCTAATTCTCAAAGC-30 22 363
R: 50-GTGTATATCCCGGAATCTTTACA-30 23
4 F: 50-TGTGCTGTTTGTGTTAGACCTTG-30 23 408
R: 50-ATCTATCTGTTAAGCAGCTTAGAGG-30 25
5 F: 50-GAGGAGGCCAGATGCAGCTA-30 20 315
R: 50-GTGGAAAGCTACAGTCAGACAAAC-30 24
6 F: 50-GTGCCAGAGGCTCTAGGTTGTC-30 22 377
R: 50-CGGAATCTCAGAGTAGCTGGACT-30 23
7 F: 50-GTGCCAGAGGCTCTAGGTTGTC-30 22 412
R: 50-AGTTAACAGAGATCAACGGATGC-30 23
Table 3 Types of mutation, amino acids, and number seen for previously reported mutation (NM_000320)
Codon and nucleotide changes c.DNA change Amino acid change No. seen Genotype References
Cd18GGC>GAC c.[233G>A];[233G>A] p. [(Gly18Asp)] 4 Homozygous Scrutton et al. (1990)
Cd 23GGT>GAT c.[248G>A];[248G>A] p. [(Gly23Asp)] 1 Homozygous Romstad et al. (2000)
Cd150TAC>TGC c.[629A>G];[629A>G] p. [(Tyr150Cys)] 3 Homozygous (Dianzani et al. 1993)
Cd221CGA>TGA c.[661C>T];[661C>T] p.(R221*) 2 Homozygous Smooker and Cotton (1995)
Cd158CAC>TAC c.[652C>T];[652C>T] p. [(His158Tyr)] 1 Homozygous Smooker et al. (1993)
Cd97DelC c.472delC – 1 Homozygous Romstad et al. (2000)
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Discussion
Frequency of PKU in Iran has been estimated to be about
one per 5000 live births (Setoodeh et al. 2015). The above
study and also data obtained at the molecular level show
that approximately 3–5 of the hyperphenylalaninemia cases
ended up being BH4. This number is about 3–5 per
100,000 live births. This number is higher than 1 in 106
reported in some Mediterranean countries (Blau et al. 2001).
We found that most of the mutations (10 out of 16) were
novel, perhaps because of disease rarity in other popula-
tions: eight missense, one nonsense, and one single
nucleotide deletion mutations. The p. (S115*) mutation
changes serine to a stop codon in exon 4. This causes a
truncated protein that lacks the active site of the enzyme.
The active site of the enzyme, which is also a proton
acceptor site, is situated on the 150th amino acid. As a
result of this mutation, protein synthesis stops before
reaching the active site. It can be postulated that the
enzyme should have no or very little activity. However,
SIFT predicted that this mutation can be tolerated.
However, we can argue that the phenotype of the affected
child is more aligned with our claim.
DHPR has a NADH binding fold at the N-terminus
formed by two b-sheets and an a-helix, named the 13c43-
fold or the “Rossmann fold” (Scrutton et al. 1990). Within
this fold, there is a motif that contains three highly
conserved glycine residues in the order of Gly-X-Gly-X-
X-GIy. These glycines are positioned in codons 18, 20, and
23. Two mutations have already been reported in these
codons (Romstad et al. 2000), and we found them again in
five Iranian families. We found a novel mutation in codon
17: p. [(Gly17Cys)] (Table 4). This mutation substitutes a
hydrophilic amino acid cysteine with neutral glycine. This
residue is 100% conserved, and its substitution can disturb
the multimeric interactions and affect the catalytic activity.
Therefore, this change has a high potency for being
pathogenic. The result of Polyphen2 and SIFT also
confirms this (Kumar et al. 2009; Adzhubei et al. 2010;
Venselaar et al. 2010).
Substitution of p. [(Gly23Asp)] (Table 3) has been found
to be a frequent mutation in patients of Mediterranean
origin (Smooker et al. 1993). We did not see this mutation.
However, we observed that p. [(Gly18Asp)] mutation was
more frequent in the Iranian population. The mentioned
mutation had been reported in a Turkish patient with severe
phenotype (Romstad et al. 2000).
Four amino acid substitutions, namely, p. [(Gly17Cys)],
p. [(Leu185Pro)], p. [(Gly225Arg)], and p. [(Thr237Met)],
are potentially pathogenic since they are not present in the
single nucleotide polymorphism database (Exome Variant
Server, http://evs.gs.washington.edu/EVS/). This was sup-
ported by bioinformatics predictions by Polyphen-2 (Adz-
hubei et al. 2010) which indicated that all of these are
Table 4 Novel mutations identified in this study and related information (NM_000320)
Codon and
nucleotide
changes
Type of
mutation Exon
Amino acid
change cDNA change
No.
seen
SIFT
suggestion Polyphen suggestion
Cd115 Nonsense 4 p.(S115*) c.[344C>A];
[344C>A]
2 Tolerated –
TCG>TAG
Cd17 Missense 1 p. [(Gly17Cys)] c.[49G>T];
[49G>T]
1 Damaging Probably damaging sensitivity: 0.00;
specificity: 1.00GGC>TGC
Cd217 Deletion 7 – c.649 del A 1 – –
del A
Cd185 Missense 6 p. [(Leu185Pro)] c.[554 T>C];
[554 T>C]
1 Damaging Probably damaging sensitivity: 0.00;
specificity: 1.00CTG>CCG
Cd89 Missense 3 p. [(Gly89Arg)] c.[265G>A];
[265G>A]
1 Damaging Probably damaging sensitivity: 0.00;
specificity: 1.00GGA>AGA
Cd 115 Missense 4 p. [(Ser 115Leu)] c.[344C>T];
[344C>T]
1 Tolerated Probably damaging sensitivity: 0.00;
specificity: 1.00TCG>TTG
Cd225 Missense 7 p. [(Gly225Arg)] c.[673G>A];
[673G>A]
1 Damaging Probably damaging sensitivity: 0.00;
specificity: 1.00GGA>AGA
Cd 237 Missense 7 p. [(Thr237Met)] c.[710C>T];
[710C>T]
1 Damaging Probably damaging sensitivity: 0.00;
specificity: 1.00ACG>ATG
Cd 114 Missense 4 p. [(Thr114Ile)] c.[341C>T];
[341C>T]
2 Damaging
Score: 0.02
Probably damaging score: 0.998;
sensitivity: 0.27; specificity: 0.99ACA>ATA
Cd 163 Missense 5 p. [(Ser163Asn)] c.[488G>A];
[488G>A]
1 Damaging
Score: 0.01
Possibly damaging score: 0.885
sensitivity: 0.82; specificity: 0.94AGC>AAC
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“probably damaging” (score 1.00), and SIFT (Kumar et al.
2009) indicated that they may be “damaging” (score 0).
Regarding the p. [(Leu185Pro)] mutation, proline is a
very rigid residue that might abolish the required flexibility
of the protein at the highly conserved position 185. Since
proline residue is smaller than leucine, this will cause a
possible loss of external interactions and prevents multi-
meric contacts. The 225th amino acid has been shown to be
100% conserved residue (Venselaar et al. 2010), and it
would damage the protein if it is replaced with an arginine
which is a bigger amino acid with different charge. Also,
methionine in comparison with threonine at residue 237
shows differences in hydrophobicity. Therefore, it is
expected that this substitution affects hydrogen bond
formation. This threonine residue is much conserved and
also methionine is a bigger residue; therefore, it is expected
that it cannot be buried in the core of the protein. In
conclusion, based on the HOPE project’s (Venselaar et al.
2010) information, these changes are possibly damaging to
the protein.
Also, other mutations including p. [(Gly89Arg)], p. [(Ser
115Leu)], p. [(Thr114Ile)], p. [(His158Tyr)], and p.
[(Ser163Asn)] are potentially pathogenic because they have
not been reported in the single nucleotide polymorphism
database (Exome Variant Server). Moreover, bioinformatics
prediction by Polyphen-2 and SIFT indicated that these
changes are either “probably damaging” or “damaging”
with different scores (see Table 4). The p.[(Gly89Arg)]
amino acid substitution introduces a bigger and a less
hydrophobic residue at this position that can disturb the
multimeric interactions. At the 89th amino acid, only
glycine is flexible enough to make torsion angles, so
mutation into arginine will force the local backbone into an
incorrect conformation which may disturb the local struc-
ture. At 115th, wild-type residue is a highly conserved
glycine that forms a hydrogen bond with the serine on
111th position. Therefore, mutation in this site will cause
loss of hydrogen bonds in the core of the protein and as a
result disturbs correct folding. Besides, at this position the
mutant leucine residue is bigger than serine and probably
will not be buried in the core of the protein which is
important for the main activity of the protein.
By substitution of threonine with isoleucine at amino
acid 114, the multimeric contacts would be disturbed. Since
the mutated isoleucine is located in a domain that is
important for the main activity of the protein, differences
between the wild-type and mutant residue can damage the
core structure of this important domain and thereby affect
the catalytic activity. The histidine at position 158 is a
conserved residue and is buried in the core of the protein.
The mutant tyrosine residue is bigger and probably will not
fit in the space neatly. Also, because of different hydro-
phobicity, the mutation p.H158Y will cause loss of
hydrogen bonds in the core of the protein and as a result
disturbs correct folding.
Finally, mutation p. [(Ser163Asn)] changes serine into
asparagine at position 163 which can damage the protein.
One reason to support this claim is that the wild type is
highly conserved. Serine forms a hydrogen bond with the
glutamine on position 159, so because of the size
difference, the mutant residue cannot make the same
hydrogen bond as the original wild-type residue. The
mutant asparagine residue is bigger with less hydrophobic-
ity, so it can disturb interactions with other molecules or
other parts of the protein which results in a defective protein.
Regarding genotype/phenotype correlation in our
patients, we conclude that no clear correlation was observed
between various mutations and also the type of the gene
involved. One reason could be due to the age of admission,
age at treatment, prior management by other physicians,
parental adherence to the physicians’ orders, etc. (see Table 5).
Molecular analysis of the remaining families is ongoing.
Number of recurrent mutations found was limited in the
studied population. This may be due to either small sample
size or the heterogeneity of Iranian population. Since BH4
deficiency is a rare disease, therefore, 24 samples may not
be few. This finding may also be supported by a suggestion
(Blau et al. 2001) that recurrent mutations, in unrelated
individuals with BH4 deficiency, are more likely to be due
to recurrent mutations at the CpG dinucleotide rather than
founder effects. Multi-founder effect hypothesis may also
be valid in large and heterogeneous populations like Iran,
with several ethnicities and long history of civilization and
human migrations (Najmabadi et al. 2003).
Table 5 Distribution of different abnormalities in PTPS- and DHPR-deficient patients
Mean age at diagnosis CNS abnormality Convulsions Abnormal movement Impaired tonus No symptoms Retardation
PTPS 2 month 9 12 4 15 4 16
% – 30 40 13.3 50 13.3 53
DHPR 2 month 11 20 3 24 6 20
% – 45.8 83 12.5 100 25 83
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Take-Home Message of the Article
QDPR accounts for the majority of BH4 deficiency with a
variety of mutations in Iran.
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